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Bone tissue is continuously being turned over and possesses substantial regenerative 
capacity througout the adult life (Urist et al. 1954, Gianoudis et al. 2007). Most tissues in 
the body heal by scar formation of connective tissue, meant to immediately patch and re-
establish homeostasis (Thorne et al. 2014). In contrast, bone healing results in complete and 
scarless healing with restored properties of bone as before or even with higher mechanical 
properties (Thorne et al. 2014, Gianoudis et al. 2007). The full process of bone healing is not 
yet understood, but studies show a complex proces with a large number of gene-regulated 
molecular factors combined with physiological en biomechanical principles (Thorne et al. 
2014, Gianoudis et al. 2007). A disruption in this process can lead to complications, such as 
infections and non-union (Gianoudis et al. 2007). It has been estimated that 5-10% of all bone 
fractures lead to non-unions, and hence require further treatment (Gianoudis et al. 2011). 
Surgical intervention for bone defects can aid bone healing, for which autologous bone graft 
(transplantation of bone tissue from one site to another within the same individual) remains 
the golden standard (Van der Stok et al. 2011, Dimitriou et al. 2011).
Bone grafting is used for various indications
Bone grafting involves transplantation of autologous bone, which possesses osteogenic (by 
osteogenic cells), osteoconductive (guiding bone growth), and osteoinductive properties (by 
growth factors and/or cells) (Dimitriou et al. 2011). This surgical technique is well-described 
in trauma and reconstructive surgery to repair and augment damaged or diseased bone. 
Almost two decades ago, an estimated number of >500,000 bone grafting procedures were 
performed annually in the United States only, and this number easily doubles on a global 
basis (Greenwald et al. 2001). Despite the desirable properties, several downsides accompany 
the use of autologous bone, including limited availability, increased donor site morbidity, 
and additional surgical efforts (Dimitriou et al. 2011, Finkemeier 2002). In view of these 
disadvantages, multiple biological and synthetic bone substitutes have been explored over 
the last few decades.
Allograft and xenograft use bone from another source than the patient, with allograft derived 
from human donors and xenografts from other species (e.g. bovine). These graft types are 
an alternative for autologous bone, although immunological issues need to be considered 
regarding safe use (Greenwald et al. 2001). Allografts and xenografts have a long track of 
clinical use and already several approved products are commercially available, e.g. DBXTM 
by DePuy Synthes (demineralised human bone) or Bio-Oss® by Geistlich (devitalised bovine 
bone) (Gruskin et al. 2012, Kurien et al. 2013, Urist 1965).
Alternatively, synthetic bone grafts have emerged as an appealing modality to overcome the 
disadvantages of autologous and allografts. Worldwide endeavors are made to develop safe 
and reliable synthetic bone grafts (Van der Stok et al. 2011, Bongio et al. 2010). Commercially 
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available synthetic bone substitutes are off-the-shelf available in various forms and shapes, 
adapted to the specific needs of different bone defects (Bongio et al. 2010, Van der Stok et 
al. 2013).
When considering a surgical intervention for bone healing next to the addition of the desired 
biological properties, a stable environment is mandatory to achieve uneventful bone healing 
(Calori et al. 2011, Giannoudis et al. 2007, Van der Stok et al. 2013). Bone grafts alone do 
not possess the mechanical properties to secure a stable environment under load-bearing 
conditions or at vital locations. Therefore, bone grafts are often combined with a stabilization 
method, such as pins, screws, plates, or intramedullary nails, often made out of stainless 
steel or alloys of cobalt, titanium or tantalum (Mantripragada et al. 2013). Titanium is a 
metallic material that is successfully used for a wide variety of medical applications due 
to its strength, low density and resistance to corrosion (Mantripragada et al. 2013, Matassi 
et al. 2013). With the use of advanced techniques such as selective laser sintering (SLS), 
tailor-made titanium implants can be generated in the form of porous scaffolds, which can 
provide stability and are osteoconductive (Van der Stok et al 2013, Mantripragada et al. 2013).
Bone substitutes and their different compositions
To evaluate the bone regenerative capacity of synthetic bone substitutes, one first needs 
to know the various types of materials and their properties that are currently used for 
their fabrication. Several ‘off-the-shelf’ synthetic bone substitutes are available for clinical 
bone regenerative treatments nowadays and worldwide research is done to enhance the 
properties of synthetic bone substitutes and improve their clinical performance. Synthetic 
bone substitutes can be subdivided into three main material classes, i.e. polymers, ceramics 
and composites (Bongio et al. 2010).
Figure 1: Benefits and drawbacks of the different materials used in bone surgery.
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Chapter 1 
A polymer is a long molecule consisting of many small, repeating units, called monomers, 
joined end to end and either or not containing ramifications. Polymers of either synthetic 
or natural origin are intertwined in everyday life and have a wide variety of purposes. For 
instance, DNA as the genetic information carrier of all proteins in all flora and fauna is a 
natural polymer; further, multiple types of synthetic polymers find application in industrial 
and consumer markets, such as industrial rubbers and plastic bags. Polymer‐based 
bone substitutes have a wide range of properties due to the versatility regarding their 
composition, including stiff and strong polymers (e.g. polyaryletherketones, PAEK (Kurtz 
2007); polymethylmethacrylate, PMMA) and injectable and flexible polymers (e.g. hydrogels, 
a class of highly hydrated polymers that have overall properties similar to those of natural 
soft tissues) (Drury et al. 2003).
Ceramics, especially those based on calcium phosphates (CaPs), are favorable materials due 
to their biocompatible, bioactive and osteoconductive properties resulting from a chemical 
composition that shows high similarity to the mineral phase of bone (Kolk et al. 2012, Verron 
et al. 2012, Zhang et al. 2014). In view of optimized handling properties, CaP ceramics have 
become available in the form of injectable CaP cement (CPC) (Bohner 2010). First proposed 
in the early 80s, CPCs were designed to overcome the handling difficulties of the traditional 
ceramic blocks and granules (Brown et al. 1983, Bohner et al. 2005).
With the use of bone graft substitutes, one must also consider the degradation time of the 
material. For each material or combination of materials, different forms of degradation 
are applicable, resulting in different speed of degradation. Even within a material, there 
can be differences. For example, depending on the end-product after setting, CPCs can be 
classified into two main groups, i.e. brushite and apatitic CPCs. Brushite CPCs have the ability 
to be resorbed under physiological conditions, whereas apatitic CPCs degrade relatively 
slowly, limiting new bone formation (Tamimi et al. 2012). Resorption of CPC occurs either via 
active resorption (a cell-mediated process of osteoclasts and macrophages) or via passive 
resorption (based on CPC solubility) (Grossardt et al. 2010, Bohner et al. 2012, LeGeros 1993, 
Koerten et al. 1999). Passive resorption is mainly influenced by porosity and CPC composition, 
i.e. apatite being less soluble than brushite. Brushite CPCs, however, have low mechanical 
properties and handling can be difficult due to a fast setting time (~30 s) (Tamimi et al. 2012).
Different material properties can influence the regenerative capacity of bone defects. 
Therefore, the choice of material and their properties are important. Local and patient-
specific conditions influence bone regenerative capacity and influence the material 
properties, such as degradation, as well. The relevancy of some regularly occurring local 
and patient-specific conditions that compromise bone healing are further addressed.
Compromising conditions, increasing life expectancy
Severe trauma, bone tumors, congenital malformation or extensive infection of bone tissue 
can be the cause of complex and large bone defects. Patients presenting such a defect often 
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Introduction
1 need surgical intervention to stabilise or recontruct the defect. Beside the challenge to 
succesfully overcome these complex bone defects, the situation can be further compromised 
by other local and/or systemic conditions such as soft tissue defects, osteoporosis, immune 
system malfunction, malignancy and/or diabetes. The more we age, the more we risk to 
encounter co-morbidities that might affect tissue healing and with the increased life-
expectancy of the world population, we can also expect an increase in the number of bone 
defects that need to heal under compromised conditions. We further will discuss in detail 
these challenging aspects of bone defect healing.
Critical sized defects
The term critical size bone defect is defined as an orthotopic intraosseous wound that 
does not spontaneously heal without surgical intervention (Spicer 2012). Urist concluded 
already in 1954 that there is no limited amount of time after which a pseudarthrosis cannot 
unite anymore by prolonged immobilization (Urist 1954). This suggests that even very 
large bone defects can spontaneously heal, but the prolongation of the immobilization 
sometimes expands the life time of the patient, making it a critical size defect. Urist further 
concluded that a new proliferative process begins after any surgical intervention and after 
the implantation of any type of bone graft (Urist 1954). In case of a critical size defect, bone 
grafting surgery can be performed to obtain bone healing and reduce recovery time. Since 
critical sized defects can be very large, autologous bone graft availability is often insufficient 
and other options need to be explored, such as allografts or synthetic bone graft substitutes.
Figure 2: (A) The balance between bone formation and bone resorption in osteoporotic conditions 
is disturbed in favor of bone resorption. (B) Schematic representation of trabecular bone in the rat 
femoral condyle in healthy and osteoporotic conditions, showing decreased bone mass in osteoporotic 
conditions.
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Osteoporosis is a compromised condition that can interfere with bone healing and is 
affecting a rapidly increasing number of people. In the United States, osteoporosis affects 
~10 million individuals aged >50 years, with an additional 34 million people considered to 
be at risk (Carmona et al. 2004). Worldwide, 9 million new osteoporosis-related fractures 
are estimated to occur each year (Johnell et al. 2006), two million of which occur in the 
United States alone (Burge et al. 2007). As osteoporosis is associated with an immense 
socioeconomic significance, it has been recognized as a major public health problem (Baran 
2000). Osteoporosis is a complex systemic disease characterized by a decrease of bone mass 
and associated with (i) a decreased proliferative activity of osteoblast progenitor cells and 
gene expression (Meyer et al. 2001), (ii) an impaired osteoblast function (Xiao et al. 2007), 
(iii) a diminished osteoblast response to signalling (Kubo et al. 1999), and (iv) an imbalance 
between bone formation and resorption (Hollinger et al. 2008) (Figure 2A).
In view of the increasing number of osteoporotic patients encountered in the clinics (Fini et 
al. 2004) and the limitations in quantity and quality of autologous bone transplants in these 
patients (Fini et al. 2004), the question to what extent osteoporotic bone conditions affect 
the regeneration of bone defects is important from a clinical perspective. It has already been 
reported that patients with osteoporosis present an impaired healing process of the bone 
wound (Sanfilippo et al. 2003). Osteoporosis is characterized by reduced bone mineral density 
causing lower bone mass and deterioration of bone tissue micro-architecture (Figure 2B). 
This results from an imbalance in the continuous bone remodeling process, involving bone 
formation and resorption, and an altered variety of proteins in the bone (Fini et al. 2004). 
Osteoporosis is primarily observed after menopause in women, or in elderly women and men 
(elderly women being more affected than men in a ratio of 2:1), or secondarily by chronic 
predisposing medical problems. The number of elderly people is expected to significantly 
increase over the next 50 years as will the sex ratio of the elderly population, increasing 
the number of elderly women. As osteoporosis is related to age and is more prominent in 
women, this will increase the challenges for bone grafting in the near future, which hence 
causes a major clinical problem for healthcare professionals.
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1 Main objectives and thesis outline
The main objective of this thesis was to evaluate bone regeneration using bone graft 
substitutes, both commercially available and novel materials, in healthy and compromised 
conditions using in vivo animal models. For this, we focused on evaluation of bone 
regeneration in osteoporotic conditions, challenged bone regeneration using defect size, 
and explored novel experimental bone substitute materials with appealing properties for 
stimulation of bone regeneration. This is further divided into the following objectives:
1. Evaluate the efficacy of two commercially available bone substitute materials, i.e. 
Biosilicate® and Bio-Oss®, in healthy and osteoporotic conditions at both the tissue and 
molecular level;
2. Evaluate the efficacy of calcium phosphate cement with porogens for healing bone defects 
in healthy and osteoporotic conditions;
3. Evaluate bone regeneration and material degradation by altering the PLGA porogen 
content in calcium phosphate cement;
4. Challenge bone regeneration by introducing demineralized bone matrix as bone substitute 
material into a critical sized calvarial bone defect;
5. Evaluate bone regeneration using an “enhanced” novel material by adding alendronate 
into calcium phosphate cement in osteoporotic conditions;
6. Evaluate bone regeneration in a critical size defect under osteoporotic conditions using 
an experimental bone substitute material (a self-healing hydrogel containing BP and 
calcium phosphate) with BMP-2.
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CHAPTER 2
Bone regeneration and gene 
expression in bone defect 
under healthy and osteoporotic 
bone conditions using two 
commercially available bone 
graft substitutes
van Houdt CIA, Tim CR, Crovace MC, Zanotto ED, Peitl O, Ulrich DJO, Jansen 
JA, Parizotto NA, Renno AC, van den Beucken JJJP.
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Bone tissue is continuously being turned over and possesses substantial regenerative 
capacity 1,2. Surgical intervention for bone defects can aid bone healing, for which autologous 
bone graft (i.e. transplantation) remains the golden standard 3,4. However, drawbacks for this 
procedure are increased donor site morbidity, the limited amount and quality of autologous 
bone available, and a prolonged surgical time 3-7. To overcome these disadvantages, research 
has focused on the development of either organic or synthetic bone substitutes to replace 
the need for autologous bone grafting 3,6.
Especially in compromised conditions such as infections, malignancy or increased age 
of the patient, bone healing is impaired and requires surgical intervention. Osteoporosis 
is such a compromised condition that can interfere with bone healing and is affecting a 
rapidly increasing number of people. In the United States, osteoporosis affects ~10 million 
individuals aged >50 years, with an additional 34 million people considered to be at risk 8. 
Worldwide, 9 million new osteoporosis-related fractures are estimated to occur each year 9, 
two million of which occur in the United States alone 10. As osteoporosis is associated with 
an immense socioeconomic significance, it has been recognized as a major public health 
problem 11. Osteoporosis is a complex disease characterized by a decrease of bone mass and 
associated with (i) a decreased proliferative activity of osteoblast progenitor cells and gene 
expression 12, (ii) an impaired osteoblast function 13, (iii) a diminished osteoblast response 
to signalling 14, and (iv) an imbalance between bone formation and resorption 15.
To summarise, compromised patients such as those suffering from osteoporosis could benefit 
greatly from the use of bone graft substitutes with enhanced osteogenic activity. From a 
bone substitute material perspective, interaction of the material with bone tissue should 
favour bone regenerative processes for compromised patients 16,17. Several bone substitute 
materials are commercially available for clinical applications nowadays. Worldwide, 
research is performed to enhance the properties of bone substitute materials and hence 
their biological performance 18. Bio-Oss®, made from the mineral part of bovine bone, 
is a well-established bone substitute material and represents the major clinically-used 
product for dental bone regeneration 19. It has been documented that Bio-Oss® promotes 
osteogenesis in vitro 20,21. During the production process, the organic parts are removed from 
the bovine bone and the remaining calcium-containing bone structures are processed to 
slowly degradable granules 22. Furthermore, many approaches have explored the potential 
of materials with a high bioactivity rate, such as bioactive glasses (BGs) and glass-ceramics 
(BGCs), for bone regenerative applications 23-25. BGCs, including Biosilicate®, are synthetic 
silica-based bioactive materials, with the unique ability to directly bond to bone tissue, 
making these materials appealing for bone regeneration 25-28. Research results indicate that 
upon degradation of such a silica-based material, silicon, calcium (Ca2+), phosphate (PO42-), 
and sodium (Na+) ions are released in the physiological environment and suggest that a 
combination of these ions stimulates cells to form new bone tissue 29. Biosilicate® is a novel 
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bone substitute glass-ceramic (crystalline) material and there are various studies underlining 
its suitability for bone replacement and potential to facilitate new bone formation 30-32. For 
example, Granito et al. 30,31 investigated the effects of Biosilicate® with 2 different particle 
size distributions (180–212 µm and 300–355 µm) on bone healing in a tibial bone defect 
model in rats. At 20 days after implantation they observed that bone defects filled with 
particles of Biosilicate® (180–212 µm in diameter) showed a higher amount of newly formed 
bone in the area of the callus and improved biomechanical properties compared to (empty) 
control animals and to animals treated with original 45S5 Bioglass®. Furthermore, molecular 
biology studies have shown that a solution containing Ca, P and Si ions stimulates gene 
expression (of amongst other growth-related genes, cell adhesion receptor genes, and matrix 
metalloproteinase genes) in osteoblasts 33.
Pre-clinical testing of newly developed bone substitute materials is generally done using 
healthy animals. In view of the heterogeneity of patients that require bone regenerative 
treatment, these studies do not provide information on bone substitute material 
performance in compromised bone conditions, such as in osteoporotic bone. In view of the 
lack of knowledge on the performance of clinically available bone substitute materials in 
different bone conditions, we aimed at comparatively using a rat femoral condyle bone defect 
model for rats that had either or not undergone ovariectomy to induce an osteoporotic bone 
condition 34. Within the created bone defects in healthy and osteoporotic bone, we used 
Biosilicate® or Bio-Oss® and evaluated the biological performance of these bone substitute 
materials as well as their effects on in vivo gene expression. Additionally, we evaluated the 
in vitro cellular response to these bone substitute materials.
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Biosilicate® (fully crystallized bioactive glass ceramic of the quaternary Na2O-CaO-SiO2-P2O5 
system, containing weight percentages of respectively 23.75%, 23.75%, 48.5% and 4%) was 
provided by Vitreous Materials Laboratory, Department of Materials Engineering, Federal 
University of São Carlos (São Carlos, São Paulo, Brazil) 35. Bio-Oss® was purchased from 
Geistlich Pharma AG (Wolhusen, Switzerland). The materials used were in the form of dense 
particles (size: 0.25-1 mm).
In vitro biological response to Biosilicate® and Bio-Oss®
Cell culture
Cryo-preserved rat bone marrow stromal cells (BMSC) were employed in this study. BMSCs 
were grown in Minimum Essential Medium (MEM-α; Gibco BRL, Life Technologies, Breda, 
the Netherlands) supplemented with 10% foetal bovine serum (FBS; Gibco), and penicillin/
streptomycin (100 units/ml; Gibco). All tissue culture procedures were performed under strict 
aseptic conditions in a biological safety cabinet. BMSCs were grown in sterile, vented, tissue 
culture flasks (75 cm2; Greiner Bio-one, Utrecht, the Netherlands) in a humidified incubator 
at 37°C in 5% carbon dioxide (CO2), 95% air. The cells were expanded for five passages using 
standard tissue culture techniques.
Pre-incubation of Biosilicate® particles and cell seeding
Prior to cell seeding, Biosilicate® (0.025 grams) was placed in 24-well ThinCert™ cell culture 
inserts (Greiner Bio-one) and incubated in tissue culture growth medium supplemented 
with 25 mM HEPES (Sigma-Aldrich, Zwijndrecht, Netherlands) and 10% FBS (Gibco) at 37°C, 
5% CO2 for at least 48 hours, in order to decrease the pH of the medium to allow for cell 
culture. After this period, the medium was discarded. This pre-incubation of Biosilicate® 
is needed, because the ion exchange reaction which are known to occur at the surface of 
bioactive glasses in physiological environment can lead to an increase of media pH with 
cytotoxic effects 36. Bio-Oss® particles (0.025 grams) were also placed in 24-well ThinCert™ 
cell culture inserts (Greiner Bio-one), but without the need of pre-incubation. Subsequently, 
BMSCs were seeded in direct contact with the particles at a density of 20.000 cells/insert. Cell 
culture medium was changed every 2-3 days, and the cells were cultured for up to 28 days.
Determination of cell metabolic activity
Cell metabolic activity was evaluated using AlamarBlue® (Invitrogen, Life Technologies, Breda, 
the Netherlands) according to the manufacturer’s instructions. Briefly, AlamarBlue® (1 ml) 
was added directly to BMSCs in cell culture media (n=8) and the plate was incubated for 4 
hours at 37°C in a cell culture incubator. Subsequently, 200 μl of each sample was transferred 
to a 96 well plate (in duplicates). Finally, the plate was read in a spectrophotometer (Bio-Tek 
Instruments, Winooski, United States) at 570 nm.
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Cell proliferation
Cell proliferation was determined by quantifying the amount of DNA (QuantiFluor® dsDNA 
quantitation kit; Promega, Leiden, the Netherlands). After 7, 14 and 28 days of culture, 
BMSCs were washed with PBS (n=8), homogenized in ultrapure water (1 ml), frozen, and 
thawed twice before analysis. Then, the DNA sample (100 µl) or standard was incubated 
with working solution (100 µl) in the dark for 10 minutes. Finally, the samples were read in 
a spectrophotometer (Bio-Tek Instruments) at 530 nm.
ALP activity
The specific activity of alkaline phosphatase (ALP) was assayed by the use of an ALP activity 
assay (Sigma). Briefly, 80 µl sample (n=8) or standard (serial dilutions of 4-nitrophenol at the 
concentrations of 0–25 nM) and 20 µl buffer solution (0.5 M 2-amino-2-methyl-1-propanol) 
were added into a 96-well plate. Then, a substrate solution (p-nitrophenyl phosphate; 100 
µl) was added to all the wells and subsequently the mixture was incubated at 37°C for 
1 hour. The reaction was stopped by adding of 0.3M NaOH (100 µl), and the ALP activity 
was measured in a spectrophotometer (Bio-Tek Instruments) at 405 nm with subsequent 
normalization for DNA content.
Calcium content
After 7, 14, and 28 days of culture, the amount of deposited calcium by BMSCs (n=8) was 
quantified using the ortho-cresolphthalein complexone method (Sigma). Briefly, cell layers 
were washed twice with PBS, and then incubated in 0.5 N acetic acid (1 ml) on a shaking 
platform overnight. For analyses, a sample (10 μl) or standard was incubated with work 
reagent (300 µl) in a 96-well plate at room temperature for 10 minutes. The standards (0 - 100 
mg/ml) were generated by serial dilutions of a CaCl2 stock solution. Finally, the plate was read 
in a spectrophotometer reader (Bio-Tek Instruments) at 570 nm. Negative control reactions 
with particles (Biosilicate® and Bio-Oss®) without cells were also included in each assay 
and it was used to normalize deposition calcium data. 
Scanning electron microscopy (SEM)
On days 7, 14 and 28 days post-seeding, biomaterial particles with attached cells were washed 
twice with PBS and fixed for 10 minutes using glutaraldehyde (2% in 0.1 M cacodylate buffer). 
Subsequently, the samples were washed with 0.1 M cacodylate buffer (pH 7.4) and dehydrated 
in graded series of ethanol. Finally, samples were dried with tetramethylsilane (Sigma), 
sputter coated with gold and examined using a scanning electron microscope (JEOL 6310, 
Nieuw-Vennep, the Netherlands).
RNA isolation
Total RNA was isolated from the cells using TRIzol reagent (Invitrogen) (n=5 per group) 
according to the manufacturer’s instructions. In brief, after removing the culture medium, 
TRIzol reagent (1 ml) was added to each well. The cell extract was mixed vigorously with 
chloroform (0.2 ml) and centrifuged at 12,000 g for 15 minutes at 4°C. The aqueous phase 
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of the sample was collected and mixed with 100% isopropanol (0.5 ml). After incubation at 
room temperature for 10 minutes, the extract was centrifuged and then washed with 75% 
ethanol. Successively, the RNA pellet was dissolved in RNase-free water and concentration 
and purity were determined using the NanoDrop (ND-2000; Thermo Scientific, Waltham, MA 
USA). RNA samples with an A260/A280 ratio <1.8 were excluded.
Real-time PCR
Total RNA (1 µg) was applied as template for cDNA synthesis using the iScript cDNA synthesis 
kit (Bio-Rad, Veenendaal, the Netherlands) following the manufacturer’s instructions. The 
cDNA samples were subjected to quantitative real time polymerase chain reaction (qRT-PCR) 
using a BIORAD CFX96 real-time system.
Oligonucleotide primers were designed for RPS18 (NM_181374.2), Runx-2 (NM_053470.2), 
alkaline phosphatase (ALP) (J03572.1), Osteocalcin (OC) (NM_013414.1) (Table 1) using Primer 
Express Software 2.0 (Applied Biosystems, Foster City, USA). All real-time primers were initially 
tested against standards and a standard curve was generated.
The optimized PCR conditions were: initial denaturation at 94°C for 10 minutes, followed by 
40 cycles consisting of denaturation at 94°C for 15 seconds, annealing at 60°C for 1 minute, 
and extension at 72°C for 45 seconds, with a final extension step at 72°C for 2 minutes. 
Negative control reactions with no template (deionised water) were also included in each 
run. For each gene, all samples were amplified simultaneously in duplicate in one assay run. 
Analysis of relative gene expression was performed using the 2-∆∆CT method. RPS18 was 
used as a housekeeping gene to normalize expression data.
Animal experiment 
Animal model and validation
For this experiment, 36 mature female Wistar rats were used (weight ~250 g; Charles River 
Nederland B.V., Leiden, The Netherlands). A 1-week acclimatization period was maintained 
in standard housing (i.e. 2 rats per box). All rats received two surgical procedures during 
the course of the experiment: the first surgery was a bilateral ovariectomy (OVX; 19 rats) to 
induce an osteoporotic bone condition or a sham operation (SHAM; 17 rats) for a healthy 
bone condition; in the second surgery, bone defects were created in both femoral condyles 
(bilateral) of all animals, which were left empty as control or filled with Biosilicate® or 
Bio-Oss®. Access to food and bottled water was maintained ad libitum. All experiments 
were in accordance with institutional, national and international guidelines for animal care 
and the Dutch law concerning animal welfare. The studies were reviewed and approved in 
advance by the Experimental Animal Committee of the Radboud University (RUDEC 2013-187).
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Surgery to induce osteoporotic condition
Nineteen animals received an ovariectomy (OVX) through two separate incisions in the lateral 
abdominal wall 34. The remaining seventeen rats received a sham surgery (SHAM) using an 
identical surgical approach as for the other animals without removal of the ovaries. Pre-
operatively, pain medication was provided 15 minutes before surgery by injecting Carprofen 
(5 mg/kg; Rimadyl®, Pfizer Animal Health, New York, USA). Anaesthesia was induced and 
maintained by isoflurane inhalation (2-5%; Rhodia Organique Fine Limited). The back area 
was shaved and disinfected with a povidone iodine solution. The animal was placed on an 
electric heating mat in prone position to prevent hypothermia. A dorsal midline incision (~2 
cm) caudal to the posterior border of the ribs was created to enter the abdominal cavity. 
The ovary was located in a fat pad and gently pulled outside the abdominal cavity. A single 
ligature was placed around the fallopian tube using a surgical polyester suture (Terylene® 
2.0 undyed, Serag-Wiessner GmbH & Co, Naila, Germany). The ovary was removed by cutting 
above the ligated area and after haemostasis the tuba was returned into the abdomen. 
The abdominal muscles were closed with continuous absorbable sutures (Vicryl® 4.0, 
Ethicon, Amersfoort, the Netherlands) after which the skin was sutured with multiple single 
absorbable sutures (Vicryl® 4.0, Ethicon). The procedure was repeated for the contro-lateral 
ovary using the same incision design. Postoperative pain medication for a minimum of 2 
days was provided by injection of Carprofen every 24 hours and Buprenorfine (0.02 mg/kg; 
Temgesic®, Reckitt Benckiser Health Care Limited) every 12 hours. To ensure progression 
toward an osteoporotic bone condition, the OVX group received a low calcium diet of 
pellets containing 0.01% calcium and 0.77% phosphorous (Ssniff Spezialdiäten GmbH, Soest, 
Germany) for six weeks, whereas the SHAM group received no dietary restrictions.
Surgery for femoral bone defect and material implantation
Six weeks after OVX or SHAM surgery, a bone defect was created in both femoral condyles of 
each animal. Anaesthesia and pain medication were administered as described for the first 
operation. Both hind limbs of the rats were shaved and disinfected with povidone iodine. 
The rats were immobilized in supine position on a heating mat. A longitudinal incision 
through skin and muscle was made on the medial surface of the knee in flexed position. 
After exposure of the medial side of the distal femoral condyle the knee capsule was incised. 
By extension of the knee, luxation of the patella laterally was possible. When a clear view of 
the femoral side of the knee joint was established, a defect longitudinal to the length of the 
femur (Ø 2.5 mm by 6 mm in depth) was created. To create the defect, a dental drill (Elcomed 
9927 SPS; W&H Dentalwerk Burmoos GmbH, Burmoos, Austria) with a series of increasing 
bur diameters were used at a speed of maximum 5000 rpm and a constant cooling using 
saline. The defect was either left empty as control or filled with Biosilicate® or Bio-Oss®. The 
muscular layer and skin were closed with single resorbable sutures (Vicryl® 4.0 Ethicon). After 
implant surgery, both experimental groups (SHAM and OVX) had free access to normal pellet 
food and water. The animals were housed per pair under the same conditions. In the initial 
postoperative period, the intake of water and food was monitored as well as the weight of 
the animals. In addition, the animals were observed for signs of pain, infection and proper 
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activity and weighed again postoperatively once a week to identify significant weight loss 
(>20%) compared to preoperative body weight of each rat.
Validation of osteoporotic condition by ELISA for serum TRAP analysis
The osteoporotic condition by OVX was evaluated by a serum analysis for TRAP enzyme 
activity performed with the RatTRAPTM Assay kit (Immunodiagnostic Systems GmbH, Frankfurt 
am Main) at the end of the experiment, 4 weeks after implantation surgery.
Retrieval of specimens
The femurs were retrieved 4 weeks after implantation surgery. The femurs used for gene 
expression of both osteoporotic (n≥6) and healthy conditions (n≥5) were placed on ice for 
transport and immediately processed for RNA isolation. The femurs needed for histology 
of both osteoporotic (n≥5) and healthy conditions (n≥4) were immediately fixed in 10% 
formaldehyde for 24 hours, and then dehydrated in 70% ethanol. After dehydration, one 
femur of each group was scanned by micro-CT, then all femurs for histology were embedded 
in polymethylmethacrylate (pMMA), prepared by mixing methylmethacrylate (600 ml; Acros 
Organics BVBA, Geel, Belgium) with dibutyl phthalate (60 ml; Merck KGaA, Darmstadt, 
Germany) and Perkadox 16 (1.25 g; AkzoNobel, Amersfoort, The Netherlands).
Micro-CT
A desktop micro-CT system (Skyscan-1072, TomoNT version 3N.5, Skyscan®, Kontich, Belgium) 
was used for 3D imaging. The specimens were placed with the long axis of the implant 
perpendicular to the scanning beam, after which a high resolution scan was performed. 3D 
reconstruction and imaging processing was performed using NRecon V1.4 and CTvox v2.7 
(Skyscan®), respectively.
Histology
After polymerization, thin sections (~10-15 μm) in perpendicular to the longitudinal direction, 
were prepared using a diamond blade microtome (Leica® Microsystems SP 1600, Nussloch, 
Germany). A minimum of three sections of each specimen were stained with methylene blue 
and basic fuchsine and examined using light microscopy (Leica® Microsystems AG, Wetzlar, 
Germany).
Histomorphometry
Using an imaging microscope (Axio Imager Microscope Z1, Carl Zeiss Micro Imaging GmbH, 
Göttingen, Germany), the pMMA-embedded histological sections were digitalized (5x 
magnification). Quantitative analysis of the digitalized images was performed using ImageJ 
software (Java® ImageJ 1.47, Image processing and analysis in Java). Within a circular region 
of interest (ROI) with an equal diameter (2.5 mm) to the created bone defects, the amount 
of newly formed bone was determined. Vital bone could be distinguished by the pink colour 
and distinctive cell morphology including a nucleus, allowing to be easily discerned from 
other tissues as wells as from Biosilicate® and Bio-Oss® particles. The maturity of bone was 
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differentiated by morphology, as mature trabecular bone is formed in lamellae, whereas 
newly formed bone has a more woven structure. Detection of different cell types could be 
performed as osteocytes are trapped within the lacunae of bone, osteoblasts are arranged in 
rows with basophilic eccentric nuclei and osteoclasts are relatively larger and multinucleated 
cells.
In vivo gene-expression
For RNA isolation, the femurs were dissected and the bone defect area was trephined (inner 
diameter of 2.5 mm) using drilling equipment (Weiss Machine WMD20LV, Jiangsu Province, 
China). The retrieved tissues were placed in sterilized microtubes (1.5 ml) and frozen at -80°C 
until analysis. To facilitate processing of multiple samples, the Bullet Blender (Next Advance, 
New York, United States) was used with centrifuge technology that homogenizes tissue 
by bead disruption of the tissue. The bone sample was added to a pre-chilled microtube 
containing the beads recommended by the manufacturer for RNA isolation (~50 μl stainless 
steel blend, 6 x 3.2 mm stainless steel) followed by the addition of TRIzol reagent (600 μl; 
Invitrogen). The bone was homogenized in the Bullet Blender (Next Advance) centrifuge 
(kept in a cold room at 4°C) for 5 minutes, then the solubilised bone extract was isolated 
by centrifugation for 15 seconds at 8.600 rpm at room temperature and the solution was 
transferred to a new microtube. Then, the RNA protocol was performed using TRIzol reagent 
according to the manufacturer’s instructions.
The cDNA and real time PCR procedures were performed as described above for in vitro 
experimental work. In addition to the primers used for in vitro experimental work, primers 
for osteoprotegerin (OPG; NM_012870.2) and RANKL (AF187319.1; Table 1) were used.
Table 1: Primers and the expected PCR product size at indicated annealing temperatures for each 
gene analyzed. RPS18: ribosomal protein S18; Runx-2: runt-related transcription factor 2; ALP: alkaline 
phosphatase; OC: Osteocalcin; RANKL receptor activator of nuclear factor kappa-B ligand; OPG: 
Osteoprotegerin.
Gene Forward primer Reverse primer Annealing temperature 
RPS18 GTGATCCCCGAGAAGTTC AATGGCAGTGATAGCGAA 60 °C
Runx-2 TTATGTGTGCCTCCAACCTGTGT GGTTTCTTTCCCCCTCAATTTGT 60 °C
ALP AACTACATCCCCCACGTCATG CCCAGGCACAGTGGTCAAG 60 °C
OC ACGAGCTAGCGGACCACATT CCCTAAACGGTGGTGCCATA 60 °C
RANKL CCGTTTGCTCACCTCACCAT TGGTACCAAGAGGACAGACTGACTT 60 °C
OPG GATATTGCCCCCAACGTTCA AGGGCGCATAGTCAGTAGACACT 60 °C
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Data are presented as mean with SDs. Statistical analysis of quantitative data was performed 
using one-way analysis of variance (ANOVA) with a Tukey post-hoc test. GraphPad Software 
(PRISM; La Jolla CA, USA) was used to carry out the statistics analysis. For a comparison 
between both conditions and for the analysis of the serum TRAP enzyme, a one-tailed 
student t-test was used. Values of p<0.05 were considered statistically significant.
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Results
In vitro biological response of Biosilicate® and Bio-Oss®
The metabolic activity of rat bone marrow stromal cells (BMSCs) seeded on the materials 
and control samples showed a temporal evolution during the culture period. On days 7, 14 
and 28, the cell metabolic activity was significantly higher for controls (on tissue culture 
plastic) compared to either Biosilicate® or Bio-Oss® (p<0.001; Figure 1 (a)). Furthermore, the 
cell metabolic activity of rat BMSCs on Biosilicate® was significantly increased compared 
to Bio-Oss® on both day 7 and 28 (p<0.001; Figure 1 (a)). For cell proliferation (Figure 1 (b)), 
controls showed significantly increased DNA-content values (p<0.001) compared to both 
Biosilicate® and Bio-Oss® at each time point. As a marker for early osteogenic differentiation, 
ALP-activity showed a peak for both Biosilicate® and Bio-Oss® on day 14 (Figure 1 (c)), 
whereas a continuous increase in ALP-activity was observed for controls. BMSCs cultured 
on Biosilicate® showed a significantly increased ALP-activity compared to controls at day 
14 (p<0.001) and compared to Bio-Oss® at 28 days (p<0.05). As a marker for late osteogenic 
differentiation, extracellular calcium deposition (Figure 1 (d)) on both Biosilicate® and Bio-
Oss® was significantly higher (p<0.001) compared to controls at all time points. Further, cells 
in contact with Biosilicate® deposited more calcium by day 14 and 28 compared to Bio-Oss® 
(p<0.001). Morphologically, SEM analysis showed that rat BMSCs were successfully grown on 
Biosilicate® and Bio-Oss® particles at all time points (data not shown). 
Real time PCR 
Figure 2 (a-b) represents the gene expression data of rat BMSCs cultured on Biosilicate®, 
Figure 1 (a-d): In vitro biological response analysis (mean ±SD; n=8); (a) Cell metabolic activity. (b) DNA 
content (cell proliferation). (c) ALP-activity (as a marker of early differentiation). (d) Calcium content (as 
a marker of late differentiation); * p< 0.05, *** p< 0.001
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Bio-Oss®, and tissue culture plastic controls after culture for 7, 14 and 28 days. Significantly 
increased Runx-2 expression (Figure 2 (a); p<0.05) was observed for rat BMSCs cultured on 
Biosilicate® compared to controls after 14 days. For rat BMSCs cultured on Biosilicate® and 
Bio-Oss®, the expression of OC (Figure 2 (b)) was significantly increased compared to controls 
after 7 and 14 days (p<0.05) and 28 days (p<0.05), respectively. Similar ALP gene expression 
levels were observed for all experimental groups (Figure 2 (c)). 
Figure 2 (a-c): In vitro results of the relative quantification of gene expression levels from BMSCs (n=8), 
mean ±SD; (a) Runx-2 gene-expression (b) OC gene-expression (c) ALP gene-expression; * p<0.05
Figure 3: Serum TRAP enzyme activity (mean 
±SD) in rats with osteoporotic and healthy 
bone condition (n=5); *** p<0.001
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Animal experiment
Animal model and validation
Validation of the osteoporotic condition in this study was performed by a serum TRAP ELISA 
analysis. Our data showed that rats with osteoporotic bone condition had significantly 
decreased serum TRAP enzyme activity (p<0.0001) compared to healthy rats (Figure 3). 
Clinical observations after OVX and bone defect surgery showed that SHAM surgery led to 
euthanisation of one rat, due to >20% weight loss in the first week postoperatively related to 
intestinal problems. Upon implantation surgery, two rats (one OVX, one SHAM) were euthanized 
due to fracture of the femur during the drilling of the bone defect. All remaining rats recovered 
without clinical signs of complications and remained healthy during course of the experiment. 
Micro-CT
An overview of 3D reconstructed bone defects from ex vivo micro-CT is presented in Figure 4, 
showing sagittal, frontal and transverse planes through the defect area for each experimental 
group after 4 weeks of implantation. The images provide information on the amount and 
space between trabecular bone as well as the distribution of and space between the 
particles. 
Figure 4: Representative 3D-reconstructions of the defect area obtained via ex vivo micro-CT
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Representative histological images at 4 weeks after implantation for each of the 
experimental groups are presented in Figure 5. Histological differences were observed 
between osteoporotic and healthy bone conditions regarding the amount and spacing of 
the trabecular bone outside the ROI. The space between the trabeculae was filled with bone 
marrow. The empty defects clearly showed that bone regeneration starts at the edges of 
Figure 5: Images of histological slides of osteoporotic and healthy conditions with detailed images (black 
box), yellow circle= ROI (equal to defect of 2.5 mm), BS= Biosilicate® particles, BO= Bio-Oss® particles; 
arrows indicate the Biosilicate® silica-layer
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the defect, growing inwards. The circumference of Biosilicate® and Bio-Oss® particles was 
mostly covered with newly formed bone, all the way to the centre of the defect. This shows 
the osteoconductive properties of both Biosilicate® and Bio-Oss®, as this was never reached 
by the empty defects in the osteoporotic conditions. Our histological images clearly showed 
a gel-like layer to be present on the Biosilicate® particles implanted in both conditions 
(black arrows in Figure 5). 
Histomorphometry
Quantitative histomorphometry showed material new bone formation around the Biosilicate® 
and Bio-Oss® particles with remnant amounts for both osteoporotic and healthy conditions 
compared to empty controls (Table 2 & Figure 6 (a-c)). Osteoporotic conditions lead to bone 
formation (means with SDs) of respectively 5±8%, 11±4% and 15±5% for the empty control, 
Biosilicate® and Bio-Oss®, compared to respectively 20±9%, 14±5% and 16±4% in healthy 
conditions. For the empty defects, a significant difference (p<0.05) for bone formation was 
seen between the osteoporotic and healthy conditions, again underlining the systemic effect 
of OVX surgery. 
Real time PCR
To progress in the understanding of the mechanisms by which the process of bone healing is 
influenced in the presence of Biosilicate® and Bio-Oss®, an evaluation of gene expression for 
bone formation-related genes was performed. Expressions of the selected osteogenic genes 
in osteoporotic and healthy conditions are shown in Figure 7 (a-e), measured at 4 weeks 
after implantation of Biosilicate® and Bio-Oss®. The relative gene expression showed that in 
osteoporotic conditions, Biosilicate® increases Runx-2, ALP, OC, OPG and RANKL expression. 
Bio-Oss® did not up-regulate either of the selected genes in osteoporotic conditions 
compared to controls. In healthy conditions, Biosilicate® demonstrated an up-regulation of 
Runx-2, ALP, OC and RANKL, while Bio-Oss® up-regulated only Runx-2, ALP and RANKL gene 
expression. Between the materials significantly more expression of Runx-2 and RANKL was 
seen for Biosilicate® in osteoporotic conditions and of OC and RANKL in healthy conditions.
Table 2: Percentages (mean ±SD) of new bone formation within the ROI of osteoporotic (n≥5) and healthy 
conditions (n≥4); significant difference compared to the osteoporotic control group; * p<0.05, ** p<0.01
Control Biosilicate® Bio-Oss®
Mean SD mean SD mean SD
Osteoporotic condition 5 ± 8 11 ± 4 15* ± 5
Healthy condition 20** ± 9 14 ± 5 16 ± 4
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Figure 6 (a-c): (a) Percentage (mean ±SD) of new bone formation and material remnants within ROI 
of osteoporotic (n≥5) and healthy conditions (n≥6) (b) new bone formation with addition of material 
remnants within ROI of osteoporotic and (c) healthy conditions; * p<0.05, a p<0.01
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 37
37
Bone regeneration and gene expression under healthy and osteoporotic bone conditions
2
Figure 7 (a-e): In vivo results (mean ±SD) of the relative quantification of gene expression in osteoporotic 
(n≥6) and healthy conditions (n≥5); (a) Runx-2 gene-expression. (b) ALP gene-expression (c) OC gene-
expression (d) OPG gene-expression (e) RANKL gene-expression; * p<0.05, ** p<0.01 and *** p<0.001, b) 
p<0.01 and c) p<0.001 compared to osteoporotic condition of same material
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The biological performance as well as the effects on in vivo gene expression of Biosilicate® 
and Bio-Oss® were comparatively examined using a rat femoral condyle bone defect model 
for rats that had either or not undergone ovariectomy to induce an osteoporotic bone 
condition 34. Additionally, we evaluated the in vitro cellular response to these bone substitute 
materials.
Our in vitro experiments showed BMSCs can proliferate on tissue culture plastic. More 
importantly however, the addition of Biosilicate® and Bio-Oss® stimulated osteogenic 
differentiation compared to controls. These data corroborates the results of Ozawa et al. 37 
showing stimulated osteogenic differentiation of rat BMSCs upon culturing rat bone marrow 
cells on hydroxyapatite (HA). When cultured on Biosilicate®, there was significantly more 
mineralization compared to Bio-Oss®, suggesting Biosilicate® to have more osteogenic 
potential in vitro. These findings are supported by the study by Renno et al. 38, who using in 
vitro experiments observed that osteogenic cells were successfully grown on Biosilicate® 
scaffolds. Moreover, the study by Herten et al. 39 showed, when seeding cells on Bio-Oss® 
granules, a smaller number of viable osteoblasts were detectable on the granules compared 
to other bone graft substitutes.
A significant up-regulation of Runx-2 was induced in vitro by Biosilicate® after 14 days. 
Although in our study Bio-Oss® did not induce an up-regulation of Runx-2, Sollazzo et al. 40 
showed that cells cultured on Bio-Oss® for 7 days increase the osteoblast transcriptional 
factor Runx-2 together with other bone-related genes, i.e. SPP1 and FOSL1. Both Biosilicate® 
and Bio-Oss® increased the expression of OC, which corroborates with our biochemical 
results showing an increased mineralization compared to controls.
For evaluation of the effect of osteoporosis on bone healing in animal studies, several animal 
models have been utilized 41,42. The ovariectomised rat model is a well-established small 
animal model for local osteoporosis 41-44. Ovariectomy leads to estrogen deficiency and hence 
mimics post-menopausal osteoporosis. Since dietary factors play an important role in the 
multi-factorial nature of bone loss, an additional low calcium diet can further establish the 
osteoporotic effect 34,45. Previous studies based on in vivo micro-CT analysis demonstrated 
significant effects on bone density and morphological characteristics within the femoral 
condyles of rats at six weeks after ovariectomy and a low calcium diet 34.
Our serum analysis results for TRAP enzyme activity are in agreement with the study of 
Rissannen et al. 46, who also showed significantly lower serum TRAP-activity in the OVX 
operated rats. Serum TRAP is a marker for the bone homeostasis, providing information 
about bone resorption, as the TRAP enzyme activity is derived exclusively from osteoclasts 
46. The amount of active osteoclasts on a systemic level is indicated by serum TRAP-activity. 
Initially, serum TRAP-activity is expected to rise after OVX surgery, because bone resorption is 
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increased. However, due to the resorption the absolute number of osteoclasts is significantly 
decreased, consequently lowering TRAP-activity in serum 46. The additional value of serum 
TRAP analysis has over in vivo micro-CT, is to confirm that the osteoporotic condition is still 
effective locally at defect site (created 6 weeks post-ovariectomy) and even systemically after 
an additional implantation period of 4 weeks.
Images from ex vivo micro-CT 3D reconstructions provide information on the amount 
and space between trabecular bone as well as the distribution of and space between the 
particles. An osteoporotic condition had apparently less trabecular bone compared to 
healthy condition and the trabecular spacing appeared larger. Filling of the defects with 
Biosilicate® and Bio-Oss® showed different packing, with a loose filling for Biosilicate® and 
more compact filling for Bio-Oss®. Despite similar granule sizes and amounts, granule size 
distribution differences, apparently led to packing differences in the defects 47. Also surface 
area can vary due to these granule size distribution differences. Both materials were used 
in the form available for clinical application for translational power.
The histological images clearly showed a gel-like layer on the Biosilicate® particles implanted 
in both conditions. It is well known that bioactive glasses (BG) undergo a series of reactions 
following implantation 47. Release of ions (Si, Na, Ca and P) occurs immediately upon contact 
of BG with fluids, resulting in an increased pH 23,47,48. Dissolution and repolymerisation of silica 
occur to form a silica gel on the surface. Amorphous calcium phosphate nucleates and grows 
onto and into the SiO₂-rich layer. With time, the CaO-P₂O₅ mineral incorporates carbonate 
and hydroxyl species from the ambient fluid, and hydroxycarbonate apatite (HCA) crystallizes. 
This layer is a necessary requirement for bone bonding to occur 17.
In the osteoporotic conditions, Bio-Oss® significantly improved bone formation. Several 
studies on Bio-Oss® already described the excellent in vivo performance of this bone graft 
material 49,50. The in vivo results of this study demonstrate that local osteogenic effects are 
significantly induced by Bio-Oss® compared to empty defects. The surfaces of the Bio-Oss® 
granules provide a source of calcium ions, possibly facilitating bone formation around the 
granules 51.
For the healthy condition, both Biosilicate® and Bio-Oss® did not improve bone formation, 
showing the limits of using bone substitute materials in non-critical sized defect in healthy 
conditions. Because trabecular bone is spaced, to calculate the maximal amount of bone 
normally present in that area of the femur, a reference measurement could be taken from 
undamaged bone. This was performed earlier in the study of van de Watering et al. 52, where 
a femoral condyle defect was used filled with injectable calcium phosphate cement. Bone 
formation was calculated and comparatively evaluated to the contra lateral undamaged 
bone. These bone volumes were 43 ±3% and 32 ±2% at 4 weeks after ovariectomy respectively 
for healthy and osteoporotic bone conditions (unpublished data by van de Watering et al. 
2013), using a similar strain of rats and dietary protocol as in our study. Our results show 
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that bone formation has not reached the optimal amount after 4 weeks, because even for 
the empty bone defects a lower amount of bone area was detected. To understand more 
about the long term results, a second and later time point is needed.
Bioactive glasses and glass-ceramics, including Biosilicate®, belong to the third 
generation of biomaterials that are able to stimulate bone regeneration by cell response 
at a molecular level 29,33,47. Our study confirms the positive effect of Biosilicate® at a 
molecular level by an increased relative expression of Runx-2, ALP, OPG, OC and RANKL. 
However, by histomorphometry bone formation was not increased significantly compared 
to Bio-Oss®. These results are in line with the study of Välimäki et al. 48, who found that 
bioactive glass-ceramics not only promote osteoblastic functions, but also osteoclastic 
bone resorption and thereby enhancing bone turnover. Our study showed a significant 
up-regulation of osteoclastic RANKL expression by Biosilicate®, leading to a stimulation 
of osteoblasts enhancing bone turnover. The exact underlying mechanism of this effect 
remains unclear, but an enhanced bone turnover could explain why up-regulated osteogenic 
gene-expression does not lead to more bone formation. An additional explanation for the 
discrepancy between gene-expression and histomorphometric quantification is related to 
the osteoconductive capacity of both Biosilicate® and Bio-Oss®. The bone formation toward 
the centre of the defect is guided over the surface of the particulate materials, which likely 
masks the osteopromotive effects of Biosilicate®.
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Conclusions
The present study comparatively evaluated the performance of two commercially available 
bone substitutes, Biosilicate® and Bio-Oss®, by measuring in vitro biological responses and 
in vivo experiments with rats in osteoporotic and healthy bone conditions. The main in 
vitro findings showed that Biosilicate® had a favourable osteopromotive effect on rat bone 
marrow-derived mesenchymal stem cells compared to Bio-Oss®. 
While for the healthy condition, both Biosilicate® and Bio-Oss® did not improve bone 
formation, the in vivo performance of both materials showed improved bone regeneration 
in osteoporotic bone condition, particularly for Bio-Oss®. Gene-expression analysis in 
vivo showed that Biosilicate® increases the expression for both osteoblast and osteoclast 
regulating genes, while Bio-Oss® only increases expression of genes for osteoblast 
differentiation. Since both materials improved bone regeneration in osteoporotic conditions, 
these data suggest that bone defects in osteoporotic conditions can be efficiently treated 
with synthetic bone substitutes.
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An estimated number of >500,000 bone grafting procedures are performed annually in 
the United States and this number easily doubles on a global basis 1. Autologous bone 
grafting still is the gold standard despite of the disadvantages, such as shortage in the 
availability of donor tissue, donor site morbidity, and increased surgery and recovery time. 
Allografts and xenografts can be used as a substitute for autologous grafts, but have the 
disadvantage of immunological issues and an increased risk of cross-species transmission 
of viral contaminants 1. Alternatively, synthetic bone grafts have an increasing interest to 
overcome these disadvantages and worldwide endeavors are made to develop safe and 
reliable synthetic bone grafts 2, 3.
In view of the increasing number of osteoporotic patients encountered in the clinics 4 and 
the limitations in quantity and quality of autologous bone transplants in these patients 4, the 
question to what extent an osteoporotic bone condition affects the biological performance of 
bone grafts is important from a clinical perspective. It has already been reported that patients 
with osteoporosis present an impaired healing process of the bone wound 5. Osteoporosis is 
characterized by reduced bone mineral density causing lower bone mass and deterioration 
of bone tissue micro-architecture. This results from an imbalance in the continuous bone 
remodeling process, involving bone formation and resorption, and an altered variety of 
proteins in the bone 4. Osteoporosis is primarily observed after menopause in women, or by 
age in both women and men (ratio of 2:1), or secondarily by chronic predisposing medical 
problems. The number of elderly people is expected to significantly increase over the next 50 
years as will the sex ratio of the older population, increasing the number of elderly women. 
As osteoporosis is related to age and is more prominent in women, this will result in bone 
grafting in osteoporotic patients being an even greater challenge in the future, which hence 
causes a major challenge for healthcare professionals.
In view of the aforementioned, patients with bone defects suffering from osteoporosis could 
greatly benefit from synthetic bone grafts. Several ‘off-the-shelf’ synthetic bone substitutes 
are available for clinical bone regenerative treatments nowadays and worldwide research is 
done to enhance the properties of synthetic bone substitutes. For dental applications, Bio-
Oss® 6-9 is the mostly used commercially available bone substitute, consisting of devitalized 
bovine bone 8. Alternatively, calcium phosphate (CaP) based materials are synthetic inorganic 
biomaterials that show high similarity to bone tissue by resembling the mineral phase of 
bone and are already popular implant materials in several fields of surgery 10-17. Among the 
CaPs, CaP cement (CPC) is injectable and hence can be molded to perfectly fit within any 
irregularly-shaped bone defect 18. The main disadvantage of CPC is its low degradation rate 
mainly due to the inadequate intrinsic porosity of the material. By adding poly(lactic-co-
glycolic acid) (PLGA) particles to CPC, a composite system (CPC/PLGA) has been obtained 
that allows for controlled CPC degradation 19 as well as the possibility of controlled release 
of bioactive agents, e.g. osteoinductive growth factors 19.
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For the evaluation of the performance of bone substitute materials in osteoporotic 
conditions, several pre-clinical animal models are available 20-22. Osteoporotic conditions 
can be induced by either a chemical stimulation, for example by the administration of 
prednisolone 23 or via ovariectomy or orchidectomy in respectively female and male animals 
20, 21. The removal of the ovaries or testis induces a decline in estrogen or androgen levels, 
respectively, which leads to a rapid loss of cancellous bone mass and strength 20, 21. The most 
conventional osteoporotic animal model is the ovariectomized (OVX) rat, which mimics the 
bone changes in humans following menopause or oöphorectomy 20, 21, 24. Bone loss occurs first 
in trabecular bone, after which cortical bone is affected 20, 21, 24. Furthermore, the degree of 
bone loss at various trabecular bone sites occurs in different time lapses after OVX surgery 
20, 21, 24. Consequently, studying the performance of bone substitute materials in OVX rats 
requires adequate selection of timing and location.
The present study comparatively evaluated the biological performance of CPC/PLGA and the 
dental predicate device Bio-Oss® in ovariectomized and healthy rats. We hypothesized that 
osteoporotic conditions would affect the biological performance of both bone substitute 
materials. Additionally, we hypothesized that the differences in degradation rate between 
CPC/PLGA and Bio-Oss® would lead to different bone forming capacity. The assessments 
were performed by histology, histomorphometry and micro-CT after implantation periods 
of 4 and 12 weeks in rat femoral condyle bone defects.
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The chemical composition of CPC/PLGA consisted of 70 wt% milled, pure alpha tri-calcium 
phosphate (α-TCP) powder with a mean particle size of ~4.0 µm (CAM Bioceramics BV, Leiden, 
The Netherlands) and 30 wt% PLGA powder with a mean particle size of ~60 µm, containing 
both a lactic and glycolic weight percentage of 50% (manufactured at Corbion Purac®, 
Amsterdam, The Netherlands, and provided at the given particle size by CAM Bioceramics BV) 
and 0,5% carboxymethylcellulose (CMC) with a mean particle size ~106 µm (CAM Bioceramics 
BV). An aqueous solution of 4 wt% sodium dihydrogen phosphate dihydrate (NaH2PO4•2H2O) 
was used as liquid component to create the cement paste and was made by dissolving 
4.0 g of NaH2PO4•2H2O in 100 ml Milli-Q water. Bio-Oss® (Geistlich Pharma AG, Wolhusen, 
Switzerland) in the form of small granules of 0.25-1 mm was used as a dental predicate device 
after consultation of the Food and Drug Administration (FDA).
Preparation of CPC/PLGA scaffolds
To the CPC/PLGA powder fraction, a liquid solution was applied of NaH2PO4•2H2O dissolved 
in sterile distilled water, with a ratio of 750 µl solution per 1.5 g powder. Then, CPC/PLGA was 
manually mixed with a spatula and applied into a Teflon mold containing cylindrical holes 
(2.5 mm in diameter and 5 mm in height). After setting for 24 h at room temperature, CPC/
PLGA scaffolds were removed from the mold and sterilized by gamma radiation at a maximum 
of 50 kGy (SynergyHealth Ede B.V., Ede, Netherlands).
Animals
For this experiment, thirty-two healthy mature female Wistar rats were used at 3 months of 
age with an average weight of ~200 g. Animals were allowed to acclimatize for 7 days and 
housing was provided per pair in a standard macrolon type 3 cage, with sawdust as bedding 
material. In order to induce an osteoporotic condition, the rats were subjected to bilateral 
ovariectomy (OVX) or sham operation (SHAM). All rats received two surgical procedures 
during the course of the experiment, i.e. either OVX or SHAM surgery and bone defect surgery. 
Standard rodent chow and bottled tap water was provided ad libitum, except for the OVX 
group, which received a low calcium diet with pellets containing 0.01% calcium and 0.77% 
phosphorous (Ssniff Spezialdiäten GmbH, Soest, Germany). The housing room was maintained 
under standard laboratory conditions (light-dark cycle: 12:12h, temperature: 20-22°C, relative 
humidity: 45-55%). All experiments were conducted in accordance with institutional, national 
and international guidelines for animal care and the Dutch law concerning animal welfare. 
The studies were reviewed and approved by the Experimental Animal Committee of the 
Radboud University (RUDEC 2013-047).
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Methods
Surgical procedure to induce osteoporotic conditions
Sixteen randomly assigned animals received OVX surgery through two separate incisions in 
the lateral abdominal wall. The remaining sixteen rats received a SHAM surgery. The surgical 
approach was the same as for the OVX animals, exposing both ovaries but these were not 
removed.
Anesthesia was induced and maintained by Isoflurane inhalation (Rhodia Organique Fine 
Limited) combined with oxygen delivered by mask. Pre-operatively pain medication was 
provided by an injection of Carprofen (Rimadyl®, Pfizer Animal Health, New York, USA) in 
dosage of 5 mg/kg, given 15min before surgery.
After confirmation of effective anesthesia, the animal was placed on an electric heating 
blanket in prone position exposing the dorsal part of the lumbar region. The area was shaved 
with electric clippers and disinfection was performed by application of a povidone iodine 
solution. To enter the abdominal cavity a dorsal midline incision was created caudal to the 
posterior border of the ribs. The incision was approximately 2 cm in length at the midpoint 
between the costal inferior border and the iliac crest, and a few millimeters lateral to the 
lateral margin of the lumbar muscle. Using blunt dissection, the muscles of the posterior 
abdominal wall were separated. The ovary was located in a fat pad just beneath the muscles 
and exteriorized by gentle retraction using forceps. Then using a mosquito forceps, the 
fallopian tube was clamped and a single ligature was performed using a surgical polyester 
suture (Terylene® 2.0 undyed, Serag-Wiessner GmbH & Co, Naila, Germany). The ovary 
was disconnected by cutting above the clamped area and the tuba including surrounding 
fat was returned into the abdomen. After checking for hemostasis, the abdominal wall 
(peritoneum and muscle layers) was closed with continuous absorbable sutures (Vicryl® 
3.0, Ethicon, Amersfoort, The Netherlands) after which the skin was stapled by metal wound 
clips (Agraven®, InstruVet Bv, Cuijk, The Netherlands). The procedure was repeated for the 
opposite ovary using the same incision design. The SHAM group received the same surgical 
procedure except for the clamping and removal of the ovaries. For a minimum duration of 2 
days postoperatively, Carprofen was given every 24h. Additionally, to diminish postoperative 
pain, Buprenorfine (Temgesic®, Reckitt Benckiser Health Care Limited, Schering-Plough, UK) 
was given every 12h in a dosage of 0.02 mg/kg.
Validation of osteoporotic bone condition
Of six animals (3 OVX and 3 SHAM), in vivo CT images of both femoral condyles were 
acquired 6 weeks after the first surgery, using an animal micro-CT scanner (Inveon, Siemens 
Preclinical Solutions, Knoxville, TN, USA). To acquire CT images, anesthesia was induced and 
maintained by isoflurane inhalation (Rhodia Organique Fine Limited, Avonmouth, Bristol, 
UK). The animals were placed in supine position in the scanner with the legs fixed with 
tape in order for optimal acquirement of the micro-CT images (spatial resolution 30 μm, 
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80 kV, 500 μA, exposure time 1000 ms). Projected files were then reconstructed using a 
cone beam algorithm. The bone architecture was analyzed using image analysis software 
(Inveon Research Workplace 2.0, Siemens Medical Solutions USA Inc., Knoxville, USA). 
From reconstructed CT scans, 3D models were built for visualization and morphometric 
analysis. For the morphometric analysis, a region of the femoral condyle was selected, 
which included the metaphysal bone of the femoral condyle head starting at the growth 
plate (without cortical bone layer) until 300 micro-tomographic slices more proximal. By 
auto-interpolation of the layers, a volume of interest (VOI) was obtained. Within this VOI, 
the amount of trabecular bone and bone marrow were determined on basis of the density 
in Houndsfield units. Thereafter, bone morphometric parameters (bone volume, trabecular 
spacing, and trabecular thickness) were calculated using the Inveon Research Workplace 
Bone Morphometry tool (Siemens Medical Solutions USA Inc.).
Surgical procedure to create and fill femoral bone defects
Six weeks after OVX or SHAM surgery, and after confirmation of significantly altered bone 
morphometric parameters (via in vivo CT; see previous section “Validation of osteoporotic 
bone condition”), a defect was created in both femoral condyles of each animal. Alternating 
the left and right femur, the materials CPC/PLGA and Bio-Oss® were used to fill the defects. 
Anesthesia and pain medication were administered similarly as described for the first 
surgical procedure (see section “Surgical procedure leading to osteoporotic conditions”).
Before starting the operation of creating the femoral defect, both hind limbs of the rats were 
shaved and disinfected with povidone iodine. The rats were immobilized in supine position 
and with the knee maximally flexed a longitudinal incision through skin and muscle was 
made on the medial surface. After exposure of the medial side of the distal femoral condyle 
the knee capsule was incised. Then, the knee was extended to luxate the patella laterally. 
When a clear view of the knee joint was established, a bone defect (Ø 2.5 mm, depth 5 mm) 
was created longitudinal to the axis of the femur, using a dental drill (Elcomed 9927 SPS; 
W&H Dentalwerk Burmoos GmbH, Burmoos, Austria). A series of increasing bur diameters 
(1.5–2.0–2.3–2.5 mm) were used at a speed of maximum 5000 rpm and a constant cooling by 
dripping saline. The drilled cavity was then washed with saline and dried using sterile gauze.
Subsequently, the materials were alternatingly placed into the defect. Firstly, the small 
Bio-Oss® granules (0.25 - 1mm in diameter) were manually mixed with a drop of saline 
using a spatula and inserted. For the CPC/PLGA, preset cylinders were used (see section 
“Preparation of CPC/PLGA cylinders”). After introducing the materials into the defects, the 
muscular tissue layer was closed with absorbable sutures (Vicryl® 4.0, Ethicon, Amersfoort, 
The Netherlands) after which the skin was closed by small staples (Agraven®; InstruVet BV, 
Cuijk, The Netherlands).
After implant surgery, both experimental groups (OVX and SHAM) had free access to normal 
pellet food and water. In the initial postoperative period, the intake of water and food was 
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monitored as well as the weight of the animals. In addition, the animals were observed for 
signs of pain, infection and proper activity and weighed again postoperatively once a week 
to identify significant weight loss (>20%) compared to preoperative body weight of each rat.
Fluorochrome labeling for bone dynamics
The rats in the 12 week groups received a series of four fluorochromes by subcutaneous 
injection, with a 2-week interval, starting two weeks after implantation surgery. Calcein blue 
(product no. M1255, dose 30mg/kg; week 2), calcein green (C0875, 10mg/kg; week 4), alizarine 
complexone (A3882, 25mg/kg; week 6) and rolitetracycline (R2253, 25mg/kg; week 8) were 
consecutively used. All fluorochromes were obtained from SigmaAldrich (Munich, Germany). 
Before injection, the solutions were set to a pH between 7.2-7.4, then filtered through a 0.22 
sterile millipore filter, and finally checked for fluorescence.
Specimen retrieval
After both implantation periods of 4 and 12 weeks, the animals were euthanized by 
suffocation with CO2. The femurs including the implanted materials were harvested, stripped 
from soft tissues and immediately fixed in 10% formalin solution. Using a diamond saw, 
the specimens were cut smaller to become suitable for ex vivo micro-CT scanning and 
histological processing. After fixation, specimens were stored in 70% ethanol.
Micro-CT
A desktop X-ray micro-CT system was used (Skyscan-1072, TomoNT version 3N.5, Skyscan®, 
Kontich, Belgium) for 3D imaging. The specimens were placed onto the sample holder with 
the long axis of the femur perpendicular to the scanning beam. 3D reconstruction and 
imaging processing was performed using NRecon V1.4 and CTvox v2.7 (Skyscan®, Kontich, 
Belgium), respectively.
Histological processing
After performing micro-CT scanning, the specimens were dehydrated in a graded series of 
ethanol (70% - 100%), after which they were embedded in polymethylmethacrylate (pMMA). 
After polymerization, thin sections of 10μm were prepared in a cross-sectional direction 
perpendicular on the longitudinal direction of the defect using a diamond blade microtome 
(Leica Microsystems SP 1600, Nussloch, Germany). The first section of each specimen was 
aimed at the center of the defect or slightly more proximal on the femur and continued 
distally. Then, three sections of each specimen were stained with methylene blue and 
basic fuchsine. For the 12-week group, first 3 sections were made and left unstained for 
fluorescence analysis and immediately stored in the dark.
One specimen of each experimental group was decalcified in ethylenedinitrilotetraacetic 
acid (EDTA; Merck KGaA, Darmstadt, Germany), dehydrated through a series of graded ethanol 
and embedded in paraffin. Using a microtome (Leica RM 2165, Leica Microsystems, Nussloch, 
Germany) 6μm thick sections were prepared. The sections were stained with hematoxylin-
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eosin (HE) to verify bone tissue within the defect area. In addition, tartrate-resistant acid 
phosphatase (TRAP) staining was applied to determine osteoclastic activity.
Descriptive histology and histomorphometrical analysis
At both implantation periods of 4 and 12 weeks, the pMMA and paraffin histological sections 
(3 sections per specimen) were examined by light microscopy (Leica Microsystems AG, 
Wetzlar, Germany). Using different filters on the light microscope, pictures could be made of 
the fluorescent labels at the four different time points. Quantitative assessment of the pMMA 
specimens was performed using ImageJ computer-based image analysis software (Java® 
ImageJ 1.47, Image processing and analysis in Java) 25. From digitalized images of the sections 
(magnification: 5x), a circular region of interest (ROI) with a diameter equal to the created 
defects was positioned. Within this ROI, the amount of newly formed bone and material 
remnants were measured using color discrimination and morphology for verification. The 
baseline values (zero time point) for material area within this ROI were determined as 
described previously26 or theoretically set at 100% (CPC/PLGA).
Statistical analysis
Data are presented as mean with SD. Statistical analysis of quantitative data was performed 
using one-way analysis of variance (ANOVA) with a Tukey post-hoc test for comparison 
between the three different time points. GraphPad Software (PRISM; La Jolla CA, USA) was 
used to carry out the statistical analysis. For a comparison between both conditions at 
selected time points and for the analysis of the in vivo micro CT analysis, Student’s t-tests 
were used. Values of p<0.05 were considered statistically significant.
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Of the thirty-two animals, two animals were excluded from the experiment. One animal 
(assigned to OVX 4 weeks) died due to a respiratory depression near the end of the bone 
defect surgery. A second animal had an opened wound on the left leg two days after 
implantation surgery, for which antibiotics and further pain medication was provided. 
Initially, this rat seemed to recover well, but on the fourth postoperative day, the animal 
was limping. At this point, it was decided that the animal (assigned to SHAM 12 weeks) had 
reached the humane endpoint and was euthanized. After examining the leg post-mortem, 
no signs of infection or active bleeding were observed but the femur shaft was fractured 
(data not shown).
The thirty remaining animals remained in good health during the entire experimental period. 
One week after subcutaneous injection of the fourth fluorochrome (Rolitetracycline), nine 
animals showed a skin reaction by hair loss and crust formation. This did not seem to hinder 
the animals and the skin healed for all animals within two weeks. At sacrifice, no signs of 
inflammation or adverse tissue reaction were seen in the wound areas.
Figure 1 A-C: [A] Screenshot of in vivo micro CT analysis program of trabecular bone in osteoporotic and 
healthy animals. Representative in vivo CT image of [B] osteoporotic and [C] healthy rat femur.
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Figure 2A-C: [A] Representative micro CT images of each experimental group. Representative histological 
images of pMMA sections for each experimental group with images at [B] 4 weeks and 12 weeks and [C] 
corresponding images at 20x magnification; methylene blue and basic fuchsine staining; red arrows] new 
bone (pink color); *] CPC/PLGA (black*) or Bio-Oss® (white*); BM] bone marrow (blue color).
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Confirmation of the osteoporotic bone condition by in vivo micro-CT
Six weeks after OVX or SHAM surgery, three of the OVX rats and three of the SHAM rats underwent 
in vivo micro-CT (Figure 1A-C). The bone morphometric data deduced from CT images are shown 
in Table 1, which revealed that OVX surgery significantly reduced trabecular bone volume and 
disorganized trabecular architecture in the femoral condyle compared to SHAM surgery. These 
alterations in bone morphology were further confirmed by significant effects on quantitative 
parameters (p<0.01), shown by lower trabecular bone volume, trabecular thickness and number, 
and higher trabecular separation for OVX compared to SHAM.
Micro-CT analysis
Reconstructed 3D micro-CT images were sliced to obtain an internal view of the bone 
defects. An overview with sagittal, frontal and transversal slices through the defect region 
for each experimental group is presented in Figure 2A. Color settings were adjusted to 
distinguish between different densities of bone and material, coloring bone yellow. The 
slices showed lower amounts of trabecular bone for osteoporotic rats with apparently larger 
spacing between the trabeculae compared to healthy rats. Further, the bone substitute 
materials showed clear differences in appearance, with CPC/PLGA present as a mass within 
the created femoral condyle bone defect and Bio-Oss® as dispersed particulate material. 
Color differences between both bone substitute materials showed higher radio density for 
Bio-Oss® particles (yellow color) compared to CPC/PLGA (purple color).
Descriptive histological evaluation of pMMA and paraffin sections
Representative images of the histological sections of specimens embedded in pMMA are 
depicted in Figure 2B. In general, histology of the pMMA-sections showed higher trabecular 
number and denser spacing for SHAM compared to OVX bone condition. Descriptive histology 
confirmed that Bio-Oss® granules presented as a more dispersed material, allowing more 
space within the defect area, compared to the more dense filled defects by CPC/PLGA, at 
both 4 and 12 weeks. New bone formation was observed at both 4 and 12 weeks for Bio-Oss®, 
and at 12 weeks for CPC/PLGA in both OVX and SHAM rats.
Table 1: Quantitative bone morphometric data using in vivo micro-CT (mean ±SD) for trabecular bone in 
distal femurs of rats 6 weeks following OVX and SHAM operations, **] Student’s t-test showed significant 
difference between columns (p<0.01).
OVX SHAM
Bone volume fraction % 28.2 ± 4.2 71.8 ± 2.5**
Trabecular thickness (Tb.Th) µm 0.1 ± 0.01 0.2 ± 0.01**
Trabecular number (Tb.N) mm-1 3.1 ± 0.4 4.2 ± 0.2**
Trabecular separation (Tb.Sp) µm 0.2 ± 0.01 0.1 ± 0.01**
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Figure 3A-C: Representative images of [A] HE stained paraffin section images of each experimental group, 
[B] TRAP stained paraffin sections with [C] detailed images at 20x magnification for each corresponding 
experimental group; Bone] bone; BM] bone marrow; *] materials CPC/PLGA or Bio-Oss®; blue arrows] 
TRAP staining red colored. 
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Images at 20x magnification (Figure 2C) showed new bone formation that was in direct 
contact with the implanted material, i.e. CPC/PLGA or Bio-Oss®. For CPC/PLGA, newly formed 
bone was mainly formed at the peripheral edge of the material and where degradation had 
occurred. Almost no bone formation was seen in the center of the material, except for one 
OVX specimen after 4 weeks and three specimens after 12 weeks. For Bio-Oss®, the granules 
were surrounded by newly formed bone and bridging was observed by newly formed bone 
between Bio-Oss® granules. At 12 weeks, the Bio-Oss® granules seemed to be completely 
covered by newly formed bone. Areas within the ROI where neither bone nor material was 
present, were filled with bone marrow. Material degradation became apparent at 12 weeks 
for CPC/PLGA, showing marginal degradation predominantly on the peripheral edge of the 
material. At 4 weeks CPC/PLGA did not show clear degradation and PLGA seemed still 
present within most pores. After 12 weeks, PLGA was dissolved and bone marrow was able 
to penetrate the cement and fill the pores, including the center. Still, only few specimens 
(all OVX) contained slides showing gross degradation of CPC/PLGA that could reach to the 
center of the defect (data not shown). 
HE-stained paraffin sections (Figure 3A) showed in general similar observations as described 
for pMMA sections. The sections showed an increased bone formation into the defect for 
SHAM animals compared to OVX when using Bio-Oss® at both time points. For the defects 
filled with CPC/PLGA, bone formation was seen mainly at the edges of the original defect. 
Paraffin sections stained with TRAP (Figure B-C) showed low osteoclastic activity for OVX, 
irrespective of bone substitute material used. For SHAM, more activity was observed mostly 
where bone made contact with the surface of the bone substitute materials.
Figure 4: Representative fluorochrome microscopy images at 12 weeks for both OVX and SHAM using both 
CPC/PLGA and Bio-Oss® with 20x magnification images; red box] area of 20x magnification; green color] 
calcein green (week 4); red color] alizarine complexone (week 6); yellow color] rolitetracycline (week 8).
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Figure 5: Accumulated area percentages (mean ±SD) of new bone formation (red bars) and material 
remnants (blue bars) within ROI at 0, 4 and 12 weeks after implantation (numbers in bars indicate 
percentages, blue for material, red for bone); ANOVA showed significant difference for both bone 
formation and material remnants between CPC/PLGA and Bio-Oss® of similar time point and condition, 
*] p<0.05, ***] p<0.001; a] significant increase (ANOVA, p<0.001) in bone volume compared to 0 time point 
for Bio-Oss® in OVX after 4 weeks and b] 12 weeks and c] in SHAM after 4 weeks and d] 12 weeks; significant 
decrease in material remnants for CPC/PLGA in e] OVX between 0 and 12 weeks (ANOVA, p<0.005), f] 
between 4 and 12 weeks (ANOVA, p<0.05) and g] in SHAM between 0 and 12 weeks (ANOVA, p<0.05) and 
for Bio-Oss® only in h] OVX between 0 to 12 weeks (ANOVA, p<0.05).
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Bone dynamics by fluorochrome labeling
Incorporation of fluorochrome labels into newly formed bone (Figure 4) was observed for 
calcein green (green; week 4), alizarine complexone (red; week 6) and rolitetracycline (yellow; 
week 8). However, none of the sections showed calcein blue (blue; week 2).
Bone dynamics by fluorescent microscopy showed that bone was formed in the center of 
the defect for defects filled with Bio-Oss®, for both osteoporotic and healthy conditions, 
at 4, 6 and 8 weeks. For CPC/PLGA, these fluorochrome labels were observed at the defect 
edge (i.e. interface between bone and bone substitute material). For the CPC/PLGA three 
sections in OVX group the center of the defect was reached by all three colors and in one 
section of the SHAM group.
For OVX incorporation of all three colors was homogeneous containing Bio-Oss®, whereas 
CPC/PLGA showed more yellow incorporation, followed by red and then green. For the SHAM 
animals the incorporation of fluorochrome calcein green was the most abundant in both 
Bio-Oss® and CPC/PLGA, followed by yellow and then red for Bio-Oss® and followed by 
yellow and red equally in CPC/PLGA.
Histomorphometrical analysis
For histomorphometrical analysis, the baseline material area within the region of interest 
(zero-time point) was (theoretically) set at 100% for CPC/PLGA and (experimentally) 
determined to be 57.0 ± 14.3% for Bio-Oss®. Histomorphometry in OVX rats after 4 weeks 
showed material areas within the ROI of 92.7 ± 8.6% for CPC/PLGA and 38.9 ± 10.0% for 
Bio-Oss®. After 12 weeks, materials areas within the ROI were 72.4 ± 13.6% for CPC/PLGA 
and 37.7 ± 5.2% for Bio-Oss®. In SHAM rats, material areas within the ROI after 4 weeks were 
90.3 ± 11.2% for CPC/PLGA and 39.5 ± 7.4% Bio-Oss® and after 12 weeks 75.6± 8.2% and 39.1 
± 5.5%, respectively. Statistical analysis showed material remnants were significantly lower 
for Bio-Oss® compared to CPC/PLGA at all time points and in both conditions (ANOVA, all 
p<0.001; Figure 5). There were no significant differences between both conditions at each 
time point for each material (Students t-test, p>0.05).
Temporal material degradation has been depicted separately in a graph for both CPC/PLGA 
and Bio-Oss® (Figure 6). In order to better illustrate the differences between the materials, 
data for Bio-Oss® was to set to 100% and therefore Figure 6 is showing relative percentages. 
Material remnants decreased significantly over a time period from 0 to 12 weeks for CPC/
PLGA in both conditions (ANOVA, p<0.01 in OVX and p<0.05 in SHAM; Figure 5 & 6) and only 
in OVX for Bio-Oss® (ANOVA, p<0.05). Only CPC/PLGA in OVX showed a significant temporal 
decrease of materials remnants from 4 to 12 weeks (ANOVA, p<0.05). None of the other groups 
showed significant temporal decrease of material.
New bone formation within the ROI after 4 weeks in OVX rats was 1.2 ± 1.2% for CPC/PLGA 
and 13.7 ± 3.3% for Bio-Oss®. After 12 weeks, bone formation in OVX rats was 6.5 ± 5.5% for 
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CPC/PLGA and 17.5 ± 3.4% for Bio-Oss®. For SHAM rats at 4 weeks this was 1.9 ± 2.0% and 18.8 
± 4.1%, respectively and at 12 weeks 3.3 ± 1.2% and 18.6 ± 3.6%, respectively. Bone formation 
was significantly increased for Bio-Oss® compared to CPC/PLGA at 4 and 12 weeks in both 
OVX and SHAM animals (ANOVA, all p<0.001; Figure 5). There was a significant temporal 
increase in bone formation using Bio-Oss® after both 4 and 12 weeks compared to the 0 
week time point in both OVX and SHAM (ANOVA, all p<0.001). After 12 weeks, bone formation 
was twice as high in OVX as for SHAM for CPC/PLGA, however, this difference did not prove 
to be significant. No significant differences were observed between both conditions at each 
time point for each material (Students t-test, p>0.05).
Figure 6: Temporal graph showing relative percentage and decrease of material remnants [all lines are 
to guide the eye]; ANOVA showed a significant temporal decrease of material remnants indicated by 
colored bars; red bar] Bio-Oss® OVX from 0 to 12 week; green bar] CPC/PLGA SHAM from 0 to 12 weeks; 
blue bars] for CPC/PLGA OVX from 0 to 12 and 4 to 12 weeks; *] p<0.05 and **] p<0.01.
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Discussion
The aim of this study was to comparatively evaluate the performance of CPC/PLGA and 
Bio-Oss® in ovariectomized and healthy rats. We hypothesized that osteoporotic conditions 
would affect the performance of bone substitute materials. Additionally, we hypothesized 
that the differences in degradation rate between CPC/PLGA and Bio-Oss® would lead to 
different bone forming capacity. The main findings by histomorphometry showed significant 
degradation, especially in the period from 4 till 12 weeks, for CPC/PLGA over implantation 
time in both healthy and osteoporotic conditions, whereas Bio-Oss® degraded slightly within 
the first 4 weeks and showed no further degradation till 12 weeks. Bone formation was similar 
in healthy and osteoporotic conditions, with a rapid increase from 0-4 weeks for BioOss® 
and no further increase till week 12, whereas CPC/PLGA showed marginal bone formation 
over the course of 12 weeks.
Despite the overall higher degradation rate for CPC/PLGA compare to Bio-Oss®, we found 
relatively high amounts (>72%) of CPC/PLGA after 12 weeks, when compared to previous 
studies 19, 27. An explanation for the relatively high amounts of CPC/PLGA material remnants 
could be the use of CMC in this study. To promote cohesion and improve injectability as 
well as washing resistance, previous studies have shown that addition of cellulose-based 
lubricants can be used 28-30. Recent work by An et al., who also used CMC to enhance 
injectability of CPC and filled defects created in rabbit femoral condyles 31, showed 
corroborating degradation data. In their work, the CPC with CMC was compared to a composite 
of CPC with CMC and PLGA particles (60/40 wt% CPC/PLGA), as well as the commercially 
available apatite-forming cement, HydroSetTM. After an implantation period of 26 weeks, they 
showed material remnants of 87 ± 8% for CPC/CMC and 59 ± 6% for CPC/CMC/PLGA, and also 
speculated that the limited degradation was caused by the use of CMC. Histologically, they 
noticed the presence of an acellular layer formed around the CPC, which they interpreted as 
a CMC-rich capsule formed after swelling of CMC. Although we did not observe this capsule, 
CMC likely compromises the accessibility of the intrinsic porosity within the CPC matrix, and 
hence prevents perfusion and cellular infiltration, reducing degradation rate. Future studies 
should be performed to examine the effect of CMC addition on CPC degradation.
For this study, preset cylinders of CPC/PLGA were used to exactly fit into the created defect. 
This allowed for shorter surgery time and more consistent and complete filling of the defects. 
Theoretically, this could have influenced CPC/PLGA performance, when compared to injecting 
directly into the defect. It could be hypothesized, when CPC/PLGA is injected directly into 
the bone defect, that mixing of bodily fluids (i.e. blood) could influence CPC hardening and 
comprise stability of the cement. Future studies should be performed to evaluate the effect 
of hardening of cement in vivo compared to the use of preset samples. 
Irrespective of bone condition, our histomorphometrical data showed a temporal increase 
in bone to a maximum of 6.5% for CPC/PLGA and 18.8% for Bio-Oss®, which was significantly 
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higher for Bio-Oss®. Since Bio-Oss® already initially had space between the granules, 
bone formation could occur relatively early in comparison to the initially dense CPC/PLGA. 
Previous studies have shown that CPC/PLGA completely degrades over time, being replaced 
by new bone formation 19, 27, 32-35. Bio-Oss®, on the other hand, is known to degrade slowly and 
remains present till years after implantation 36, 37, hampering more bone formation and full 
regeneration in those areas.
An osteoporotic bone condition significantly accelerated material degradation compared to 
a healthy condition, as observed for CPC/PLGA from 4 to 12 weeks and for Bio-Oss® from 0 
to 12 weeks. TRAP staining showed no apparent increased intensity for osteoporotic bone 
versus healthy bone. This observation corroborates earlier studies 27, 38, and indicates that 
osteoclastic activity is not solely responsible for enhanced degradation in osteoporotic 
conditions 4. On the other hand, degradation of especially CPC/PLGA can be both active (i.e. 
based on osteoclastic activity) and passive (i.e. based on dissolution) 39-41. Because TRAP 
staining did not show increased osteoclastic activity, the increased surface area of CPC/PLGA 
after PLGA porogen degradation likely enhanced the passive dissolution of the CPC matrix 
in the period from 4-12 weeks.
In osteoporotic bone, CPC/PLGA showed a 5.4-fold increase in bone from 4 to 12 weeks, 
whereas in healthy bone only a 1.7-fold increase was observed. Similarly, Bio-Oss® showed a 
1.3-fold increase in bone in osteoporotic bone and no increase in healthy bone. Furthermore, 
analyses of bone dynamics using fluorochromes for CPC/PLGA showed an apparent higher 
bone formation in the late period of implantation for osteoporotic versus healthy bone 
conditions, based on more incorporation of fluorochromes administered in this period. 
The earlier mentioned faster degradation rate of CPC/PLGA in osteoporotic conditions 
could explain the increased bone growth after 4 weeks, as bone formation can only occur 
after sufficient material degradation. In view of this, the use of a relatively porous and 
fast degrading material seems recommendable for treating bone defects in osteoporotic 
conditions. Additionally, it needs to be emphasized that osteoporotic patients often receive 
systemic medical treatments (i.e. bisphosphonates), possibly influencing material degradation 
and new bone formation. Consequently, further research is necessary, comparing treated to 
untreated osteoporotic conditions, to examine the effect on the biological performance of 
bone substitute materials.
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Conclusion
This study showed CPC/PLGA degraded relatively faster and more steadily compared to 
Bio-Oss®. However, in absolute values, Bio-Oss® showed significantly less material remnant 
and more bone growth compared to CPC/PLGA. Our data confirmed our hypothesis that 
osteoporotic conditions affect degradation of CPC/PLGA, which is of vital information for its 
future use in osteoporotic patients. Alternatively, no effects of an osteoporotic condition on 
bone formation were observed. Consequently, different bone conditions require the selection 
of a bone graft material with suitable degradation characteristics.
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Synthetic bone substitutes are widely accepted materials in the field of bone reconstruction 
to promote bone regeneration and replace autologous bone grafting. Commercially available 
synthetic bone substitutes are available in various forms and shapes, adapted to the specific 
needs of different bone defects 1,2. Synthetic bone substitutes can be subdivided into three 
material classes, i.e. polymers, ceramics and composites 1. Ceramics, especially those based 
on calcium phosphates (CaPs), are favorable materials due to their biocompatible, bioactive 
and osteoconductive properties resulting from a chemical composition that is similar to 
the mineral phase of bone 4-8. In view of optimized handling properties, CaP ceramics have 
become available in the form of injectable CaP cement (CPC) 3. First proposed in the early 
80s, CPCs were designed to overcome the handling difficulties of the traditional ceramic 
blocks and granules 9,10. 
Depending on the end-product after setting, CPCs can be classified into two main groups, 
i.e. brushite and apatitic CPCs. Brushite CPCs have the ability to be resorbed under 
physiological conditions, whereas apatitic cements degrade relatively poorly, limiting new 
bone formation 11. Resorption of CPC occurs either via active resorption (a cell-mediated 
process of osteoclasts and macrophages) or via passive resorption (based on the cement 
solubility) 12-15. Passive resorption is mainly influenced by porosity and cement composition, 
i.e. apatite being less soluble than brushite. Brushite CPCs, however, have low mechanical 
properties and handling can be difficult due to a fast setting time (~30 s) 11. The favorable 
mechanical and handling properties of apatitic cements lead research to focus on improving 
their degradation properties.
Ideally, the rate of material degradation is equal to the rate of bone formation gradually 
providing room for bone to grow 16. Balancing degradation rate to new bone formation rate is 
an important material property to control. Accelerated degradation of CPC has been achieved 
via addition of porogens 17,18. Generally, macropores (pores>100µm) are used to increase 
the surface of the CPC leading to a faster degradation. The term “macropores” is used to 
distinguish between the pores from the scaffold’s own micro- or nanoporosity 18. Macropores 
are mainly created by leaching or degradation of incorporated particles, gas foaming, and 
droplet emulsion. 10,17,19-24.
Poly(D,L-lactic-co-glycolic) acid (PLGA) is a rapidly degradable synthetic polymer and hence 
interesting to use as porogen in CPC. PLGA has a long clinical history and already several 
PLGA incorporated medical devices have been approved by the FDA for clinical use 25. In vivo 
degradation of PLGA occurs via hydrolysis and is a relatively fast process. During degradation, 
lactic acid and glycolic acid monomers are released, which are metabolized into carbon 
dioxide and water and excreted by the body 25. Parameters influencing the degradation of 
PLGA are molecular weight, end-group functionalization (acid terminated or end capped) 
and ratio of lactic and glycolic acids 8,26-31. Previously, it was shown that PLGA microspheres 
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enhance the degradation of apatitic CPC and improve bone regeneration 26,27,32,33. When 
incorporated into CPC, the degradation is influenced by the particle size, morphology (hollow 
or dense spheres), and relative amount of PLGA 8,26-31.
PLGA porogens can be fabricated following several methods, such as water-in-oil-in-water 
emulsion or oil-in-water emulsion 25. These chemical processes are associated with an 
acceptable yield (i.e. 60-80%), but such loss of product during synthesis and the time 
consuming nature are impeding large-scale utilization. Alternatively, PLGA milling can be 
applied to generate PLGA porogens 32,33. In this way, irregularly-shaped PLGA particles are 
obtained relatively fast and in a cost-effective manner.
The aim of this study was to comparatively evaluate the in vitro degradation effects of dense 
PLGA microspheres with milled PLGA particles as porogens in apatitic CPC. We hypothesized 
that milled PLGA particles would degrade CPC/PLGA similarly when compared to dense PLGA 
microspheres. Additionally, we aimed to examine the effect of PLGA porogen amount in 
CPC/PLGA via an in vivo rat femoral bone defect model to determine degradation and bone 
formation. For this, we hypothesized that a higher PLGA porogen amount would increase 
the porosity, leading to faster degradation and consequently more bone formation in vivo.
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The CPC used for both in vitro and in vivo experiments consisted of 100% α-TCP (kindly 
provided by CAM Bioceramics B.V., Leiden, the Netherlands) sieved at <150 µm. Carboxymethyl 
cellulose (CMC; 0.75 wt%) was added to the CPC to improve injectabilty. PLGA (Purasorb®, 
PDLG 5002A, Mw=17kDa, acid-terminated) was obtained from Corbion B.V. (Gorinchem, the 
Netherlands). Milled PLGA (PDLG 5002A, acid-terminated) was kindly provided by CAM 
Bioceramics B.V. Custom-made cylindrical thumbtack-shaped titanium implants (grade 2) 
were obtained from Machinefabriek G. Jansen B.V. (Valkenswaard, the Netherlands).
Preparation of dense PLGA microspheres
Dense PLGA microspheres, used for in vitro analysis, were fabricated by an emulsion 
technique as described previously 30. Briefly, PLGA was dissolved in 12 ml of dichloromethane 
(DCM, Merck, Germany). The solution was decanted over three beakers containing 150 ml 
of 0.3% polyvinyl alcohol (PVA, Acros Organics, the Netherlands). This second emulsion 
was stirred (800 rpm) for 5 minutes and then 200 ml of 2% isopropanol (Labscan Ltd., 
the Netherlands) was added. The suspension was stirred for 1 hour, after which the PLGA 
microspheres were allowed to precipitate. Thereafter, the supernatant was decanted and 
the sediment was washed twice with ultrapure water. The microspheres were lyophilized 
and stored at −20°C.
Preparation of CPC/PLGA scaffolds (for in vitro analysis)
The α-TCP, CMC, and PLGA porogen were combined to obtain formulations with either 30 or 
50 wt% PLGA (Table 1). Per 1 gram of powder, a solution of 500 µl 4% NaH2PO4 was added. For 
the preparation of the scaffolds, a Teflon® mold was used with holes of 4.5 mm in diameter 
Table 1: Overview of CPC/PLGA formulations
In vitro CPC/PLGA PLGA 
70/30-MS 70/30 wt% microspheres
50/50-MS 50/50 wt% microspheres 
70/30-MP 70/30 wt% milled particles
50/50-MP 50/50 wt% milled particles
In vivo CPC/PLGA PLGA
Ti-70/30-MP 70/30 wt% milled particles
Ti-50/50-MP 50/50 wt% milled particles
CPC, calcium phosphate cement; PLGA, poly(lactic-co-glycolic acid); MS, microspheres; MP milled particles
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and 9.2 mm in depth. During injection into the Teflon® mold, attention was paid to completely 
fill the space and any air being trapped under the cement was removed. The cement was left 
to air dry at room temperature for a minimum of 24 hours.
Preparation of titanium-CPC/PLGA scaffolds (for in vivo analysis)
Titanium implants (thumbtack-shape; length 6 mm, base diameter 3 mm, core diameter 1 
mm), were cleaned using a tabletop ultrasonic cleaner via consecutive rinsing with acetone 
and alcohol, and then air dried. Then, the titanium implants were placed into a Teflon® mold, 
with holes of 3 mm in diameter and 6 mm in length.
CPC/PLGA was mixed with 500 µl of 4% NaH2PO4 solution per 1 gram powder and injected 
with an 18G needle into the space around the titanium implants. During injection, attention 
was paid to completely fill the space and any air being trapped under the cement was 
removed. Then, the cement was left to air dry at room temperature for a minimum of 24 
hours, after which the implants were gently removed from the mold. Dimensions of the 
Ti-CPC/PLGA implants are depicted in Figure 1. Finally, sterilization was performed by gamma 
irradiation (25-50 kGy; SynergyHealth Ede B.V., Ede, the Netherlands).
Figure 1: Schematic representation of titanium landmarks with CPC/PLGA (left) with dimensions of 
a diameter of maximum 3mm and minimum 1mm, length maximum 6mm; Photograph of titanium 
landmarks with CPC/PLGA (right); CPC, calcium phosphate cement; PLGA, poly(D,L-lactic-co-glycolic) acid
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In vitro material characterization
PLGA porogens
The size of the PLGA microspheres was measured by optical microscopy (DM RBE Leica, 
Germany) with image analysis software (Qwin Leica, Germany).
CPC/PLGA scaffolds
After removal from the mold, scaffolds were each placed in 1.5 ml of phosphate buffered 
saline (PBS) and left on a shaking apparatus at 37oC.
Scaffold morphology
A scanning electron microscope (SEM; JEOL JSM 6340, 10 kV) was used for morphological 
analysis. For each material group, samples were scanned after 4 weeks and 8 weeks of 
incubation.
Porosity calculations and measurements
The macroporosity of the different CPC/PLGA experimental formulas (n=3) was determined as 
previously described by Habraken et al. 34. The equations used to calculate the total porosity 
and macroporosity are as shown in Figure 2.
Degradation and pH changes
Degradation of the scaffolds was determined by analyzing Ca2+ release into the PBS, 
ε tot  = (1 − 𝑚𝑚 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝑉𝑉 ∗ 𝜌𝜌 HAP ) *100%      
 Equation 1 
ε macro  = (1 − 𝑚𝑚 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝑚𝑚 𝑚𝑚𝑚𝑚𝑚𝑚𝑏𝑏𝑚𝑚𝑚𝑚𝑚𝑚𝑏𝑏𝑚𝑚𝑏𝑏𝑚𝑚 ) *100%    
 Equation 2 
 
Legend 
ε tot         =  total porosity (%) 
ε macro   =  macroporosity (%) 
m burnt   = average mass sample  
(after burning out polymer) (g. n=3) 
m microporous  = average mass microporous sample (g. 
n=3) 
V    =  volume sample (cm3) 





Figure 2: Equations 1 and 2 used to calculate macro- and microporosity (%) 
of the scaffolds   
Figure 2: Equations 1 and 2 used to calculate macro- and microporosity (%) of the scaffolds 
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measured at the end of each week, for 8 consecutive weeks. The absolute amounts of 
Ca2+-ions in the PBS media were analyzed by the orthocresolphtalein complexone (OCPC) 
method (Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands) as described previously 
30. Additionally, the pH of the PBS media was monitored, using pH-indicator strips, at the 
same weekly time points.
In vivo analysis
Animals
Twenty healthy mature male Wistar rats were used for this experiment at 3 months of age 
with an average weight of 250 grams at the start of the experiment. An acclimatization 
period of 7 days was used and housing was provided per pair in a standard macrolon type 
3 cage with sawdust as bedding material. Standard rodent chow and bottled tap water was 
provided ad libitum. The housing room was maintained under standard laboratory conditions 
(light-dark cycle: 12:12 hours, temperature: 20-22°C, relative humidity: 45-55%). All experiments 
were conducted in accordance with institutional, national and international guidelines for 
animal care and the Dutch law concerning animal welfare. The studies were reviewed and 
approved by the Experimental Animal Committee of the Radboud University (RUDEC 2012-243).
Surgical procedure
A rat femoral bone defect model was used, as described previously 35. Pre-operatively, pain 
medication was provided by an injection of Carprofen (5 mg/kg; Rimadyl®, Pfizer Animal 
Health, New York, USA) given 15 minutes before surgery. Anesthesia was induced and 
maintained by Isoflurane inhalation (Rhodia Organique Fine Ltd., Avonmouth, Bristol, UK) 
combined with oxygen. After confirmation of effective anesthesia, the surgical area was 
shaved and disinfection was performed by application of a povidone iodine solution. The rats 
were placed on a heating mat to prevent hypothermia and immobilized in supine position. 
With the knee maximally flexed, a longitudinal incision through skin and muscle was made 
on the medial surface. After exposure of the medial side of the distal femoral condyle, the 
knee capsule was incised. Then, the knee was extended to luxate the patella laterally. When a 
clear view of the knee joint was established, a femoral bone defect (diameter 3 mm, depth 6 
mm) was created in the same direction as the axis of the femur, using a dental drill (Elcomed 
9927 SPS; W&H Dentalwerk Burmoos GmbH, Burmoos, Austria). A series of increasing bur 
diameters were used with the final drill of 3 mm in diameter, at a speed of maximum 5000 
rpm and constant cooling by dripping saline. The drilled cavity was then washed with a 
spray of saline and dried using sterile gauze, after which the pre-set titanium-CPC/PLGA 
scaffolds were placed into the defects. Each rat received both implants (Ti-50/50-MP and 
Ti-70/30-MP), alternating between each rat the two weight percentages for the left and right 
knee. After introducing the implants into the defects, the muscular tissue layer was closed 
with resorbable sutures (Vicryl® 4.0) after which the skin was closed with small staples 
(Agraven®; InstruVet B.V., Cuijk, the Netherlands). To diminish postoperative discomfort, 
Buprenorfine (0.02 mg/kg; Temgesic® Reckitt Benckiser Pharmacueticals Ltd., Slough, UK) 
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was given every 12 hours till 2 days after surgery. All animals had free access to pellet food 
and water. In the initial postoperative period, the intake of water and food was monitored 
daily as well as the weight of the animals. In addition, the animals were observed for signs 
of pain, infection and proper activity. Weekly weighing of each animal was continued until 
the end of the experiment.
Implant retrieval
After implantation periods of 4 and 8 weeks, the animals were euthanized by CO2-suffocation. 
The retrieved specimens were harvested and fixed in 10% neutral buffered formalin solution 
for 24 hours, after which the specimens were dehydrated in a graded series of ethanol.
Histological processing
All specimens were embedded in poly(methylmethacrylate) (pMMA). After polymerization, 
three sections per specimen of ~10 μm were prepared perpendicular to the axis of the femur 
using a diamond blade saw (Leica Microsystems SP 1600, Nussloch, Germany). Methylene 
blue and basic fuchsine staining was performed for each section.
Descriptive histology and histomorphometry
Descriptive histology was performed by light microscopy examination (Leica Microsystems 
AG, Wetzlar, Germany) comparing all histological sections. Staining allowed for discrimination 
between soft tissue, bone tissue and CPC. Attention was paid to bone and CPC morphology, 
and amounts of bone and CPC. 
Histomorphometry for both implantation periods of 4 and 8 weeks, pMMA histological 
sections (n=3 per femoral bone defect) were assessed quantitatively using computer-based 
image analysis techniques (Leica® Qwin Pro-image analysis system, Wetzlar, Germany). From 
the digitalized images of the sections at a 5x magnification, a circular region of interest 
(ROI) of 3mm in diameter was selected to assign the defect area with the titanium pin 
as the center. Quantitative measurements within this ROI for area of newly formed bone 
and area of CPC material, were performed using the Leica® Qwin computer-based image 
analysis techniques. Vital bone could be distinguished by the pink colour and distinctive cell 
morphology including a nucleus, allowing to be easily discerned from other tissues as well as 
from CPC. The maturity of bone was differentiated by morphology, as mature trabecular bone 
is formed in lamellae, whereas newly formed bone has a more woven structure. Relative bone 
forming capacity is defined as relative increment in bone area per relative decline in CPC 
area. Bone-to-implant contact (BIC) area was defined as the length around the circumference 
of the titanium pin that is in contact with bone. The standardized diameter of the defect and 
titanium pin allowed to calculate areas of bone, CPC and BIC into percentages.
Statistical analysis
Data for new bone formation and CPC remnants were presented as means with standard 
deviations (SD). The mean area percentages were statistically compared between the groups 
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using one-way ANOVA (GraphPad, Prism 5, GraphPad Software Inc., La Jolla, California USA) 
with a post-hoc Tukey-Kramer Multiple Comparisons test. Differences were considered 
significant at p<0.05.
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Figure 3 A-B: Representative SEM images of PLGA; A) microspheres and B) milled particles; SEM, scanning 
electron microscope; PLGA, poly(D,L-lactic-co-glycolic) acid
Figure 4 A-B: A) SEM images of CPC/PLGA with pore formation by degraded PLGA; B) higher magnification 
showing detail of brushite crystal formation; C) In vitro cumulative Ca2+ release in mg/scaffold for each 
CPC/PGLA formulation, differences between 70/30-MS and 70/30-MP formulations were significantly 
different at all time points compared to 50/50-MS and 50/50-MP; CPC, calcium phosphate cement; PLGA, 
poly(D,L-lactic-co-glycolic) acid; MS, microspheres; MP, milled particles
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Representative images of both PLGA porogens are depicted in Figure 3A-B, showing 
spherically-shaped PLGA microspheres and irregularly-shaped milled particles. The mean 




SEM images revealed that at the start of the in vivo experiment, the PLGA microspheres and 
milled PLGA particles were embedded within the CPC. Already after 4 weeks of incubation 
in PBS, the PLGA porogens in all four groups were degraded and the CPC showed signs 
of degradation (Figure 4A). At higher magnifications, precipitate formation in the form of 
brushite crystals was detected (Figure 4B).
Porosity calculations
Porosity calculations showed that differences in porogen amount led to significant 
differences in porosity, comparing 70/30-MS to 50/50-MS and 70/30-MP to 50/50-MP (both 
p<0.001; Table 2). Comparing the two types of porogens at the same wt% (i.e. 70/30-MS to 
70/30-MP and 50/50-MS to 50/50-MP) the differences were not significant (p>0.05; Table 2).
Degradation and pH changes
At all time points, the cumulative Ca2+ amount was significantly higher for the 70/30 CPC/











CPC only 0.213 ± 0.003 0.0305 ± 0.0004 52.9 ± 0.7 n.a. 52.9 ± 0.7
70/30-MS 0.095 ± 0.004 0.0136 ± 0.0005 78.9 ± 0.8 55.3 ± 1.8 23.7 ± 0.9
50/50-MS 0.068 ± 0.005 0.0097 ± 0.0007 85.0 ± 1.1 68.1 ± 2.3 16.9 ± 1.2
70/30-MP 0.099 ± 0.003 0.0141 ± 0.0005 78.2 ± 0.7 53.7 ± 1.6 24.5 ± 0.8
50/50-MP 0.068 ± 0.006 0.0097 ± 0.0008 85.0 ± 1.2 68.1 ± 2.6 16.8 ± 1.4
*Porosity calculations were performed based on CPC with burned out PLGA; The differences were 
significant (p<0.001) comparing both 70/30-MS and 70/30-MP to 50/50-MS and 50/50-MP; CPC, calcium 
phosphate cement; MS, microspheres; MP milled particles
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Figure 5: Representative histological images (5x magnification) of both materials at time points of 4 and 
8 weeks with detailed images (20x magnification); Ti, titanium landmarks; BM, bone marrow
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PLGA formula compared to the 50/50 CPC/PLGA (Figure 4C). CPC/PLGA formulations with the 
same amount of PLGA (microspheres or milled particles) showed similar Ca2+ release profiles 
(p>0.05) with an accelerated release from 3 to 4 weeks. In contrast, significantly higher 
(p<0.05) Ca2+ release profiles were observed for both 50/50-MS and 50/50-MP compared to 
both 70/30-MS and 70/30-MP, at all time points.
For the pH-values of the incubation media (data not shown), the initial pH-value of 7.4 
dropped to ~4 within the first week for all CPC/PLGA formulas. Subsequently, a further 
gradual decrease of the pH was observed to ~3.3 after 8 weeks of incubation.
In vivo analysis
Clinical evaluation following surgery
All twenty rats recovered well from surgery and remained in good health during the course 
of the experiment. None of the animals showed signs of illness or compromised wound 
healing. Examination of the wound and implantation areas after euthanasia at either 4 or 8 
weeks showed no inflammatory or other adverse tissue reaction. All installed implants were 
retrieved and used for further analysis.
Descriptive histology
Representative histological overview images are provided in Figure 5, with additional detailed 
images at 20x magnification. Newly formed bone could be macroscopically detected at the 
periphery of the CPC after both 4 and 8 weeks of implantation for both Ti-70/30-MP and 
Ti-50/50-MP. In all groups, this bone was in direct contact with the CPC, without intervening 
soft tissue layers. Additionally, no signs of inflammatory responses were observed for any of 
the groups. In several cases of each group, cracks were observed within the CPC with bone 
tissue growing into these cracks.
At 4 weeks, no apparent differences in CPC degradation were observed between Ti-70/30-MP 
and Ti-50/50-MP. At 8 weeks, however, a clear difference was observed, with Ti-50/50-MP 
showing faster CPC degradation than Ti-70/30-MP. Within the newly formed bone, some 
remnant CPC was detectable at a higher magnification for both Ti-70/30-MP and Ti-50/50-MP. 
For specimens showing almost fully degraded CPC, the new bone present within the defect 
area was trabecular-shaped with bone marrow between bone trabeculae.
Histomorphometry
CPC area (%)
The CPC area within the ROI showed a temporal decrease for both Ti-50/50-MP and Ti-
70/30-MP (Table 3 & Figure 6A). The area of CPC measured at 0 weeks were 81.0 ± 0.6% for 
Ti-70/30-MP and 74.8 ± 0.7% for Ti-50/50-MP (p<0.001). After 4 weeks of implantation, the CPC 
area was 60.9 ± 13.5% for Ti-70/30-MP and 53.5 ± 17.3% for Ti-50/50-MP (p>0.05). After 8 weeks 
of implantation were 35.2 ± 21.2% for Ti-70/30-MP and 9.1 ± 9.7% for Ti-50/50-MP (p<0.001). 
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Comparing the different time points revealed a significant temporal decrease after the first 4 
weeks in CPC area for Ti-50/50-MP (p<0.05). After 8 weeks the CPC area was decreased further, 
significantly for both Ti-70/30-MP (p<0.01) and Ti-50/50-MP (p<0.001). The decrease was also 
significant from 4 to 8 weeks for both Ti-70/30-MP (p<0.01) and Ti-50/50-MP (p<0.001). 
Bone area (%)
Newly formed bone within the ROI increased over time for both Ti-70/30-MP and Ti-50/50-
MP (Table 3 & Figure 6B). After 4 weeks, the bone area within the ROI was 5.8 ± 5.0% for 
Ti-70/30-MP and 8.3 ± 2.8% for Ti-50/50-MP (p>0.05). After 8 weeks, the bone area revealed 
a significant temporal increase (p<0.001) for both experimental groups and a significant 
inter-group difference (p<0.05) with values of 22.9 ± 5.2% and 35.0 ± 15.0% for Ti-70/30-MP 
and Ti-50/50-MP, respectively.
Figure 6 A-D: A) CPC area in the ROI (mean +SD); B) Bone area in the ROI (mean ±SD); C) Graph of CPC 
degradation rate versus bone formation rate; D) Bone to implant contact (BIC) (mean ±SD); Intergroup 
differences *) p<0.05, **) p<0.01, ***) p<0.001; Temporal differences ^) p<0.05 compared to 4 week equivalent, 
#) p<0.05 compared to 8-week equivalent; ##) p<0.01 compared to 8-week equivalent, ###) p<0.001 compared 
to 8-week equivalent
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Bone forming capacity
For extended visualization of temporal decreases of CPC area and increases in bone area 
(Figure 6C), calculations were made on the relative bone forming capacity (Table 4). 
In the first 4 weeks, 1% CPC degradation resulted in 0.29% new bone for the Ti-70/30-MP 
compared to 0.39% for the Ti-50/50-MP. From week 4 to 8, 1% CPC degradation allowed for 
0.67% new bone for Ti-70/30-MP compared to 0.60% for Ti-50/50-MP. Overall, more bone was 
formed within the ROI of Ti-50/50-MP over the time period of 0 to 8 weeks with a total of 
0.53% new bone per 1% CPC degradation for Ti-50/50-MP, compared to 0.50% for Ti-70/30-MP.
Bone-to-implant contact (BIC%)
Bone-to-implant contact was calculated for both time periods for each experimental group 
(Table 3 & Figure 6D). At 4 weeks, similar marginal BIC values (p>0.05) of 2.4 ± 4.7% and 0.5 
± 0.7% were found for Ti-70/30-MP and Ti-50/50-MP, respectively. At 8 weeks, BIC values for 
Table 3: Data (means +SD) for bone area, CPC area and BIC percentages at all time points 
Ti-70/30-MP Ti-50/50-MP
CPC area Mean(%) ± SD n Mean(%) ± SD n
week 0 81.0 ± 0.6 3 74.8 ± 0.7 3
week 4 60.9 ± 13.5 10 53.4 ± 17.3 10
week 8 35.2 ± 21.6 10 9.1 ± 9.7 10
Bone area Mean(%) ± SD n Mean(%) ± SD n
week 0 0.0 ± 0.0 0 0.0 ± 0.0 0
week 4 5.8 ± 4.9 10 8.3 ± 2.8 10
week 8 22.9 ± 5.2 10 35.0 ± 15.0 10
BIC Mean(%) ± SD n Mean(%) ± SD n
week 0 0.0 ± 0.0 0 0.0 ± 0.0 0
week 4 2.4 ± 4.7 10 0.5 ± 0.7 10
week 8 11.7 ± 14.6 10 11.9 ± 21.2 10
BIC, bone-to-implant contact; Ti, titanium MP, milled particles; SD, standard deviation
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both experimental groups showed a temporal increase of 11.7 ±14.7% for Ti-70/30-MP and 
11.9 ±21.2% for Ti-50/50-MP. Between the groups the difference at both time points was not 
significant. The increase of BIC% between 4 and 8 weeks was significant for Ti-70/30-MP 
(p=0.0371), but not for Ti-50/50-MP (p=0.0536).
Table 4: Relative bone formation per 1% degraded material
Ti-70/30-MP Ti-50/50-MP
0-4 weeks 0.29 % 0.39 %
4-8 weeks 0.67 % 0.60 %
0-8 weeks 0.50 % 0.53 %
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Discussion
The aim of this study was to comparatively evaluate the in vitro degradation effects of dense 
PLGA microspheres and milled PLGA particles as porogens within CPC. We hypothesized 
that milled PLGA particles would evoke similar CPC/PLGA degradation compared to dense 
PLGA microspheres. Additionally, we aimed to examine the effect of PLGA porogen amount 
in CPC/PLGA via an in vivo rat femoral bone defect model to determine CPC degradation 
and bone formation. We hypothesized that a higher PLGA porogen amount would increase 
the porosity leading to faster degradation and consequently more bone formation in vivo. 
The main finding of the in vitro study was that equal amounts of either PLGA microspheres 
or milled PLGA particles resulted in similar CPC/PLGA degradation characteristics, while 
increased amount of PLGA porogens within CPC accelerated CPC/PLGA degradation. In vivo 
results further showed that CPC/PLGA with milled PLGA particles showed favorable bone 
responses without adverse events, for which a higher amount of milled PLGA particles (i.e. 
50 versus 30 wt%) incorporated within the CPC accelerated both CPC degradation and new 
bone formation within the defect area.
Previous studies have shown that properties of PLGA porogens are critical for the 
characteristics of CPC/PLGA degradation 26,27,31. For example, dense PLGA microspheres 
accelerate CPC degradation compared to hollow PLGA microspheres, with inferior additional 
effects related to PLGA molecular weight and chemical end-group modification 26,27. In view 
of future clinical application of injectable CPC/PLGA for bone regenerative purposes and the 
cost-effectiveness thereof, our in vitro study proved similar efficacy, in terms of porosity and 
degradation, in both percentages for PLGA porogens generated in the form of microspheres 
and milled particles. 
Our in vivo results of CPC/PGLA milled particles, in two weight percentages (wt%), showed 
a correlation between the degradation rate and new bone formation. Increasing the 
degradation rate of CPC with milled PLGA particles resulted in enhanced bone formation in a 
non load-bearing site in rats. The correlation between degradation and new bone formation 
was also found in the study of Felix Lanao et al. 26. Using a distal femoral condyle model in, 
they examined the influence of varying the end-group functionalization (acid terminated 
versus end capped) as well as morphology (hollow versus dense) of PLGA microspheres. 
The rate of new bone formation after 12 weeks ranged from 5 to 55% and the increase in the 
amount of bone within the defect area could be related to a faster dissolution rate of the 
CPC. The cement area was significantly reduced for the CPC containing dense microspheres, 
which resulted in more bone formation compared to CPC with hollow microspheres. 
Ruhé et al. 31 compared different wt% of CPC/PLGA in a non-critical sized calvarial rat model 
using PLGA microspheres. In contrast to our results, Ruhé et al. concluded that the 70/30 
wt% shows the most favorable biological response, whereas the 50/50 wt% of CPC/PLGA had 
less osteogenic performance compared to lower levels of PLGA. The different defect site can 
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explain the discrepancy compared to our results, as the calvarial bone is different in terms 
of vascularization and fluid exchange compared to the femoral bone.
For osteoconductive materials, the ideal rate of degradation is balanced with the rate of new 
bone formation 16,36. By performing calculations of the amount of cement being replaced by 
bone phase over time, we proved this balance to be tunable. Although faster degradation 
leads to more bone formation this was not consistent over time, as seen in the period of 4 
to 8 weeks where the cement of Ti-50/50-MP degraded faster than bone could regenerate, 
indicating the difficulty of creating a degradable material with the optimal degradation rate 
at different time points.
For future clinical application PLGA milled particles appear to be promising as CPC porogen, 
as the manufacturing yield is much higher resulting in a more cost-effective process 
compared to PLGA microspheres. Furthermore, the different morphology and wider range 
of particle size with similar mean size do not significantly influence the outcome of CPC 
degradation and bone formation. Moreover, by varying the PLGA porogen wt% degradation 
rate of CPC can be tuned to desired demands such as for different defect sites and patient 
conditions.
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Conclusion 
The results of our in vitro study of equal amounts of either PLGA microspheres or milled 
particles showed similar scaffold morphology, CPC porosity and degradation. By increasing 
the amount of PLGA porogens within CPC accelerated CPC/PLGA degradation in vitro. The in 
vivo results of CPC/PLGA with milled PLGA showed favorable bone responses. Furthermore, 
a higher amount of milled PLGA particles (i.e. 50 versus 30 wt%) accelerated both CPC 
degradation and new bone formation. For future clinical application, milled PLGA particles 
appear to be promising as CPC porogen, since the manufacturing is more cost-effective 
while maintaining a favorable bone response. Moreover, by varying the PLGA porogen wt%, 
the degradation rate of CPC is tunable to meet desired demands of different defect sites 
and patient conditions.
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CHAPTER 5
Porous titanium scaffolds with 
injectable hyaluronic acid-DBM 
gel for bone substitution in a 
rat critical-sized calvarial defect 
model
van Houdt CIA, Cardoso DA, van Oirschot BAJA, Ulrich DJO, Jansen JA, 
Leeuwenburgh SCG, van den Beucken JJJP.
J Tissue Eng Regen Med. 2017 Sep;11(9):2537-2548.
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Bone grafting is a well-described surgical technique in trauma and reconstructive surgery 
to repair and augment (damaged or diseased) bone. The ‘golden standard’ in bone grafting 
still is transplantation of autologous bone, which possesses osteogenic (by osteogenic cells), 
osteoconductive (guiding bone growth), and osteoinductive properties (by growth factors 
and/or cells) (Dimitriou et al. 2011). Despite these desirable properties, several downsides 
accompany the use of autologous bone, including limited availability, increased donor site 
morbidity, and additional surgical efforts (Dimitriou et al. 2011, Finkemeier 2002). In view of 
these disadvantages, multiple biological and synthetic bone substitutes have been explored 
over the last few decades.
In addition to the desired biological properties related to bioactivity, osteoconductivity, 
and osteoinductivity (Bongio et al. 2010), a stable environment is mandatory to achieve 
uneventful bone healing (Calori et al. 2011, Giannoudis et al. 2007, Van der Stok et al. 2013). 
Bone grafts alone do not possess the mechanical properties to secure a stable environment 
under load-bearing conditions or at vital locations. Therefore, bone grafts are often combined 
with a stabilization method such as pins, screws, plates, and intramedullary nails, often 
made out of stainless steel or alloys of cobalt, titanium or tantalum (Mantripragada et al. 
2013). Titanium is a metallic material that is successfully used for a wide variety of medical 
applications due to its strength, low density and resistance to corrosion (Mantripragada et al. 
2013, Matassi et al. 2013). With the use of selective laser sintering (SLS), tailor-made titanium 
implants can be generated in the form of porous scaffolds, which can provide stability and 
are osteoconductive (Van der Stok et al 2013, Mantripragada et al. 2013).
Allograft is an alternative for autologous bone, although immunological issues need to be 
considered regarding safe use. Allografts have a long track of clinical use and already several 
approved products are commercially available, i.e. Bio-Oss® by Geistlich (devitalised bovine 
bone) or DBXTM by DePuy Synthes (demineralised human bone) (Gruskin et al. 2012, Kurien 
et al. 2013, Urist 1965). In view of demineralized bone matrix (DBM), demineralization can 
be achieved by treatment with either an acidic solution (e.g. hydrochloric acid, HCl), or a 
chelating agent (e.g. ethylene-diamine-tetra-acetic acid, EDTA) (Bowman 1996, Catanese III 
et al. 1999, Urist 1965, Urist et al. 1967).
To improve the handling properties of DBM during surgery, efforts have focused on 
combinations with other materials (Schwartz et al. 2007, Moore et al. 2011). Carriers, such 
as glycerol, poloxamer, gelatine, calcium sulphate, lecithin, and hyaluronic acid have been 
used to obtain DBM in different forms, such as pastes, putties and gels (Drosos et al. 2007). 
These carriers can help to improve moldability, which is especially of interest for minimally 
invasive surgical procedures. The composite material must maintain graft containment during 
wound irrigation and graft localization until stabilization by new bone formation. Hyaluronic 
acid (HA) is an interesting material for bone regeneration, as it is a natural derivative found 
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in the extracellular matrix of many tissues in the body. Interestingly, several studies already 
demonstrated that HA accelerates bone formation by stimulating mesenchymal stem cell 
differentiation (Aslan et al. 2006, Kim et al. 2007, Patterson et al. 2010, Sasaki et al. 1995). 
These favourable biological properties together with its ability to be used as a cohesive 
material render HA an interesting material to combine with other bone substitute materials.
The aim of this study was to evaluate the bone-forming capacity and biological performance 
of porous titanium scaffolds filled with novel injectable HA+DBM formulations in a critical-
sized calvarial defect model in rats. A comparison was made for DBM obtained via treatment 
with either HCl or EDTA. Our hypothesis was that DBM demineralised by HCl would result 
better outcomes in terms of osteoinductivity and biodegradability compared to DBM 
demineralised by EDTA. Secondly, we hypothesized that implantation of these constructs in a 
critical-sized calvarial defect would enhance bone regeneration compared to empty scaffolds, 
with DBM demineralised by HCl performing better compared to DBM demineralised by EDTA.
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DBM (EMCM B.V., Nijmegen, the Netherlands) used in this experiment was prepared using 
either HCl or EDTA as the demineralization agent (Table 1). After obtaining DBM granules 
from a tissue bank, these were sieved in order to obtain particles with size between 250 µm 
and 500 µm. The sieved DBM particles were tested for calcium content with the objective 
of obtaining a calcium concentration between 4% and 8%. The HA gel (pre-cross linked; 
HyalTech Ltd., Livingstone, UK) was used as received.
The preparation of the composite formulations was performed by mixing each component 
using a luer-lock syringe. The DBM particles (10, 20 or 30 wt%) were put in one of the syringes 
and the HA gel in the other syringe. After connecting the two syringes with a luer-lock 
adapter, the two different components were mixed for 20 cycles.
Swelling ratio
For evaluation of fold swelling ratios, pre-set HA+DBMHCl and HA+DBMEDTA formulations were 
prepared by injection of the formulation into Teflon® moulds (Ø 10 mm, height 5 mm) and 
leaving them to cure at room temperature for 4 hours. The formulations (n=3) were placed in 
5 ml of conventional simulated body fluid (SBF; ionic concentrations: 142.0 mm Na+, 5.0 mm K+, 
1.5 mm Mg2+, 2.5 mm Ca2+, 103,0 mm Cl−, 4.2 mm HCO32-, 1.0 mm HPO42- and 0.5 mm SO42-) 
according to the protocol from Kokubo (Kokubo et al. 1990). The mass of the formulations was 
measured before immersion, 4 hours after and 24 hours after immersion. The formulations 
were removed from the solution and the liquid removed with filtration paper. The calculated 
swelling ratio (SR) was obtained using the following formula:
SR % = ((Wt - W0)/W0) x 100%
where Wt is weight of the formulation after a respective immersion time (t) in SBF and W0 
is the weight of the formulation before immersion.
Table 1: Material composition used for in vitro analysis
DBM Name 
Demineralization process wt% 
HCl 10 HA+10%DBMHCl 
20 HA+20%DBMHCl 
30 HA+30%DBMHCl 
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Immediately after curing and after 7 days immersion in SBF, the storage modulus G’ and 
damping coefficient tan delta of the HA+DBM formulations (n=3) were tested using oscillatory 
rheometry (geometry diameter 8 mm, normal force < 0.03 N, constant stress of 0.05 Pa).
Preparation of constructs for critical-sized calvarial defect surgery
A porous titanium scaffold (Ø 8mm, height 2 mm; Future Innovations B.V., Boxmeer, the 
Netherlands) was used to contain the composite HA+DBM formulations within the 
calvarial defects and provide load-bearing strength. Preparation of the constructs was 
carried out in sterile conditions, using HA and DBM sterilized by gamma irradiation (>20 
kGy; SynergyHealth B.V., Ede, the Netherlands). The composite formulations with 30% DBM 
were obtained as described above and the porous titanium scaffolds were loaded with the 
HA+DBM formulations using a sealed chamber using luer-lock. For in vivo implantation, the 
experimental groups Ti-HA+DBMHCl and Ti-HA+DBMEDTA were included.
Animals
Thirty-six healthy mature male Wistar rats (weight: ~250g) were used for this experiment for 
the calvarial defects, five of which were additionally used for subcutaneous implantation 
of DBM (Charles River Laboratories Nederland B.V., Leiden, the Netherlands). Housing was 
provided per pair in a standard macrolon type 3 cage with sawdust as bedding material. 
Standard rodent chow and bottled tap water was provided ad libitum. The housing room was 
maintained under standard laboratory conditions (light-dark cycle: 12:12h, temperature: 20-
22°C, relative humidity: 45-55%). All experiments were performed according to institutional, 
national and international guidelines for animal care and the Dutch law concerning animal 
welfare. The studies were reviewed and approved in advance by the Experimental Animal 
Committee of the Radboud University (RUDEC 2011-299 and RUDEC 2013-206).
Surgical procedures
Subcutaneous implantation
Preoperative pain medication was provided by an injection of Carprofen (5 mg/kg; Rimadyl®, 
Pfizer Animal Health, New York, USA) given at a minimum of 15 minutes before surgery. 
Anaesthesia was induced and maintained by isoflurane inhalation (Rhodia Organique Fine 
Ltd., Avonmouth, Bristol, UK) combined with oxygen. The surgical area was shaved with 
electric clippers and disinfection was performed using a povidone iodine solution. The rats 
were placed in ventral position on a heating mat. Small incisions of 1 cm were made on the 
back of the rats on each side parallel to the spine, after which subcutaneous pockets were 
created using blunt dissection with scissors. Before placing ~0.1 gram of DBMHCl or DBMEDTA in 
the subcutaneous pocket, several drops of 0.9% NaCl were added to the material to improve 
handling properties. For three animals, DBMHCl (n=3) was placed on the right side and the 
DBMEDTA (n=3) on the left side. For two animals, also 5 µg of BMP-2 (InductOs™, Medtronic 
BioPharma B.V., Heerlen, the Netherlands) was added to the 0.9% NaCl solution, for positive 
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control purposes, again placing DBMHCl right (n=2) and DBMEDTA left (n=2). The skin was closed 
with a resorbable suture (Vicryl® 4.0, Johnson & Johnson, St-Stevens-Woluwe, Belgium). 
Carprofen was given every 24 hours for a minimum of 2 days postoperatively.
Critical-sized calvarial defect
For the preparation of critical-sized calvarial defects, the same pre-operative pain 
medication, anaesthesia and animal preparations were used as described for the 
subcutaneous implantation surgery. After confirmation of effective anaesthesia, the rats 
were intubated in order to maintain an open airway and secured anaesthesia during surgery 
and a pulse-oximeter was placed to monitor the capillary blood oxygen level during surgery. 
The calvarium was exposed using a longitudinal incision through the skin, starting just caudal 
from between the eyes to ventral between the ears. After retracting the skin sideways, the 
periosteum was incised from nasal bone to just caudal of the midsagittal crest. With an 
elevator, the periosteum was pushed laterally to fully expose the bone. To further ensure 
pain management and reduce blood loss, a solution of Xylocaine® 1% with epinephrine 
1:100.000 (AstraZeneca B.V., Zoetermeer, the Netherlands) was used. After waiting for the 
solution to have effect, the bone was drilled with a dental trephine drill (8.4 mm inner and 
8.5 mm outer diameter) at a maximum speed of 1500 rpm with constant cooling by saline 
dripping. By tilting the drill laterally left and right toward the more sloped sides, an all 
around even depth into the calvarial bone was ensured. To prevent damage of the underlying 
soft tissues, such as the sagittal blood vessels and dura, the depth of the drill was frequently 
checked during surgery by slight pressure on the edges of the defect. When the correct depth 
was reached all around the defect, the bone within the defect was carefully lifted, first from 
the lateral side to release the dura and blood vessels still (partially) attached. After blunt 
dissection with a gauze sideways, the bone was freed and removed from the defect. The 
defect area was then washed with saline and checked for haemostasis before a construct 
was placed into the defect (n=6 for each group).
After introducing a construct into a calvarial defect and ensuring correct positioning, first 
Figure 1: Representative intra-operative images of A) the construct placed inside the calvarial bone 
defect, B) halfway closure of the periosteum over the construct and C) full closure of the periosteum 
over the construct.
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the periosteum layer was closed (Figure 1 A-C), using a single continuous resorbable suture 
(Monocryl® 4.0, Johnson & Johnson, St-Stevens-Woluwe, Belgium). Then, the skin was closed 
with multiple single sutures of Monocryl (Johnson & Johnson). To diminish postoperative 
discomfort, for a minimum duration of 2 days postoperatively Buprenorfine (0.02 mg/kg; 
Temgesic®, Reckitt Benckiser Pharmaceuticals Ltd., Slough, UK) was given every 12 hours. 
Additionally, Carprofen (5 mg/kg; Rimadyl®, Pfizer Animal Health, New York, USA) was given 
every 24 hours for a minimum of 2 days postoperatively.
All animals were housed as described above and had free access to pellet food and water. 
In the initial postoperative period, the intake of water and food was monitored as well as 
the weight of the animals. In addition, the animals were observed for signs of pain, infection 
and proper activity and weighed again postoperatively once a week to identify significant 
weight loss (>20%) compared to preoperative body weight of each rat.
Explantation and histological processing
The animals were euthanized by CO2 suffocation after implantation periods of 12 weeks 
for the animals that received subcutaneous implants and after implantation periods 
of 2 and 8 weeks for animals with calvarial defects. After the animals were euthanized, 
the subcutaneous implants and calvarial bones including the implanted materials were 
harvested and immediately fixed in 10% neutral buffered formalin solution. After 24 hours 
of fixation, the specimens were dehydrated in a graded series of ethanol.
Encapsulated materials from the subcutaneous pocket were processed for paraffin 
embedding. Using a microtome (Leica® RM 2165, Leica Microsystems, Nussloch Germany), 
thin sections (6 μm) were made and stained with haematoxylin-eosin (HE) or Elastic-Van 
Gieson (EVG).
All calvarial bone specimens were embedded in poly(methylmethacrylate) (pMMA). Sections 
were prepared in the coronal plane of ~10 μm using an inner circular diamond saw and 
constant cooling (Leica® Microsystems SP 1600, Nussloch, Germany). Staining was performed 
for each section with methylene blue and basic fuchsine.
Descriptive histology and histomorphometry
Histological slides, either from paraffin or pMMA sections, were examined by light microscopy 
(Zeiss® Imager Z1 Microscope, Carl Zeiss Microimaging GmbH, Göttingen, Germany). 
Descriptive histology and histomorphometry were performed based on colour discrimination 
and morphological aspect.
For the paraffin sections, HE and EVG staining allowed to distinguish soft tissue from bone or 
DBM. Descriptive analysis was performed on all sections to detect whether bone formation 
had occurred and if DBM remnants were present.
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For sections of calvarial defects, the amount of bone formation and DBM remnants were 
quantitatively assessed using computer-based image analysis techniques (Leica® Qwin 
Microsystems Imaging Solutions Ltd., Cambridge, UK). Within the digitalized images of 
the sections, a rectangular region of interest (ROI) was set around the porous titanium 
constructs. The area percentage of newly formed bone and DBM remnants within this ROI 
was quantitatively measured for each section separately.
Statistical analysis
Data were presented as means with standard deviations (SD). The in vitro data and mean 
area percentages of new bone formation and DBM remnants were statistically analysed 
using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, California USA). The statistical 
comparisons between experimental groups were analyzed with one-way analysis of variances 
(ANOVA) combined with a Tukey Multi Comparisons post-hoc test. All intra-group temporal 
analyses, in vitro and in vivo, and in vivo inter-group analyses on DBM-remnants were 
performed using unpaired t-tests. Differences were considered significant at a p-value < 0.05.
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Figure 2 shows the effect of SBF immersion on the mass of HA+DBM formulations. All 
formulations displayed a mass increase after 4 hours, which continued after leaving 
the formulations for up to 24 hours in solution. The initial mass increased significantly 
between 4 and 24 hours for all formulations (HA+10%DBMHCl p=0.0006, HA+20%DBMHCl 
p=0.0119, HA+30%DBMHCl p=0.0138, HA+10%DBMEDTA p=0.0004, HA+20%DBMEDTA p=0.0034 and 
HA+30%DBMEDTA p=0.0056). Formulations with relatively less DBM displayed significantly 
more swelling. These differences were increased after 24 hours of immersion, when the 
formulations with 10% and 20% DBMHCl or DBMEDTA swelled significantly more than those with 
30% DBMHCl or DBMEDTA (p<0.001 and p<0.01 respectively). The difference between 10% and 20% 
DBMHCl was also significant after 24 hours (p<0.05).
Figure 2: Percentage mass change, samples measured after 4 and 24 hours of immersion, compared 
to the mass measured before immersion (n=3); between the different formulas there is more mass 
change with a lower amount of DBM: *) p<0.05, **) p<0.01 and ***) p<0.001; between 4 and 24 hours the 
mass significantly increased for all formulations: a) p=0.0006, b) p=0.0119, c) p= 0.0138, d) p= 0.0004, e) 
p=0.0034 and f) p=0.0056.
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Figure 3: A) Storage moduli of experimental HA+DBM composites (G’, n=3) (**p<0.01 and ***p<0.001; a, 
HA+20%DBMHCl p=0.0013, b, HA+30%DBMHCl p<0.0001, c, HA+20%DBMEDTA p= 0.0029, and d, HA+30%DBMEDTA 
p<0.0001). B) Loss moduli of experimental HA+DBM composites (G’’, n=3) (**p<0.01, ***p<0.001; e p=0.0005, 
f, p=0.0052, g, p= 0.0030, and h, p=0.0098. C) Tan δ values (=G’’/G’) of experimental HA+DBM composites 
showing values below 1 for all composites.
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Rheology
The storage modulus (G´) of each formulation strongly increased with increasing DBM 
content. All formulations had a tan delta value below 1, which reflects that solid-like 
behaviour dominated viscous behaviour for all formulations. After leaving each formulation 
for seven days in contact with SBF, a decrease in the storage modulus was observed for all 
formulations. The highest difference was observed for the formulations containing 30% of 
DBM, followed by the formulations containing 20% and 10%. No difference in viscoelastic 
parameters were observed related to the preparation method of the DBM particles.
Clinical observations of the experimental animals
In three of the total thirty-six animals receiving critical-sized calvarial defects, extensive 
haemorrhaging from the sagittal sinus occurred during surgery and the animals were 
euthanized whilst still under anaesthesia. All other animals recovered well from surgery and 
remained in good health during the entire experimental period without any signs of illness 
or postoperative wound healing complications. At sacrifice for all implantation periods, the 
wound areas showed no signs of inflammation or adverse tissue reaction and all porous 
titanium constructs were in correct position. All remaining constructs were retrieved and 
used for further analysis.
Descriptive histological evaluation
Subcutaneous implants
Light microscopy of the encapsulated materials from the subcutaneous pockets revealed 
that the positive controls of DBMHCl and DBMEDTA with BMP-2 showed newly formed bone 
(Table 2). None of the DBM specimens without BMP-2 (i.e. neither DBMHCl nor DBMEDTA) showed 
bone formation. Remnants of DBM were observed for all specimens containing DBMEDTA 
(with or without BMP-2). In contrast, DBMHCl remnants were observed for only 1 specimen in 
combination with BMP-2.
Critical-sized calvarial defects
Representative histological images for each experimental group are presented in Figure 
4. Examination by light microscopy revealed periosteal swelling at 2 weeks, but this effect 
seemed to be fully recovered at 8 weeks for all implanted constructs. Further visual 
examination revealed no signs of severe inflammation or other adverse tissue reaction. 
New bone growing into the porous titanium construct could easily be distinguished by colour 
discrimination following the applied staining techniques. Since staining of DBM particles can 
appear similar to that of vital bone, attention was paid to cell morphology and presence of 
nuclei to distinguish between newly formed bone and DBM.
At 2 weeks, the defects with Ti-Empty constructs showed apparent bone formation in all 
sections, whereas Ti-HA+DBMHCl and Ti-HA+DBMEDTA only occasionally showed bone formation. 
For each experimental group, evidently more bone ingrowth and new bone formation was 
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Figure 4: Representative histology for all experimental groups obtained by light microscopy, showing 
an overview (left panel) and detail (right panel) after 2 and 8 weeks of implantation; Ti= titanium, B= 
bone, blue arrows indicate DBM remnants.
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observed after 8 weeks compared to 2 weeks implantation. For 8 week implantation, the 
most obvious bone ingrowth and formation was observed for Ti-Empty constructs. Bone 
ingrowth reached to the centre in several sections of Ti-Empty constructs, while remaining 
rather peripheral for both Ti-HA+DBMHCl and Ti-HA+DBMEDTA constructs.
Bone formation beneath the porous titanium construct was observed for four defects, all 
of which received Ti-HA+DBMHCl constructs. For these constructs, relatively limited bone 
formation was observed for two defects at 2 weeks and more prominent bone formation 
was seen in two cases at 8 weeks (Figure 5).
Histomorphometrical analysis
Newly formed bone (%) in critical-sized calvarial defects 
Mean percentages of newly formed bone within the calvarial defects are shown in Figure 6. 
At 2 weeks, significantly more bone was present for Ti-Empty (3.8 ± 2.2%) compared to Ti-
HA+DBMHCl (0.8 ±0.6%; p=0.022), but not to Ti-HA+DBMEDTA (1.5 ±1.3%; p>0.05). At 8 weeks, newly 
formed bone values were similar among the experimental groups (p>0.05), with values of 12.6 
± 13.0%, 3.7 ± 2.8%, and 1.5 ± 1.0% for Ti-Empty, Ti-HA+DBMHCl, and Ti-HA+DBMEDTA, respectively. 
The amount of bone formation improved significantly for both Ti-Empty and Ti-HA+DBMHCl 
from 2 to 8 weeks (p=0.0155 and p=0.134 respectively), while Ti-HA+DBMEDTA showed similar 
values for both implantation periods (p>0.05).
DBM remnants (%) in critical-sized calvarial defects
At 2 weeks, the percentage of DBM inside Ti-HA+DBMHCl and Ti-HA+DBMEDTA constructs showed 
significantly different values of 4.3 ± 2.0% and 7.2 ± 1.0%, respectively (p=0.0087; Figure 6). At 
8 weeks, DBM remnants for Ti-HA+DBMHCl showed a similar value of 3.2 ± 1.5% (p>0.05), while 
Ti-HA+DBMEDTA showed a temporally reduced value for DBM remnants of 3.0 ± 1.8% (p<0.0003).
Figure 5: Representative histological image (light microscopy) of a Ti-HA+DBMHCl construct placed in a 
rat calvarial defect after 8 weeks of implantation. The panel on the right shows a magnification of bone 
formation below the construct. (Ti= titanium, B= bone).
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Figure 6: Histomorphometrical data on new bone formation (dark blue) and DBM remnants (light blue; 
in area percentage ± SD). *p=0.022 for new bone formation, **p= 0.01 for DBM remnants. Temporal 
differences on new bone formation: a, p=0.00155, b, p=0.0134; temporal difference on DBM remnants: c, 
p=0.003.
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Discussion
The aim of this study was to evaluate the bone-forming capacity and biological performance 
of porous titanium scaffolds filled with novel injectable HA+DBM formulations in a 
critical-sized calvarial defect model in rats. A comparison was made for DBM obtained 
via a demineralization treatment with either HCl or EDTA. Our hypothesis was that DBM 
demineralised by HCl would result better outcomes in terms of osteoinductivity and 
biodegradability compared to DBM demineralised by EDTA. Secondly, we hypothesized that 
implantation of these constructs in a critical-sized calvarial defect would enhance bone 
regeneration compared to empty scaffolds, with EDTA demineralised by HCl performing better 
compared to DBM demineralised by EDTA. Our observations did not reveal any osteoinductive 
properties of DBM upon ectopic implantation. Bone forming capacity of the HA gel containing 
DBM was not enhanced compared to the osteoconductive properties of an empty porous 
titanium scaffold in a critical-sized calvarial defect in rats. Although the empty porous 
titanium scaffolds demonstrated an accelerated bone formation, similar amounts of newly 
formed bone were found after 8 weeks.
Using DBM in dry form can become cumbersome regarding its delivery to and containment 
at the surgical site (Moore et al. 2011, Schwartz et al. 2007). To overcome these handling 
difficulties, multiple types of carriers are available to improve applicability of DBM, such as 
pastes, putties and gels (Drosos et al. 2007). Several studies have shown that HA can improve 
bone formation and serve as a suitable carrier, i.e. for cells, growth factors or drugs (Aslan et 
al. 2006, Kim et al. 2007, Martinez-Sanz et al. 2011, Patterson et al. 2010). HA is one of the major 
components of the extracellular matrix found in the human body. Although predominantly 
present in soft tissues, it has been reported that HA is capable of accelerating new bone 
formation in vivo by stimulating the differentiation of mesenchymal stem cells (Aslan et 
al. 2006, Kim et al. 2007, Patterson et al. 2010, Sasaki et al. 1995). We examined different 
formulations of HA and DBM with 10, 20 or 30 wt% DBM that was demineralised using either 
treatment HCl or EDTA. Formulations with relatively more DBM displayed significantly less 
swelling. Moreover, the storage modulus (G´) of each formulation increased with increasing 
DBM content, thereby confirming that the DBM particles stiffened the formulations. The 30 
wt% DBM prepared via treatment with either HCl or EDTA in HA-gel had the highest storage 
modulus and hence was chosen as composite formulation for the in vivo study. In view of 
loading and retention issues within the porous titanium scaffold used for the in vivo model, 
only experimental groups combining HA and DBM within the porous titanium scaffold were 
used.
DBM has the advantage of excellent biocompatibility and the demineralization process has 
been suggested to expose growth factors such as BMPs rendering DBM osteoinductive (Calori 
et al. 2011, Wildeman et al. 2007, Dinopoulos et al. 2006). The osteoinductive properties, 
however, can vary depending on the donor but also on DBM processing technique (Drosos 
et al. 2007, Li et al. 2000, Pietrzak et al. 2006, Schwartz et al. 2007, Takikawa et al. 2003). We 
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aimed to detect differences in degradation and osteoinductive capacity between DBM that 
was demineralised by treatment with either HCl or EDTA. Already in 1965, Urist examined bone 
allograft demineralised by HCl and EDTA and stated that it is an excellent substitute for a 
bone graft (Urist 1965). He noticed that bone demineralised by HCl showed a slightly more 
positive result of bone formation, measured by histological and radiographic assessment, 
compared to EDTA. Our subcutaneously implanted DBMHCl and DBMEDTA showed no bone 
formation. On the other hand, positive controls consisting of either type of DBM with the 
osteoinductive agent BMP-2 showed extensive bone formation. Regarding degradation of 
DBM at this ectopic site, less remnants of DBMHCl remained after 8 weeks compared to 
DBMEDTA. The concentration of osteoinductive agents in bone matrix can greatly vary per 
donor (Takikawa et al. 2003, Pietrzak et al. 2006). To eliminate this variable and better 
compare the two preparation methods within our study, only one DBM donor was used. 
Current donor selection for bone banking is mainly based on transmittable diseases and not 
on osteoinductive properties (Schwartz et al. 1998, Abbas et al. 2007). A correlation between 
increased age and low BMP amounts has been suggested (Lohmann et al. 2001, Schwartz et 
al. 1998, Traianedes et al. 2004, Zhang et al. 1997). However, there are controversial results and 
the exact underlying mechanism remains unknown (Pietrzak et al. 2006). To improve donor 
selection more research is needed to better predict osteoinductive properties of allografts. 
Although our DBM did not present osteoinductive properties, the reported favourable 
biocompatibility (Moore et al. 2011, Schwartz et al. 2007) and long clinical history of DBM as 
a bone substitute made us hypothesize that these types of DBM might still have a positive 
effect on bone formation orthotopically, when incorporated into the HA gel. 
The critical-sized calvarial defect in rats is a reproducible and versatile model to observe 
bone forming capacity of bone substitute material. The model is convenient due to its 
easy accessibility and allows for evaluation of biomaterials for bone tissue engineering 
approaches within an orthotopic site (Mendes Brazão et al. 2010, Spicer et al. 2012). Several 
previous studies have shown bone growth within the defect already after 2 weeks after 
implantation (Jansen et al. 2005, MacIsaac et al. 2013). Depending of the different clinical 
relevance, animal models are chosen and should represent the complex environment in 
which clinical bone regeneration procedures are performed. The calvarial defect model 
can represent several cranial reconstructions in the clinic, representing a non-load bearing 
site. The calvarium is easily accessible, however, when creating a critical-sized bone defect, 
there is a risk of damaging the dura or sagital sinus. Generally, calvarial defects of 8 mm 
are considered as critically-sized (for extended evaluation periods; i.e. >6 weeks). Although 
5 mm defects have been suggested, this only seems to be critical for shorter time periods 
up to 2 weeks (Porto et al. 2012, Spicer et al. 2012). In the past, ultrasonic devices have been 
used, only cutting hard tissue without damaging soft tissues due to the ultrasonic frequency. 
However, in the study of Bodde et al. it was found that calvarial defects created with an 
ultrasonic device had less optimal bone/implant contact compared with the trephine bur 
method at 4 weeks of implantation (Bodde et al. 2008). Therefore, for this study we chose to 
create an 8 mm defect using a trephine drill to test the optimal bone regenerative properties.
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Histomorphometry was used in this study to perform bone volume analysis. There is an 
ongoing development based on analyses of bone mineral content by micro CT (Sehmisch et 
al. 2008, Umoh et al. 2009). This technique provides several advantages, such as comparison 
per subject over time (i.e. in vivo micro CT) and 3D reconstruction with quantitative 
measurements. Despite improvements in spatial resolution of micro CT images, the 
combination of histology and histomorphometry still provides the highest resolution. For 
future research, however, micro CT images can be considered simultaneously to compare 
and further improve understanding of both techniques.
In this study, we combined an injectable HA and DBM gel with a porous titanium scaffold. 
These scaffolds not only provided structural support, but additionally demonstrated 
osteoconductive capacity, as previously demonstrated by Van der Stok et al. (Van der Stok 
et al. 2013). In more detail, the osteoconductive properties of the porous titanium scaffold 
proved beneficial in a critical-sized segmental femoral defect in rats. Our result confirmed 
the osteoconductive properties of the titanium constructs, as bone reached the centre of the 
empty scaffolds after 8 weeks. Overall, our results showed bone formation into the scaffolds 
in all groups, but surprisingly both our composite constructs showed less bone formation 
compared to the empty scaffolds. Hypothetically, the lack of pores in the HA gel at time of 
implantation prevents osteogenic cells to reach the inner part of the material. The study of 
Klijn et al. showed the importance of instantaneously versus delayed porosity examined in a 
rat skull augmentation model. Instantaneous pores in calcium phosphate cement showed an 
increased amount of bone formation and also bone reached further into the scaffold (Klijn et 
al. 2010). The advantage of instantaneous porosity was hypothesized to allow direct influx of 
body fluid, proteins and cells. It was shown by Ruhé et al. using fluorochrome labelling that 
bone formation can already proceed into the macropores within one week after implantation 
(Ruhé et al. 2004). Our histological images showed that the titanium scaffolds with HA gel had 
little bone ingrowth and still contained HA gel after 8 weeks. Most likely the HA gel with DMB 
inside the scaffold hampered tissue ingrowth and hence was limiting the osteoconductive 
properties of the titanium and DBM within the constructs.
The limited infiltration of cells into the gel was also observed by others (Bongio et al. 2013, 
Nejadnik et al. 2014). In the study by Nedjadnik et al., covalently cross-linked HA gel with and 
without bisphosphonate (BP) or calcium phosphate (CaP), respectively denoted as HA, HABP 
and HA+CaP, were compared to non-covalent cross-linked HA gel with BP and CaP (HABP•CaP) 
in rats subcutaneously and in a femoral bone defect model. Bone formation was detected for 
all gels only at the bone-material interface after 1 week. However, after 4 weeks the HABP•CaP 
showed newly-formed trabecular-like bone homogeneously interspersed throughout the 
material. It was suggested that the more homogeneous nanostructure contributed to a 
more stable environment for attachment of osteoprogenitor cells resulting in a more 
homogeneous degradation.
Beside the possible lack of pores and inhomogeneous degradation, other issues need to 
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be considered when working with HA as a carrier. Previous studies have proven that HA gel 
alone is not a suitable bone substitute material and several explanations are given (Aslan 
et al. 2006, de Brito Bezerra et al. 2012, Maus et al. 2008, Mendes Brazão et al. 2010). De Brito 
Bezerra et al. examined a HA gel and collagen sponge in a critical-sized calvarial defect and 
also found no additional effect of the HA gel (de Brito Bezerra et al. 2012). In their reflection, 
this issue was related to HA being available in different molecular weights and this having 
an effect on the osteogenesis. In the study of Maus et al., a HA gel with or without BMP-2 
was used in a femoral defect in sheep (Maus et al. 2008). Less bone formation was found 
compared to autologous graft and even slightly less to an empty defect. It was argued that 
the effect of HA is transmitted by different receptors and that HA stimulates the expression 
of RANKL as proven by Cao et al. (Cao et al. 2005). This could explain the negative effect 
of the HA gel, as RANKL is associated with osteoclast differentiation and activation and 
thus indicates the need for an osteoinductive addition to the gel. Maus et al. postulated 
that possibly the BMP-2 group did not contain BMP-2 due to washing of the material intra-
operatively and therefore there was a lack of bone growth.
Our data showed no significant difference in amount of bone formation between the two 
preparation methods of DBM when placed in a critical-sized calvarial defect. However, 
there was a significant temporal increase in bone growth for Ti-HA+DBMHCl constructs from 
2 to 8 weeks of implantation. Moreover, only in Ti-HA+DBMHCl constructs bone was formed 
outside the scaffold. These data corroborate the first results of Urist (Urist 1965) and it 
could indicate that DBMHCl degrades faster and is slightly more osteopromotive compared to 
DBMEDTA. The amount of DBMEDTA remnants at 2 weeks was significantly lower in comparison 
to DBM preparation with HCl, however, after 8 weeks both DBM amounts were reduced 
to similar levels. This indicates that within the first two weeks after implantation, DBMHCl 
degrades faster compared to DBMEDTA. Also ectopically the results showed DBMHCl to have a 
faster degradation rate than DBMEDTA. The exact underlying mechanism of this effect remains 
unclear, however, this could possibly explain the significant temporal increase of bone 
formation when using DBMHCl. 
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Conclusion
Our results showed under the current experimental conditions no osteoinductive capacity 
of ectopically placed DBM. Hyaluronic gel composite with DBM in titanium constructs 
was generally well tolerated in the rat calvarial defects. Bone forming capacity of the gel 
containing DBM was not enhanced compared to the osteoconductive properties of an empty 
porous titanium scaffold.
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Osteoporosis is the most frequent human metabolic bone disorder affecting over 75 
million people in Europe, Japan and the USA 1. As such, osteoporosis represents a major 
health problem in terms of compromising bone strength and increasing the risk of bone 
fractures 2. In patients suffering from osteoporosis, the bone healing process is negatively 
influenced 3, which challenges the treatment of bone defects or bone fractures. Bone grafting 
is a widely-used therapy to reconstruct bone defects, although it remains a challenging 
problem particularly for compromised conditions such as osteoporosis. Autologous bone 
transplantation can be employed to regenerate bone defects, but its use is hampered by 
the need for additional surgical procedures and potential limitations in bone quality and 
quantity. Alternatively, the use of allografts and xenografts is related to immunological 
issues and an increased risk of cross-species disease transmission 4,5. In contrast, the use 
of synthetic biomaterials as a bone substitute has many advantages, including off-the-shelf 
availability in various shapes and sizes. Still, the biological performance of synthetic bone 
substitutes is inferior to autologous bone 6. Consequently, optimization of the biological 
performance of synthetic bone substitutes via e.g. the release of biologically active factors 
is a highly explored field within bone biomaterials research 7.
Osteoporosis is characterized by reduced bone mineral density causing lower bone mass and 
deterioration of bone tissue micro-architecture. This results from an imbalance between the 
continuous bone formation and resorption during bone remodeling and an altered variety 
of proteins in the extracellular matrix of the bone 8,9. Osteoporosis is primarily observed 
after menopause in women, with increasing age in both women and men (ratio of 2:1), or 
secondary by chronic predisposing medical problems 10. World-wide life expectancy has 
increased over the last couple of decades for both men and women, resulting in an aging 
population 1,2,11,12. This increase in elderly people is expected to continue, ultimately resulting 
in a further increased need of reliable bone grafting materials for elderly, osteoporotic 
patients.
The mostly prescribed medication for osteoporosis are bisphosphonates 13. The regular route 
of administration is oral, for which it has been observed that 24h excretion levels by the renal 
system reach percentages of 38% to 73% 14. The major disadvantage of oral administration 
of bisphosphonates is their poor absorption from the gastro-intestinal tract, generally less 
than 1% 15. This is further negatively influenced when the stomach contains food or has the 
presence of calcium 15. The bisphosphonate fraction remaining in the body predominantly 
localizes to areas with high bone turnover by exploiting its affinity to mineral within the bone 
extracellular matrix. After localizing to these areas, bisphosphonates can remain within the 
bone for many years. Among the different types of bisphosphonates, ALN and risedronate 
are frequently chosen because these both increase bone mineral density, reduce the risk of 
fracture, and are well tolerated 16.
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In view of the aforementioned, optimization of synthetic bone substitutes with 
bisphosphonates to locally adjust the imbalance in bone remodeling seems a straightforward 
approach to aid bone regeneration in osteoporotic conditions. Among the currently 
available synthetic bone substitutes, calcium phosphate (CaP) based materials are inorganic 
biomaterials that show high similarity to bone tissue by resembling the mineral phase 
of bone and are already popular implant materials in several fields of surgery 17. Calcium 
phosphate cement (CPC) represents a suitable scaffold material for bone regenerative 
treatment 18,19. CPC has the advantage of being injectable and moldable, for which it allows 
perfect filling directly into a bone defect or by pre-setting it in a specifically designed 
mold fitted to the defect requirements. When adding porogens, (e.g. poly(lactic-co-glycolic 
acid) (PLGA) microspheres) to CPC, controlled degradation of the material can be obtained 
as well as the possibility to release bioactive agents, e.g. osteoinductive growth factors 
or therapeutic drugs 18,20. Previous in vitro studies proved a successful incorporation of 
bisphosphonates into ceramic bone substitutes 21-33. Generally, these studies showed altered 
but still acceptable material properties, steady release of the bisphosphonate with inhibition 
of osteoclasts and stimulation of osteoblast. Only a few reported on ceramic implants used 
in vivo 34-37. These all showed positive results of the material on bone formation. 
Here, we used the anti-osteoporotic drug ALN to functionalize CPC/PLGA. We characterized 
the material morphologically and crystallographically, analyzed setting time and mechanical 
properties, and determined ALN release kinetics. In addition, we used a femoral condyle bone 
defect model in osteoporotic rats to comparatively evaluate the biological performance of 
ALN-loaded CPC/PLGA. We hypothesized that loading CPC/PLGA composites with ALN would 
(i) not critically affect material morphology and crystallography, (ii) promote controlled ALN 
release, and hence (iii) enhance the biological performance of CPC/PLGA in osteoporotic 
conditions by increasing bone formation rate and volumes.
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Alpha tri-calcium phosphate (α-TCP) was provided by Cam Bioceramics B.V. (mean particle 
~4.0 µm; Leiden, The Netherlands). Poly(DL-lactic-co-glycolic acid) PLGA particles (containing 
both a lactic and glycolic weight percentage of 50%; particle size ~60 µm) was obtained from 
Corbion (PLGA, Purasorb®, Gorinchem, The Netherlands). Carboxymethylcellulose (CMC) was 
purchased from Kelco (Georgia, USA) and Alendronate (ALN) was purchased from AK Scientific 
(Union City, California, USA).
Preparation of CPC/PLGA and CPC/PLGA-ALN composites
CPC/PLGA composites were prepared by weighing 0.597 g of α-TCP, 0.398 g of PLGA and 0.005 
g of CMC in a beaker. Subsequently, the liquid component (4% NaH2PO4 solution) was added 
in a liquid/power ratio of 0.50 and the composition was mixed with a spatula. Afterwards, the 
composite was injected, using a 2 ml syringe (BD Plastipakt, Becton Dickinson S.A., Madrid, 
Spain), into teflon molds to obtain cylinders of 5 mm x 3 mm (diameter and height) for in 
vitro analysis. For mechanical tests, cylinders of 6 mm x 12 mm (diameter and height) were 
prepared utilizing different molds. 
ALN was introduced into CPC/PLGA scaffolds via the liquid CPC component. Briefly, ALN 
was dissolved in 4% NaH2PO4 at different concentrations (range: 0-6 wt% for setting time 
investigations) and the pH was adjusted to ~7.4. The selected experimental groups are 
presented in Table 1.
For in vivo experiments, pre-set cylindrical CPC/PLGA composites (2.5 mm in diameter and 
5 mm in height) were prepared, either or not containing ALN (2 µg/ml for the CPC/PLGA-
lowALN) within the liquid component. This concentration corresponds to 0.5 wt.% ALN. After 
setting for 24h at room temperature, composites were removed from the mold and sterilized 
using ethylene oxide (Synergy Health, Venlo, The Netherlands).
Material characterization
Setting time
The setting time of CPC-formulations was determined using the Gillmore needle method at 
37°C, as described previously (ASTM C266, 1999) 67. For this purpose, a bronze block containing 
six holes was used as a mold (6 mm in diameter, 12 mm in height). The different formulations 
(n=3) were inserted into the mold in order to assess the initial and final setting.
Morphology
Immediately after setting, the samples were mounted on stubs with carbon tape and sputter 
coated with gold. SEM (SEM, JEOL 6310) was performed to examine the structural morphology 
of the composites.
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Physico-chemical analysis
Immediately after preparation and setting, the samples were pulverized and submitted to 
Fourier transform infrared spectroscopy (FTIR; Perkin-Elmer 1700, UK). FTIR was performed 
to characterize the chemical bonds present in the samples. Analyses were done using 
pulverized samples in the range of 520-4000 cm-1 with a resolution of 2 cm-1. The samples 
were scanned 100 times for each FTIR measurement and the spectrum acquired was the 
average of all these scans.
X-ray diffraction (XRD, Cu-Ka, 45 kV, 30 mA, Philips BV, the Netherlands) patterns of pulverized 
samples were collected (2θ range: 20-40°) to crystallographically characterize the phases. 
XRD evaluation was done at days 0, 3, 7 and 148 after incubation in 1.0 ml of phosphate 
buffered saline solution (PBS; pH 7.4).
Mechanical testing
After setting, the compressive strength (CS) of the CPC cylinders was measured, in the 
longitudinal direction of the specimens, at a loading rate of 1 mm/min using a testing bench 
machine (Model 858, Mini-Bionix II, MTS Systems Corp., Eden Prairie, MN, USA) using three 
cylinders per experimental group (n=3).
ALN release from CPC/PLGA-ALN composites
In vitro release tests were performed by soaking one sample cylinder of each CPC formulation 
in 1.0 ml of PBS and incubating the samples (n=3) under agitating conditions at 37°C. ALN 
release was determined using a ninhydrin assay on releasates collected after selected time 
periods (range: 1-148 days) 68. Briefly, 100 µL of releasate (complete removal of 1 ml and 
addition of 1 ml of fresh PBS) or standard (serial dilutions of ALN; range: 0-200 µM) was 
pipetted in a 96-well plate, after which 75 µL of ninhydrin color reagent (Sigma-Aldrich, 
St. Louis, USA) was added for incubation at 80°C for 30 min. Subsequently, the well plate 
was cooled and 100 µL of stabilizing solvent (50% ethanol) was added into each well. The 
absorbance of each well was measured on a microplate spectrophotometer at 570 nm (Bio-
Tech Instruments, Winooski, VT, USA).
Biological performance
Animals
For this experiment, twelve healthy mature female Wistar rats were used at 3 months of 
age with an average weight of ~200 g. Animals were allowed to acclimatize for 7 days and 
housing was provided per pair in a standard macrolon type 3 cage. To induce an osteoporotic 
condition, rats were subjected to bilateral ovariectomy (OVX). All rats received two surgical 
procedures during the course of the experiment: OVX surgery and 6 weeks later bone 
defect surgery. After OVX surgery, a low calcium diet was provided during six weeks with 
pellets containing 0.01% calcium and 0.77% phosphorous (Ssniff Spezialdiäten GmbH, Soest, 
Germany). After the bone defect surgery, a standard rodent chow was provided ad libitum. 
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The housing room was maintained under standard laboratory conditions (light-dark cycle: 
12:12h, temperature: 20-22°C, relative humidity: 45-55%). All experiments were conducted 
in accordance with institutional, national and international guidelines for animal care and 
the Dutch law concerning animal welfare. The studies were reviewed and approved by the 
Experimental Animal Committee of the Radboud University (RUDEC 2013-080).
Surgical procedure to induce osteoporotic conditions
All animals received OVX surgery through two separate incisions in the lateral abdominal 
wall. The same procedure was followed as previously described by Alghamdi et al 69.
Surgical procedure to create and fill femoral bone defects
Six weeks after OVX surgery, a bone defect was created in both femoral condyles of each 
animal. Alternating the left and right femur, CPC/PLGA-blank and CPC/PLGA-lowALN, pre-
set composites were used to fill the defects. Anesthesia was induced and maintained by 
Isoflurane inhalation (Rhodia Organique Fine Limited) combined with oxygen delivered by 
mask. Pre-operatively pain medication was provided by an injection of Carprofen (Rimadyl®, 
Pfizer Animal Health, New York, USA) in dosage of 5 mg/kg, given 15 min before surgery. For a 
minimum duration of 2 days postoperatively, Carprofen was given every 24h. Additionally, to 
diminish postoperative pain, Buprenorfine (Temgesic®, Reckitt Benckiser Health Care Limited, 
Schering-Plough, UK) was given every 12h in a dosage of 0.01 mg/kg. Additionally, to ensure 
adequate postoperative analgesia, before closing the wound local drop anaesthesia was 
provided by Lidocaïne (10 mg/ml Lidocaïne FNA, Centrafarm B.V., Etten-Leur, the Netherlands) 
and Bupivacaïne (5 mg/ml Bupivacaïne Actavis, Actavis B.V., Baarn, the Netherlands) diluted 
with NaCl using ~1 ml per rat containing 1 mg of Lidocaïne and 0.25 mg of Bupivacaïne.
Before creating femoral defects, both hind limbs of the rats were shaved and disinfected with 
povidone iodine. The rats were immobilized in supine position and with the knee maximally 
flexed a longitudinal incision through skin and muscle was made on the medial surface. After 
exposure of the medial side of the distal femoral condyle, the knee capsule was incised. 
Then, the knee was extended to luxate the patella laterally. When a clear view of the knee 
joint was established, a bone defect (Ø 2.5 mm, depth 5 mm) was created longitudinal to the 
axis of the femur, using a dental drill (Elcomed 9927 SPS; W&H Dentalwerk Burmoos GmbH, 
Burmoos, Austria). A series of increasing bur diameters (1.5–2.0–2.3–2.5 mm) were used at a 
speed of maximum 5000 rpm and a constant cooling by dripping saline. The drilled cavity 
was then washed with saline and dried using sterile gauze.
Subsequently, the CPC/PLGA composites were alternatingly placed into the defect. A total 
of 24 implants were used, resulting in n=6 per group. To increase statistical power paired 
analysis was made possible by combining CPC/PLGA-blank with CPC/PLGA-lowALN in each 
rat. After local drop anesthesia, the muscular tissue layer was closed with absorbable sutures 
(Vicryl® 4.0, Ethicon, Amersfoort, The Netherlands) after which the skin was closed by small 
staples (Agraven®; InstruVet BV, Cuijk, The Netherlands). In the initial postoperative period, 
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the intake of water and food was monitored as well as the weight of the animals. In addition, 
the animals were observed for signs of pain, infection and proper activity and weighed 
again postoperatively once a week to identify significant weight loss (>20%) compared to 
preoperative body weight of each rat.
Fluorochrome labeling for bone dynamics analysis
Animals assigned to a 12-week implantation period received a series of four fluorochromes 
(SigmaAldrich; Munich, Germany) by subcutaneous injection with a 2-week interval, starting 
two weeks after implantation surgery: Calcein blue (product no. M1255, dose 30 mg/kg; week 
2), calcein green (C0875, 10 mg/kg; week 4), alizarine complexone red (A3882, 25 mg/kg; 
week 6) and rolitetracycline yellow (R2253, 25 mg/kg; week 8). Before injection, the solutions 
were set to neutral pH (7.2-7.4), then filtered through a 0.22 sterile millipore filter, and finally 
checked for fluorescence.
Specimen retrieval
After implantation periods of 4 and 12 weeks, the animals were euthanized by suffocation 
with CO2. The femurs including the implanted materials were harvested, stripped from soft 
tissues and immediately fixed in 10% formalin solution. Using a diamond saw, the specimens 
were cut to become suitable for ex vivo micro-CT scanning and histological processing. After 
fixation, specimens were stored in 70% ethanol.
Micro-CT
A desktop X-ray micro-CT system was used (Skyscan-1072, TomoNT version 3N.5, Skyscan®, 
Kontich, Belgium) for 3D imaging. The specimens were placed onto the sample holder with 
the long axis of the femur perpendicular to the scanning beam. 3D reconstruction and 
imaging processing was performed using NRecon V1.4 and CTvox v2.7 (Skyscan®, Kontich, 
Belgium), respectively.
Histological processing
After performing micro-CT scanning, the specimens were dehydrated in a graded series of 
ethanol (70%-100%), after which they were embedded in polymethylmethacrylate (pMMA). 
After polymerization, thin sections of 10 μm were prepared in a cross-sectional direction 
perpendicular on the longitudinal direction of the defect using a diamond blade microtome 
(Leica Microsystems SP 1600, Nussloch, Germany) using a sawing technique as previously 
described 69,70. Using this microtome sawing technique, at least three sections of ~10 μm thick 
per specimen are cut with intermediate loss of ~300 μm (thickness of sawing blade). With this 
loss the sections are therefore 300 μm separated from each other. The first section of each 
specimen was aimed at the center of bone defect or slightly proximally and then continued 
distally on the femur. The bone defect was created at distal end of the femur with a diameter 
of 2.5 mm and depth of 5 mm (for further information also see section “Surgical procedure 
to create and fill femoral bone defects”).  Three sections of each specimen were stained 
with methylene blue and basic fuchsine. For the 12-week group, 3 additional sections were 
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made and left unstained for fluorescence analysis and immediately stored in the dark. All 
sectioning and histological processing was performed at the Radboudumc, department of 
Biomaterials (Nijmegen, the Netherlands).
Descriptive histology and histomorphometrical analysis
At both implantation periods of 4 and 12 weeks, the pMMA histological sections (3 sections 
per specimen) were examined by light microscopy (Leica Microsystems AG, Wetzlar, Germany); 
non-stained images were used for fluorescence microscopy. Digital images of the sections 
were assessed histologically and quantitative histomorphometry was performed using ImageJ 
computer-based image analysis software (Java® ImageJ 1.47, Image processing and analysis 
in Java) 71. For quantitative analysis, a circular region of interest (ROI) with a diameter equal 
to the created defects (i.e. 2.5 mm) or an enlarged ROI (eROI; 3 mm) were superimposed on 
the defect area. Within the ROI and eROI, the amounts of newly formed bone and material 
remnants were measured using a combination of color discrimination (staining) and 
morphological appearance (for verification).
Statistical analysis
Data are presented as mean with SD for characterization, bone dynamics by fluorochorme 
labeling and histomorphometrical data. Statistical analyses were performed using STATISTICA 
7.0 (StatSoft, Tulsa, Oklahoma, USA) or GraphPad Software (PRISM; La Jolla CA, USA). Shapiro-
Wilk normality test was used to check distribution. A Kruskal-Wallis test and Dunn post 
hoc were used for nonparametric data. One-way analysis of variance (ANOVA) and Tukey 
multiple comparisons post-tests were used for parametric data. Student’s t-tests were used 
for comparison of histomorphometrical data between time points for selected materials and 
paired t-tests were used for comparison between the two composites. Values of p<0.05 were 
considered statistically significant. 
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After mixing both CPC and CPC/PLGA materials with ALN, all formulations remained injectable 
using standard syringes. Setting times (Figure 1A) of CPC and CPC/PLGA formulations showed 
to range from 4 to 28 min for initial and from 8 to 58 min for final setting. ALN loading via the 
liquid phase significantly increased setting times of both CPC and CPC/PLGA formulations. 
For subsequent in vitro experiments, we chose ALN doses of 0.5 wt% (low dose) and 5.0 wt% 
(high dose), which respectively presented initial setting times of ~10-12 min and ~20-22 min 
for both CPC formulations.
Figure 1A-E. Characterization analysis for CPC/PLGA-ALN composites. [A] initial and final setting time 
at different ALN wt%, dashed lines indicate the initial setting time at 5wt% ALN for CPC and CPC/PLGA, 
a] p<0.05 for CPC initial compared to CPC/PLGA initial setting; [B] FTIR of Alendronic acid, PLGA, CPC, 
CPC-highALN and CPC/PLGA-highALN. Dashed lines indicate peaks associated to PLGA (C=O stretching) 
and CPC (PO4-3 bending) in the materials; [C] and [D] XRD at days 0 and 7 for the materials, dashed lines 
indicate HA peaks (26 and 31.8 °2θ); [E] compressive strength, b] p<0.05 for CPC-blank compared to CPC/
PLGA-highALN. Error bars represent the SD.
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 128
128
Chapter 6
Figure 2 shows SEM micrographs for all CPC formulations. PLGA could be discriminated 
due to morphological and size differences compared to the CPC matrix. The composites 
presented a homogenous aspect with PLGA particles dispersed throughout the CPC matrix 
(Figures 2B, 2D & 2F). 
FTIR analysis (Figure 1B) showed absorption peaks representative for α-TCP and PLGA. A strong 
peak of carbonyl at ~1750 cm-1 was detected in PLGA containing samples, while representative 
peaks for PO4-3 at the range of 900 to 1100 cm-1 were observed for all formulations. Due to low 
crystallinity of ALN, no characteristic peaks were observed for this component.
Figure 2A-F. Micrographs obtained by SEM. [A] CPC-blank; [B] CPC/PLGA-blank; [C] CPC-lowALN; [D] CPC/
PLGA-lowALN; [E] CPC-highALN and [F] CPC/PLGA-highALN. Asterisks and arrows indicate CPC and PLGA 
particles respectively. Magnification of 500x.
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XRD patterns of the composites at day 0 (after setting) showed an initial phase transition 
from α-TCP to hydroxyapatite (HA; Figure 1C; dashed lines) for CPC-blank, CPC-lowALN, CPC/
PLGA-blank and α-CPC/PLGA-lowALN. After 3 and 7 days of incubation, peaks for HA formation 
were observed (at ~26 and 31.8 2°θ; Figure 1D), but no HA peaks were observed for CPC-
highALN and CPC/PLGA-highALN, indicating that phase transformation was not taking place 
for high ALN formulations. This pattern was also observed after 148 days (data not shown).
The compressive strength for CPC and CPC/PLGA formulations assessed by mechanical test 
ranged from ~4 to 6 MPa (Figure 1E). The addition of ALN to CPC or CPC/PLGA tended to 
decrease the compressive strength for CPC and CPC/PLGA formulations. Statistical differences 
were found for CPC-blank compared to CPC/PLGA-highALN (p=0.0115).
ALN release kinetics
The ALN release data assessed via ninhydrin assay showed negligible ALN release for CPC-
formulations (Figure 3). In contrast, the CPC/PLGA formulations showed a 2-week lag phase 
with negligible release followed by a biphasic ALN release with 2 distinct sustained release 
phases. A first fast and sustained ALN release from day 15 to 42 (~0.02 and ~0.20 mg ALN/day 
for low and highALN, respectively) reached ~15 % (~0.7 mg) and 20 % (~10 mg) of the initially 
loaded ALN amount for CPC/PLGA-lowALN and CPC/PLGA-highALN, respectively. Thereafter, a 
second sustained release phase with lower ALN release was observed (~9.40 x 10-4 and ~0.02 
mg ALN/day for low and highALN, respectively), which after 148 days cumulatively reached 
~16 % (~0.8 mg) and 25 % (~12.0 mg) of the initially loaded ALN amount for CPC/PLGA low 
and high dosages, respectively.
Based on the in vitro data of ALN incorporation into CPC and CPC/PLGA, we proceeded with in 
vivo analysis using only degradable CPC/PLGA, since no ALN release was detected from CPC. 
Additionally, CPC/PLGA-highALN was excluded for in vivo studies, as it showed incomplete 
phase transformation (based on setting time and physicochemical analysis).
Figure 3. Cumulative Alendronate release from CPC and CPC/PLGA cylinders loaded with the 
bisphosphonate for up to 148 days. [A] Absolute ALN release (mg) [B] Relative ALN release (% of loaded 
dose). Error bars represent the SD.
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Figure 4A-C: [A] Representative micro-CT images of each experimental group. Color settings were 
adjusted to distinguish between different densities of bone and material, coloring bone yellow and 
CPC/PLGA purple. Representative histological images of pMMA sections for each experimental group 
with images at [B] 4 weeks and 12 weeks and [C] corresponding images at high magnification; methylene 
blue and basic fuchsine staining; red arrows] new bone (pink color); *] CPC/PLGA; BM] bone marrow 
(blue color).
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The micro-CT data were reconstructed to 3D representations and then sliced to obtain 
an internal view of the bone defects. A representative overview with sagittal, frontal and 
transversal slices through the defect region for each experimental group is presented in 
Figure 4A. Color settings were adjusted to distinguish between different densities of bone 
and material. After 4 and 12 weeks, both CPC/PLGA-blank and CPC/PLGA-lowALN showed 
presence of CPC in contact with surrounding bone tissue. With implantation time, both CPC/
PLGA-blank and CPC/PLGA-lowALN showed more bone formation around the composites.
Descriptive histology
Representative images of the histological sections of specimens embedded in pMMA 
are depicted in Figure 4B. In general, histological analysis showed differential material 
degradation and bone formation depending on the composition of the implant. For CPC/
PLGA-blank and CPC/PLGA-lowALN, no apparent degradation was visible at 4 weeks, and 
peripheral degradation was observed after 12 weeks. There was an increased amount of 
bone formation, macroscopically, around the composites for CPC/PLGA-lowALN compared 
to CPC/PLGA-blank. Similar as with the micro-CT images, this difference was more apparent 
after 12 weeks. The histological slides of CPC/PLGA-lowALN further showed an apparently 
higher bone density outside the ROI. At higher magnification (Figure 4C), newly formed bone 
in direct contact with CPC/PLGA-blank and CPC/PLGA-lowALN was observed. Within the ROI, 
both CPC/PLGA-blank and CPC/PLGA-low ALN showed that bone had reached the center of 
the ROI.
Bone dynamics by fluorochrome labeling
Incorporation of fluorochrome labels into newly formed bone (Figure 5A) was observed 
for calcein green (green; week 4), alizarine complexone (red; week 6) and rolitetracycline 
(yellow; week 8). However, none of the sections showed incorporation of calcein blue (blue; 
week 2). For both CPC/PLGA-blank and CPC/PLGA-lowALN, calcein green was mostly present 
Table 1: Labels and descriptions of the experimental groups
Labels Descriptions
CPC-blank Only α-TCP
CPC-lowALN α-TCP + 0.5 wt % ALN
CPC-highALN α-TCP + 5.0 wt % ALN
CPC/PLGA-blank 60 % α-TCP / 40 % PLGA
CPC/PLGA-lowALN 60 % α-TCP/40 % PLGA + 0.5 wt % ALN
CPC/PLGA-highALN 60 % α-TCP/40 % PLGA 5.0 wt % ALN
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Figure 5A-D: [A] Representative fluorochrome microscopy images at 12 weeks, with high magnification 
images; red box] area of high magnification; green color] calcein green (week 4); red color] alizarine 
complexone (week 6); yellow color] rolitetracycline (week 8).  B-D: Relative volume areas (mean +SD) of 
fluorochrome labels in contact with concentric circles for calcein green (week 4), alizarine complexone 
(week 6) and rolitetracycline (week 8) for both CPC/PLGA-blank and CPC/PLGA-lowALN [B] within ROI 
(0-2.5 mm) and [C] extended ROI (eROI, 2.5-3 mm); statistical analysis showed significantly more calcein 
green within ROI for CPC/PLGA-blank compared to CPC/PLGA-lowALN (Student’s t-test, p<0.05); analysis 
showed significantly more calcein green in the eROI for CPC/PLGA-lowALN compared to CPC/PLGA-blank 
(Student’s t-test, p<0.05); [D] Distance of the first ring that is in contact with a fluorochrome (mean +SD) 
for both CPC/PLGA-blank and CPC/PLGA-lowALN; statistical analysis showed significantly closer contact 
with calcein green for CPC/PLGA-blank compared to CPC/PLGA-lowALN (Student’s t-test, p<0.01); Range] 
0 to 55 rings, edge of defect] ring 45 (2.5 mm from centre).
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within the ROI (Figure 5B). This was significantly more for CPC/PLGA-blank compared to CPC/
PLGA-lowALN (p<0.05). However, in the peripheral area of 2.5 to 3 mm from the center of the 
ROI (Figure 5C), CPC/PLGA-lowALN showed significantly higher presence of calcein green 
compared to CPC/PLGA-blank (p<0.05). Bone formation dynamics by fluorescent microscopy 
showed that significantly more bone was formed near the center of the defect at 12 weeks 
for CPC/PLGA-lowALN compared to CPC/PLGA-blank (p<0.01; Figure 5D).
Histomorphometrical analysis
Histomorphometry data (Table 1 & Figure 6) showed CPC remnants within the ROI after 4 
weeks of 74.2 ± 5.7% for CPC/PLGA-blank and 71.7 ± 5.4% for CPC/PLGA-lowALN. After 12 weeks, 
CPC remnants within the ROI were 60.7 ± 8.9% for CPC/PLGA-blank and 66.5 ± 7.1% for CPC/
PLGA-lowALN. Statistical analysis showed significant temporal decrease from 4 to 12 weeks 
of material remnants was seen for CPC/PLGA-blank (p<0.05), but not for CPC/PLGA-lowALN 
(p>0.05).
Bone areas within the ROI after 4 weeks were 4.1 ± 1.4% for CPC/PLGA-blank and 5.5 ± 1.4% 
for CPC/PLGA-lowALN. After 12 weeks, bone areas within the ROI were 22.8 ± 8.0% for CPC/
PLGA-blank and 16.4 ± 4.1% for CPC/PLGA-lowALN. Statistical analysis for bone area within 
ROI showed no significant difference between CPC/PLGA-blank and CPC/PLGA-lowALN for 
both time points (p>0.05). Data showed significant temporal increase from 4 to 12 weeks of 
bone for CPC/PLGA-blank and CPC/PLGA-lowALN (Student’s t-test, both p<0.001).
Descriptive histology suggested increased bone formation outside the ROI, therefore, bone 
areas were also measured in an extended ROI (eROI, from 2.5 to 3 mm). After 4 weeks 
bone area outside the ROI were 17.3 ± 2.0% for CPC/PLGA-blank and 15.5 ± 3.7% for CPC/
PLGA-lowALN. Bone area for the eROI after 12 weeks, were 10.9 ± 1.8% for CPC/PLGA-blank 
and 18.1 ± 2.1% for CPC/PLGA-lowALN. Statistical analysis for bone area for the eROI showed 
significantly more bone at 12 weeks there was significantly more bone for CPC/PLGA-lowALN 
compared to CPC/PLGA-blank (Student’s t-test, p<0.05). Data showed significant temporal 
increase from 4 to 12 weeks of bone only for CPC/PLGA-lowALN (Student’s t-test, p<0.01). 
There was significantly less bone formation outside the ROI for CPC/PLGA-blank at 12 weeks 
compared to at 4 weeks (p<0.001).
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Figure 6: Accumulated volume percentages (mean ±SD) of new bone formation (green bars for eROI 
and blue bars within ROI) and material remnants (grey bars) at 4 and 12 weeks after implantation 
for CPC/PLGA-blank and CPC/PLGA-lowALN; statistical analysis showed significant increase of bone 
formation within ROI from 4 to 12 weeks for both CPC/PLGA-blank and CPC/PLGA-lowALN (***=p<0.001, 
**=p<0.01); bone formation over time in the eROI significantly decreased for CPC/PLGA-blank (p<0.001), 
but significantly increased for CPC/PLGA-lowALN (p<0.001); material remnants significantly decreased 
for CPC/PLGA-blank (*=p<0.05) but not significantly for CPC/PLGA-lowALN (ns=p>0.05); a] At 12 weeks 
there was a significant higher amount of bone in the eROI for CPC/PLGA-lowALN compared to CPC/
PLGA-blank (p<0.05).
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Discussion
The aim of this study was to develop CPC/PLGA composites loaded with ALN and investigate 
the morphological features, physicochemical properties and ALN release kinetics. 
Furthermore, we evaluated the efficacy of CPC and CPC/PLGA as a local ALN release system 
in a rat femoral condyle bone defect in osteoporotic rats. We hypothesized that addition of 
ALN would (i) not critically affect material physicochemical properties, (ii) promote controlled 
ALN release, and (iii) enhance the biological performance of the CPC for bone regeneration 
in osteoporotic rats. We showed that ALN loading increased CPC and CPC/PLGA setting times 
and marginally affected compressive strength. Loading ALN at a dose of 5 wt% impeded with 
the conversion of the alpha-TCP base powder to HA within 3 days of incubation in PBS, while 
a dose of 0.5 wt% did not. ALN release kinetics showed hardly any release from CPC, whereas 
CPC/PLGA showed a controlled release of ALN up to 148 days with 2 consecutive sustained 
release phases following a 2-week lag phase. The main in vivo findings by micro-CT imaging, 
descriptive histology and quantitative histomorphometry showed that loading of ALN within 
CPC/PLGA did not increase bone formation within the defect region, but enhanced bone 
formation within the peri-defect region compared to control CPC/PLGA.
Previous in vitro studies proved a successful incorporation of bisphosphonates into ceramic 
bone substitutes 21-32. These studies showed decrease of the mechanical properties and 
increases the setting time of the ceramic, however the range was still within acceptable limits 
21,26,31,32. This is consistent with our study and dependent of dose of the bisphosphonate added. 
By in vitro analysis the previous studies showed the release of the drug to be generally steady 
and not cytotoxic 21,22,27-29,31,32. Moreover, there was a inhibition of osteoclasts and stimulation 
of osteoblasts 22-27,29,30. Most of these studies also used ALN, however there were different 
ways of incorporation the drug into the cement. Most of the studies used the technique 
of loading the drug onto the surface of an inorganic implant by soaking the implant in a 
solution containing the drug 21-25,28-32. However, this technique has the disadvantage of limited 
drug loading content and results in a uncontrolled burst release on administration 38. The 
study by Panzavolta et al. incorporated the drug (both ALN and pamidronate) into the liquid 
phase, they do not report on the release properties 26. In the study by Shi et al. the ALN was 
incorporated into the liquid phase of PLGA which was then incorporated as a porogen into 
the cement 27. Their results showed a controlled release which is in concurrence with our 
study. There are previous in vivo studies using a cement enhanced with bisphophonate, 
showing positive results on bone formation 34-37. However, a fair comparison between these 
four studies is compromised, due to use of all different cements in combination with other 
bisphosphonates and also the animal models were different. 
For clinical application, handling properties of injectable bone substitutes that harden in situ 
are of utmost importance. Alterations in the composition of CPC or CPC/PLGA have shown 
to affect important handling properties, including injectability 39 and setting time 40,41. Here, 
addition of ALN into the liquid phase of the cement formulation make it possible to obtain 
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injectable materials that were extruded by standard syringes 42, which corroborates previous 
work 43. For setting time evaluation, we used systematic increases of ALN loading (0.5-6 wt%) 
and observed clinically acceptable initial setting times (i.e. <20 min) 19 for ALN amounts up to 
5 wt%. ALN act on the CPC hydration process which is a reaction of dissolution-precipitation 
of CPC particles and Ca2+/PO4-3 ions respectively, affecting the curing of CPC 43. In view of 
eventual clinical application, CPC/PLGA composites with low (0.5 wt%) and high (5.0 wt%) 
doses of ALN were subsequently used for further experimental in vitro work. As a less 
important characteristic for injectable bone substitutes meant for application under minimal 
loading, ALN loading showed marginal lowering effects on compressive strength. Panzavolta 
et al. 44 and Li et al. 45 also demonstrated a lowering effect of ALN on the CPC compressive 
strength, but with values of ~5.0 MPa these remain close to those of human cancellous 
bone 45.
From a material perspective, FTIR analysis and XRD confirmed the conversion of the alpha-
TCP base powder to HA formed through hydration (HA, JCPDS 01-074-0566) 46 within 3 days 
of incubation in PBS for CPC and CPC/PLGA formulations without or low ALN loading. In 
contrast, high ALN loading inhibited this conversion. It is well-known that α-TCP hydrolyses 
to hydroxyapatite through dissolution and successive precipitation of the more stable phase, 
and the high affinity of ALN for calcium ions retards this process 43. 
ALN release kinetics showed negligible release from CPC, whereas CPC/PLGA showed a 
controlled release of ALN with 2 distinct consecutive sustained release phases after a 2-week 
lag phase. Apparently, the dense configuration of the CPC and related lack of degradation 
is responsible for the observed negligible ALN release. Similarly, the relatively dense CPC/
PLGA composite configuration upon setting limits ALN release during a 2-week lag phase. 
Subsequently, sustained ALN release coincides with the generation of a porous network 
within the ceramic matrix due to PLGA degradation. The second sustained ALN release phase 
takes place after PLGA degradation from ~day 40 onwards, when liquid can penetrate the 
ceramic matrix via an interconnective porosity system 47. The difference in average daily 
ALN relative release (~20 and ~10 times greater in the 1st compared to 2nd phase for CPC-
lowALN and CPC-highALN, respectively) is likely due to the additional acidifying effect of PLGA 
degradation products in the 1st phase, while a sole dissolution-controlled release process 
from a porous ceramic matrix remains thereafter 48,49. Our observations are in accordance with 
those of Panyam and coworkers 50, who studied the use of PLGA micro- and nanoparticles 
for drug-delivery, and previous work from our group using CPC/PLGA as a drug-delivery 
vehicle 51,52.
Over the last decade, several studies examined the effect of bisphosphonates on peri-implant 
bone response using metallic bone implants 53-66 and showed enhanced bone formation 
(using mainly ALN and Zolendronate) compared to controls without bisphosphonate, with 
evaluation periods up to one year 59. This is in accordance with our results, which showed 
enhanced peri-defect bone formation in response to locally released ALN from CPC/PLGA 
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composites. However, these studies differ in the use of non-degradable metallic implants 
versus degradable CPC/PLGA in our study. Remarkably, we did not observe any influence 
of ALN loading on bone formation within the defect region, for which the reason remains 
unclear.
CPC has the advantage as a bone substitute material of being injectable and moldable, 
allowing to directly adapt or being pre-set to the shape of a bone defect 18,19. For this study 
we used pre-set composite of CPC/PLGA with and without ALN, specifically shaped to the 
measurements of our defect. With these pre-set CPC/PLGA composites we aimed to ensure 
the implants contained consistent amounts of cement and alendronate for both our in vitro 
and in vivo studies, as well as reduce operative time.
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This study showed by in vitro analysis that ALN-loaded CPC/PLGA presents clinically 
acceptable handling, suitable compressive strength, and a controlled ALN release. The in vivo 
bone defect model showed that a relative low dose of ALN (0.5 wt%) significantly increases 
bone formation in the peri-defect region in osteoporotic conditions, without effects on CPC/
PLGA degradation. The data suggest that future clinical application of ALN-loaded CPC/PLGA 
could be benificial for bone healing in compromised conditions.
Author Contribution statement
Authors Claire IA van Houdt and Paulo R Gabbai-Armelin equally contributed in writing of 
the main manuscript text. Paula M Lopez-Perez aided in the in vitro part of this study. Ana 
Claudia M Renno and Jeroen JJP van den Beucken supervised both the experimental analysis 
and the writing of the manuscript. All authors reviewed the manuscript. All the listed authors 
have agreed to all of the contents. 
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 139
139
Alendronate release from CPC for bone regeneration in osteoporotic conditions
6 
Acknowledgements
The authors would like to acknowledge ms. N. van Dijk for her assistance with the histological 
sectioning and fluorochrome labeling, dr. V. Cuijpers for his assistance on the ex vivo micro-
CT and histological imaging and dr. ing. Bronkhorst for his with statistical and methodological 
guidance. The author P. R. Gabbai-Armelin would like to acknowledge the Conselho Nacional 
de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do 
Estado de São Paulo (FAPESP) for the scholarships (grants no. 209507/2013-6 and 2015/20704-
8 respectively).
Additional Information
We have no conflicts of interest to disclose. We confirm that all experiments were performed 
in accordance with relevant guidelines and regulations.
559619-L-bw-vanHoudt




1 Prevention and management of osteoporosis. World Health Organization technical report series 
921, 1-164, back cover (2003).
2 Riggs, B. L. & Melton, L. J., 3rd. The worldwide problem of osteoporosis: insights afforded by 
epidemiology. Bone 17, 505S-511S (1995).
3 Kubo, T. et al. Osteoporosis influences the late period of fracture healing in a rat model prepared 
by ovariectomy and low calcium diet. The Journal of steroid biochemistry and molecular biology 
68, 197-202 (1999).
4 Greenwald, M. A., Kuehnert, M. J. & Fishman, J. A. Infectious disease transmission during organ 
and tissue transplantation. Emerging infectious diseases 18, e1, doi:10.3201/eid1808.120277 (2012).
5 Greenwald, A. S. et al. Bone-graft substitutes: facts, fictions, and applications. The Journal of 
bone and joint surgery. American volume 83-A Suppl 2 Pt 2, 98-103 (2001).
6 Klijn, R. J., Meijer, G. J., Bronkhorst, E. M. & Jansen, J. A. A meta-analysis of histomorphometric 
results and graft healing time of various biomaterials compared to autologous bone used as 
sinus floor augmentation material in humans. Tissue Eng Part B Rev 16, 493-507, doi:10.1089/ten.
TEB.2010.0035 (2010).
7 Agarwal, R. & Garcia, A. J. Biomaterial strategies for engineering implants for enhanced 
osseointegration and bone repair. Adv Drug Deliv Rev 94, 53-62, doi:10.1016/j.addr.2015.03.013 
(2015).
8 Fini, M. et al. A new austenitic stainless steel with a negligible amount of nickel: an in vitro study 
in view of its clinical application in osteoporotic bone. Journal of biomedical materials research. 
Part B, Applied biomaterials 71, 30-37, doi:10.1002/jbm.b.30068 (2004).
9 Finigan, J. Bone up on osteoporosis. Nursing standard 17, 104, doi:10.7748/ns2003.09.17.51.104.c3449 
(2003).
10 Fitzpatrick, L. A. Secondary causes of osteoporosis. Mayo Clin Proc 77, 453-468, doi:10.4065/77.5.453 
(2002).
11 Anderson, G. F. & Hussey, P. S. Population aging: a comparison among industrialized countries. 
Health affairs 19, 191-203 (2000).
12 Blume, S. W. & Curtis, J. R. Medical costs of osteoporosis in the elderly Medicare population. 
Osteoporosis international : a journal established as result of cooperation between the 
European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 
22, 1835-1844, doi:10.1007/s00198-010-1419-7 (2011).
13 Duque, G. Osteoporosis in older persons: current pharmacotherapy and future directions. Expert 
Opin Pharmacother 14, 1949-1958, doi:10.1517/14656566.2013.822861 (2013).
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 141
141
Alendronate release from CPC for bone regeneration in osteoporotic conditions
6 
14 Russell, R. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: 
similarities and differences and their potential influence on clinical efficacy. Osteoporosis 
international : a journal established as result of cooperation between the European Foundation 
for Osteoporosis and the National Osteoporosis Foundation of the USA 19, 733-759, doi:10.1007/
s00198-007-0540-8 (2008).
15 Ezra, A. & Golomb, G. Administration routes and delivery systems of bisphosphonates for the 
treatment of bone resorption. Adv Drug Deliv Rev 42, 175-195 (2000).
16 G, D. in Expert Opin Pharmacother Vol. 14   1949-1958 (2013).
17 Dorozhkin, S. V. Calcium orthophosphates: occurrence, properties, biomineralization, pathological 
calcification and biomimetic applications. Biomatter 1, 121-164, doi:10.4161/biom.18790 (2011).
18 Habraken, W. J., Wolke, J. G., Mikos, A. G. & Jansen, J. A. PLGA microsphere/calcium phosphate 
cement composites for tissue engineering: in vitro release and degradation characteristics. 
Journal of biomaterials science. Polymer edition 19, 1171-1188, doi:10.1163/156856208785540136 
(2008).
19 Komath, M. & Varma, H. K. Development of a fully injectable calcium phosphate cement for 
orthopedic and dental applications. Bulletin of Materials Science 26, 415-422, doi:Doi 10.1007/
Bf02711186 (2003).
20 Felix Lanao, R. P., Leeuwenburgh, S. C., Wolke, J. G. & Jansen, J. A. Bone response to fast-degrading, 
injectable calcium phosphate cements containing PLGA microparticles. Biomaterials 32, 8839-
8847, doi:10.1016/j.biomaterials.2011.08.005 (2011).
21 Denissen, H., van Beek, E., Lowik, C., Papapoulos, S. & van den Hooff, A. Ceramic hydroxyapatite 
implants for the release of bisphosphonate. Bone Miner 25, 123-134 (1994).
22 Josse, S. et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 26, 2073-2080, 
doi:10.1016/j.biomaterials.2004.05.019 (2005).
23 Seshima, H. et al. Control of bisphosphonate release using hydroxyapatite granules. Journal of 
biomedical materials research. Part B, Applied biomaterials 78, 215-221, doi:10.1002/jbm.b.30446 
(2006).
24 Boanini, E., Torricelli, P., Gazzano, M., Giardino, R. & Bigi, A. Alendronate-hydroxyapatite 
nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 
29, 790-796, doi:10.1016/j.biomaterials.2007.10.040 (2008).
25 Boanini, E., Torricelli, P., Gazzano, M., Fini, M. & Bigi, A. The effect of alendronate doped calcium 
phosphates on bone cells activity. Bone 51, 944-952, doi:10.1016/j.bone.2012.07.020 (2012).
26 Panzavolta, S., Torricelli, P., Bracci, B., Fini, M. & Bigi, A. Alendronate and Pamidronate calcium 
phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast 
cells. J Inorg Biochem 103, 101-106, doi:10.1016/j.jinorgbio.2008.09.012 (2009).
27 Shi, X., Wang, Y., Ren, L., Gong, Y. & Wang, D. A. Enhancing alendronate release from a novel PLGA/
hydroxyapatite microspheric system for bone repairing applications. Pharm Res 26, 422-430, 
doi:10.1007/s11095-008-9759-0 (2009).
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 142
142
Chapter 6
28 Capra, P. et al. A preliminary study on the morphological and release properties of 
hydroxyapatite-alendronate composite materials. J Microencapsul 28, 395-405, doi:10.3109/0265
2048.2011.576783 (2011).
29 Schnitzler, V. et al. Investigation of alendronate-doped apatitic cements as a potential technology 
for the prevention of osteoporotic hip fractures: critical influence of the drug introduction mode 
on the in vitro cement properties. Acta Biomater 7, 759-770, doi:10.1016/j.actbio.2010.09.017 (2011).
30 Zhang, X., Hu, J., Li, Y., Yin, G. & Luo, E. Effects of ibandronate-hydroxyapatite on resorptive activity 
of osteoclasts. Arch Med Sci 7, 53-60, doi:10.5114/aoms.2011.20604 (2011).
31 Gong, T. et al. Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium 
silicate cement as a risedronate delivery system. Journal of biomedical materials research. Part 
A 102, 2295-2304, doi:10.1002/jbm.a.34908 (2014).
32 Pascaud, P. et al. Adsorption on apatitic calcium phosphates for drug delivery: interaction with 
bisphosphonate molecules. J Mater Sci Mater Med 25, 2373-2381, doi:10.1007/s10856-014-5218-0 
(2014).
33 Faucheux, C. et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial 
inhibits osteoclastic resorption in vitro. Journal of biomedical materials research. Part A 89, 
46-56, doi:10.1002/jbm.a.31989 (2009).
34 Matuszewski, L. et al. Effect of implanted bisphosphonate-enriched cement on the trabecular 
microarchitecture of bone in a rat model using micro-computed tomography. Int Orthop 37, 
1187-1193, doi:10.1007/s00264-013-1855-z (2013).
35 Verron, E. et al. Vertebroplasty using bisphosphonate-loaded calcium phosphate cement in a 
standardized vertebral body bone defect in an osteoporotic sheep model. Acta Biomater 10, 
4887-4895, doi:10.1016/j.actbio.2014.07.012 (2014).
36 Gong, T. et al. Osteogenic and anti-osteoporotic effects of risedronate-added calcium phosphate 
silicate cement. Biomed Mater 11, 045002, doi:10.1088/1748-6041/11/4/045002 (2016).
37 Ma, J. H., Guo, W. S., Li, Z. R. & Wang, B. L. Local Administration of Bisphosphonate-soaked 
Hydroxyapatite for the Treatment of Osteonecrosis of the Femoral Head in Rabbit. Chin Med J 
(Engl) 129, 2559-2566, doi:10.4103/0366-6999.192768 (2016).
38 Cattalini, J. P., Boccaccini, A. R., Lucangioli, S. & Mourino, V. Bisphosphonate-based strategies for 
bone tissue engineering and orthopedic implants. Tissue Eng Part B Rev 18, 323-340, doi:10.1089/
ten.TEB.2011.0737 (2012).
39 Habraken, W. J., Wolke, J. G., Mikos, A. G. & Jansen, J. A. Injectable PLGA microsphere/calcium 
phosphate cements: physical properties and degradation characteristics. Journal of biomaterials 
science. Polymer edition 17, 1057-1074 (2006).
40 Renno, A. C. et al. Incorporation of bioactive glass in calcium phosphate cement: material 
characterization and in vitro degradation. Journal of biomedical materials research. Part A 101, 
2365-2373, doi:10.1002/jbm.a.34531 (2013).
41 Klijn, R. J. et al. Three different strategies to obtain porous calcium phosphate cements: 
comparison of performance in a rat skull bone augmentation model. Tissue engineering. Part 
A 18, 1171-1182, doi:10.1089/ten.TEA.2011.0444 (2012).
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 143
143
Alendronate release from CPC for bone regeneration in osteoporotic conditions
6 
42 Bohner, M. & Baroud, G. Injectability of calcium phosphate pastes. Biomaterials 26, 1553-1563, 
doi:10.1016/j.biomaterials.2004.05.010 (2005).
43 Shen, Z., Yu, T. & Ye, J. Microstructure and properties of alendronate-loaded calcium phosphate 
cement. Mater Sci Eng C Mater Biol Appl 42, 303-311, doi:10.1016/j.msec.2014.05.043 (2014).
44 Panzavolta, S., Torricelli, P., Bracci, B., Fini, M. & Bigi, A. Functionalization of biomimetic calcium 
phosphate bone cements with alendronate. J Inorg Biochem 104, 1099-1106, doi:10.1016/j.
jinorgbio.2010.06.008 (2010).
45 Li, Y. H. et al. The biocompatibility of calcium phosphate cements containing alendronate-
loaded PLGA microparticles in vitro. Experimental biology and medicine 240, 1465-1471, 
doi:10.1177/1535370215579142 (2015).
46 Kumar, S. A. Eco-Friendly Nano-Hybrid Materials for Advanced Engineering Applications.  (Apple 
Academic Press, 2016).
47 Lodoso-Torrecilla, I. et al. Multimodal pore formation in calcium phosphate cements. Journal of 
biomedical materials research. Part A 106, 500-509, doi:10.1002/jbm.a.36245 (2018).
48 Tung, I. C. In vitro drug release of antibiotic-loaded porous hydroxyapatite cement. Artif Cells 
Blood Substit Immobil Biotechnol 23, 81-88, doi:10.3109/10731199509117669 (1995).
49 Mitra, A. K., Mitra, C. C. P. P. S. U. M. K. C. M. A. K., Kwatra, D. & Vadlapudi, A. D. Drug Delivery.  (Jones 
& Bartlett Learning, LLC, 2014).
50 Panyam, J. et al. Polymer degradation and in vitro release of a model protein from poly(D,L-
lactide-co-glycolide) nano- and microparticles. J Control Release 92, 173-187, doi:https://doi.
org/10.1016/S0168-3659(03)00328-6 (2003).
51 Felix Lanao, R. P. et al. RANKL delivery from calcium phosphate containing PLGA microspheres. 
Journal of biomedical materials research. Part A 101, 3123-3130, doi:10.1002/jbm.a.34623 (2013).
52 Felix Lanao, R. P. et al. Porous calcium phosphate cement for alveolar bone regeneration. Journal 
of tissue engineering and regenerative medicine 8, 473-482, doi:10.1002/term.1546 (2014).
53 Kurth, A. H. et al. The bisphosphonate ibandronate improves implant integration in osteopenic 
ovariectomized rats. Bone 37, 204-210, doi:10.1016/j.bone.2004.12.017 (2005).
54 McKenzie, K., Dennis Bobyn, J., Roberts, J., Karabasz, D. & Tanzer, M. Bisphosphonate remains 
highly localized after elution from porous implants. Clinical orthopaedics and related research 
469, 514-522, doi:10.1007/s11999-010-1527-x (2011).
55 Tanzer, M., Karabasz, D., Krygier, J. J., Cohen, R. & Bobyn, J. D. The Otto Aufranc Award: bone 
augmentation around and within porous implants by local bisphosphonate elution. Clinical 
orthopaedics and related research 441, 30-39 (2005).
56 Peter, B. et al. Local delivery of bisphosphonate from coated orthopedic implants increases 
implants mechanical stability in osteoporotic rats. Journal of biomedical materials research. 
Part A 76, 133-143, doi:10.1002/jbm.a.30456 (2006).
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 144
144
Chapter 6
57 McLeod, K. et al. Adsorption of bisphosphonate onto hydroxyapatite using a novel co-
precipitation technique for bone growth enhancement. Journal of biomedical materials research. 
Part A 79, 271-281, doi:10.1002/jbm.a.30792 (2006).
58 Jakobsen, T. et al. Local bisphosphonate treatment increases fixation of hydroxyapatite-coated 
implants inserted with bone compaction. J Orthop Res 27, 189-194, doi:10.1002/jor.20745 (2009).
59 Bobyn, J. D., McKenzie, K., Karabasz, D., Krygier, J. J. & Tanzer, M. Locally delivered bisphosphonate 
for enhancement of bone formation and implant fixation. The Journal of bone and joint surgery. 
American volume 91 Suppl 6, 23-31, doi:10.2106/JBJS.I.00518 (2009).
60 Jakobsen, T., Baas, J., Bechtold, J. E., Elmengaard, B. & Soballe, K. The effect on implant fixation 
of soaking tricalcium phosphate granules in bisphosphonate. The open orthopaedics journal 6, 
371-375, doi:10.2174/1874325001206010371 (2012).
61 Bobyn, J. D. et al. Local alendronic acid elution increases net periimplant bone formation: a 
micro-CT analysis. Clinical orthopaedics and related research 472, 687-694, doi:10.1007/s11999-
013-3120-6 (2014).
62 Meraw, S. J., Reeve, C. M. & Wollan, P. C. Use of alendronate in peri-implant defect regeneration. 
Journal of periodontology 70, 151-158, doi:10.1902/jop.1999.70.2.151 (1999).
63 Niu, S. et al. Peri-implant and systemic effects of high-/low-affinity bisphosphonate-
hydroxyapatite composite coatings in a rabbit model with peri-implant high bone turnover. 
BMC musculoskeletal disorders 13, 97, doi:10.1186/1471-2474-13-97 (2012).
64 Linderback, P., Areva, S., Aspenberg, P. & Tengvall, P. Sol-gel derived titania coating with 
immobilized bisphosphonate enhances screw fixation in rat tibia. Journal of biomedical 
materials research. Part A 94, 389-395, doi:10.1002/jbm.a.32708 (2010).
65 Peter, B. et al. Calcium phosphate drug delivery system: influence of local zoledronate release 
on bone implant osteointegration. Bone 36, 52-60, doi:10.1016/j.bone.2004.10.004 (2005).
66 Alghamdi, H. S. et al. Synergistic effects of bisphosphonate and calcium phosphate nanoparticles 
on peri-implant bone responses in osteoporotic rats. Biomaterials 35, 5482-5490, doi:10.1016/j.
biomaterials.2014.03.069 (2014).
67 ASTM. Standard Test Method for Time of Setting of Hydraulic-Cement Paste by Gillmore Needles, 
Document Number: ASTM C266-99, ASTM International.  (1999).
68 Taha, E. A. & Youssef, N. F. Spectrophotometric determination of some drugs for osteoporosis. 
Chemical & Pharmaceutical Bulletin 51, 1444-1447, doi:DOI 10.1248/cpb.51.1444 (2003).
69 Alghamdi, H. S., van den Beucken, J. J. & Jansen, J. A. Osteoporotic rat models for evaluation of 
osseointegration of bone implants. Tissue engineering. Part C, Methods 20, 493-505, doi:10.1089/
ten.TEC.2013.0327 (2014).
70 van der Lubbe, H. B., Klein, C. P. & de Groot, K. A simple method for preparing thin (10 microM) 
histological sections of undecalcified plastic embedded bone with implants. Stain Technol 63, 
171-176 (1988).
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 145
145
Alendronate release from CPC for bone regeneration in osteoporotic conditions
6 
71 Lopez-Heredia, M. A. et al. Bone formation analysis: effect of quantification procedures on the 
study outcome. Tissue engineering. Part C, Methods 18, 369-373, doi:10.1089/ten.TEC.2011.0353 
(2012).
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 146
7
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 147
CHAPTER 7
Regenerating critical size rat 
segmental bone defects with 
a self-healing hybrid nano- 
composite hydrogel: effect of 
bone condition and BMP-2 
incorporation
van Houdt CIA, Koolen MKE, Lopez-Perez PM, Ulrich DJO, Jansen JA, 
Leeuwenburgh SCG, Weinans HH, van den Beucken JJJP.
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Severe trauma, bone tumors, congenital malformation or extensive infection of bone 
tissue can be the cause of critical size bone defect. The term critical size bone defect is 
defined as an orthotopic intraosseous wound that does not spontaneously heal without 
surgical intervention 1. Urist concluded in 1954 that there is no limited amount of time 
after which a pseudarthrosis cannot unite anymore by prolonged immobilization 2. Urist 
further concluded that a new proliferative process begins after any surgical intervention 
and after the implantation of any type of bone graft 2. In case of a critical size defect, bone 
grafting surgery is generally performed to obtain bone healing and reduce recovery time. 
An estimated 500,000 bone grafting procedures are performed annually in the United States 
and this number easily doubles on a global basis 3.
Autologous bone grafting is the golden standard for treating bone defects 4-7. Drawbacks of 
autologous bone grafting are need for two surgical sites, donor site morbidity, increased 
surgery and recovery time, and shortage in the availability of donor tissue 8. Over the next 50 
years, the number of elderly patients with the need for bone grafting is expected to increase, 
including their comorbidities. Especially the increase in osteoporotic patients represents 
a major challenge for medical care 9. Osteoporosis compromises bone strength (both 
trabecular and cortical), hence increases fracture risks, and further negatively influences 
the bone healing process 10-13.
Over the past decades, different types of synthetic bone graft have emerged, of which 
particularly calcium phosphate (CaP) based ceramics have shown large potential 14,15. In 
view of increased demands for synthetic bone grafts with advantageous properties, we 
previously designed an injectable, self-healing hydrogel consisting of bisphosphonated (BP) 
hyaluronan (HA) and CaP nanoparticles 16. The major biological advantage of this material 
was the observed ingrowth of newly-formed trabecular-like bone interspersed throughout 
the material after 4 weeks in a femoral condyle defect in rats 16.
In view of the BP-moiety in the material and the used of BPs as a drug in the treatment of 
osteoporosis, in the current study bone regeneration was challenged using a rat critical size 
segmental defect model, in which the effect of bone condition (healthy versus osteoporotic 
bone) on bone defect healing using HABP-CaP gel was comparatively evaluated. Additionally, 
the effect of enriching this HABP-CaP gel with BMP-2 was explored. We hypothesized that (i) 
an osteoporotic condition would negatively affect defect healing, and (ii) that enrichment of 
the HABP-CaP gel with BMP-2 would improve defect healing in both healthy and osteoporotic 
conditions.
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The hyaluronan with bisphosphonate and calcium phosphate hydrogel (HABP-CaP) was 
prepared as previously described 16, mixing equal volumes of hyaluronan-bisphosphonate 
with a CaP suspension in connected syringe. This resulted in a non-covalently cross-linked 
HABP-CaP hybrid nanocomposite gel.
To further enhance bone healing, BMP-2 (InductOs™, Medtronic BioPharma B.V., Heerlen, The 
Netherlands) was added to the liquid component of the gel in 3 µg (HABP-CaP-lowBMP2) and 
30 µg (HABP-CaP-highBMP2) per implant from a 1.5 mg/ml solution.
In order to maintain the gel inside the defect, we used polytetrafluorethylene (PTFE) tubing 
of ±7 mm in length, 4.2 mm in diameter of 0.25 mm ± 0.07 mm (Polyfluor Plastics BV, Breda, 
the Netherlands), as is used in e.g. vascular surgery. To allow for fluid exchange, the tubing 
was perforated using a 1 mm biopsy punch (Kai Europe GmbH, Solingen, Germany) creating 
4 holes in a row in 4 directions resulting in 16 holes per tube.
Animals
For this experiment, 56 healthy mature male Wistar rats (age: 3 months; weight: ± 250 g) were 
used. All animals received either orchidectomy to induce an osteoporotic bone condition 
or sham surgery, as described previously 17. Six weeks after, all animals received 1 unilateral 
segmental defect in the right femur, which was treated with HABP-CaP (8 healthy and 8 
osteoporotic animals), HABP-CaP-lowBMP2 (8 healthy and 8 osteoporotic animals), HABP-CaP-
highBMP2 (8 healthy and 8 osteoporotic animals), empty PTFE tubing (4 healthy animals), or 
left empty (4 healthy animals).
All experiments were conducted in accordance with institutional, national and international 
guidelines for animal care and the Dutch law concerning animal welfare. The studies were 
reviewed and approved by the Experimental Animal Committee of the Radboud University 
(RUDEC 2013-206).
Surgical procedure to induce osteoporotic condition
Anaesthesia was induced and maintained by Isoflurane inhalation (Rhodia Organique Fine 
Limited) combined with oxygen delivered by mask. Pre-operative pain medication was 
provided by an injection of Carprofen (5 mg/kg; Rimadyl®, Pfizer Animal Health, New York, 
USA), given 15 min before surgery. After confirmation of effective anaesthesia, the animal 
was placed on an electric heating blanket in supine position. The area disinfection was 
performed by application of a povidone iodine solution. A skin incision was made over the 
scrotum, followed by blunt dissection of subcutaneous connective tissue and creating a 5 
mm opening in the tip of the scrotal sac. The gonadal tissue was pulled through, including 
the caudal epididymis, caput epididymis, vas deferens, and spermatic blood vessels. A single 
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ligature was performed around the blood vessels and the vas deferens using a surgical 
polyester suture (Terylene® 2.0 undyed, Serag-Wiessner GmbH & Co, Naila, Germany) after 
testis and epididymis were removed. Remaining vas deferens and fat was replaced in the sac. 
After haemostasis, the skin was closed with subcutaneous absorbable sutures (Vicryl® 3.0, 
Ethicon, Amersfoort, The Netherlands). Finally, the animals were covered with paper or cloth 
in order to avoid hypothermia. The ORX animals received a low calcium diet for six weeks. 
The sham operated animals underwent the same surgical procedure except for the actual 
removal of the gonads and normal food pellets were provided. For a minimum duration of 2 
days postoperatively, Carprofen was given every 24 h. Additionally, to diminish postoperative 
pain, Buprenorfine (Temgesic®, Reckitt Benckiser Health Care Limited, Schering-Plough, UK; 
0.02 mg/kg) was given every 12 h.
Surgical procedure to create critical size segmental femur defect and placement of bone 
substitute material
A critical size segmental defect was created unilaterally in the femur of the rats. A single dose 
of antibiotics (Enrofloxacin, 5 mg/kg body weight) was administered 1 h before surgery. To 
reduce intra-operative and post-operative pain, Temgesic® (0.02 mg/kg) was administered 
Figure 1 A-I: A-H] Photographs during surgery of creating the critical-sized segmental defect in male 
rats and implantation of the material (in chronological order from left to right and top to bottom). I] A 
removed bone segment of 6 mm next to a polyurethane tube containing experimental HABP-CaP gel.
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subcutaneously pre-operatively. All surgeries were performed under general inhalation 
anaesthesia with pre-operative pain medication and sterile conditions as mentioned above 
(see Surgical procedure to induce osteoporotic conditions). The right leg was shaved, and 
the rat was placed in a left lateral position on heating mat. The surgical area was disinfected 
with povidone iodine. Through an anterolateral approach, the vastus lateralis and biceps 
femoris were separated and elevated while cautioning to keep the periosteum intact 
along the surface of the bone (Figure 1A-B). Firstly, a PEEK plate was inserted and fixed 
in the anterolateral plane (RatFix, RISystem AG, AOFoundation, Davos, Switzerland; Figure 
1C-E). Then, a segmental defect was created with the use of a Gigli saw with saw guide to 
ensure the 6 mm length of the femoral segment (both saw and guide were purchased from 
RISystem) under constant cooling with saline (Figure 1F-G). After removing the segment, we 
left the defect empty or placed a tube of polytetrafluorethylene in the defect, filled with 
our experimental material (HABP-CaP, HABP-CaP-lowBMP2 or HABP-CaP-highBMP2) or with an 
empty tube (Figure 1H-I). Subsequently, the muscles and fascia were closed with absorbable 
sutures (Vicryl® 4.0, Ethicon Products, Amersfoort, the Netherlands) and the skin with both 
absorbable suture and agraves (Vicryl® 4.0 and agraves, Ethicon Products, Amersfoort, the 
Netherlands). Postoperatively, Temgesic® (0.02 mg/kg) and Carprofen® (5.0 mg/kg) were 
administered for 2 days post-operatively every 12 h.
Animal euthanasia and specimen retrieval
Twelve weeks post-operatively, specimens were retrieved for ex vivo X-ray imaging and micro-
CT scanning, as well as histological assessment. All rats were euthanized by CO2-suffocation 
in accordance with ISO standards and protocols of the Radboud University Nijmegen Medical 
Center, The Netherlands. The femurs including the implanted materials were harvested, 
stripped from soft tissues and immediately fixed in 10% formalin solution. After fixation, 
specimens were stored in 70% ethanol.
Validation of osteoporotic condition by ELISA for serum TRAP analysis
During specimen retrieval, blood was taken from several rats of both SHAM and ORX (8 and 10 
rats respectively) to validate osteoporotic condition. This was evaluated by a serum analysis 
for TRAP enzyme activity performed with the RatTRAPTM Assay kit (Immunodiagnostic Systems 
GmbH, Frankfurt am Main).
X-ray imaging
After specimen retrieval and formalin fixation, X-ray images were made of the femora using 
dental X-ray equipment and imaging plate (Planmeca ProXTM 2016 & SoredexTM DIGORATM 
Optime 2015; Dental Union Plandent, Nieuwegein, the Netherlands).
Micro-CT scanning
Micro-computed tomography (micro-CT) scanning of the femora were performed to assess 
bone formation at the end point of 12 weeks with a micro-CT imaging system (Quantum FX; 
PerkinElmer, Waltham, MA, USA). Three minutes of scan time was required per bone for an 
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 152
152
Chapter 7
isotropic voxel size of 42 μm (voltage 90 kV, current 180 mA, field of view = 21 mm). To analyze 
the results, all datasets were aligned. A region of interest (ROI) of 4.6 x 5 x 6 mm (bone 
volume inside the defect; BVi) and of 6 x 8.4 x 8.4 mm (total bone volume; TBV) was selected. 
The ROI was segmented with a global threshold. Bone volume was measured in mm3 using 
image processing software (Image-J; Java, Redwood Shores, CA, USA).
For 3D imaging, one sample of each group was selected and scanned with a desktop X-ray 
micro-CT system (Skyscan-1072, TomoNT version 3N.5, SkyscanVR, Kontich, Belgium). The 
specimens were placed onto the sample holder with the long axis of the femur perpendicular 
to the scanning beam. The 3D reconstruction and imaging processing was performed using 
NRecon V1.4 and Dataviewer V1.4.3.0 (SkyscanVR, Kontich, Belgium), respectively.
Histological processing
After performing the X-ray imaging and micro-CT scanning, the obtained specimens were 
dehydrated in a graded series of ethanol (70-100%), and embedded in polymethylmethacrylate 
(PMMA). After polymerization, thin sections of the defect of ~10 μm were prepared in a plane 
parallel to the axis of the femur using a diamond blade microtome (Leica Microsystems 
SP 1600, Nussloch, Germany) as previously described 17,18. At least three sections of each 
specimen were made and stained with methylene blue and basic fuchsine.
Descriptive histology and histomorphometrical analysis
After an implantation period of 12 weeks, PMMA histological sections (3 sections per 
specimen) were examined by light microscopy (Leica Microsystems AG, Wetzlar, Germany) 
and digitalized with an automatic scanning microscope (Panoramic250, 3DHISTECH Ltd., 
Figure 2: Example of a histological image with all three analyzed regions (colors and lettering 
are only drawn to indicate the areas in this image). ROIIN] Region of Interest within defect 
area; ROIOUT] Region of interest outside the defect area.
559619-L-bw-vanHoudt
Processed on: 3-5-2021 PDF page: 153
153
Regenerating segmental defects with a hydrogel: effect of bone condition and BMP-2
7 
Budapest, Hungary). Quantitative assessment of the PMMA sections was performed using 
ImageJ computer-based image analysis software (Java® ImageJ 1.47, Image processing and 
analysis in Java) 19. From digitalized images of the sections (magnification: 5x), a rectangular 
region of interest (ROI) was created with dimensions equal to the created defects (ROIIN). 
Secondly, a rectangular ROI above and below the implant was positioned as ROIOUT (Figure 
2). Within all ROIs, the amount of newly formed bone and material remnants were measured 
using colour discrimination and morphology for verification. Evaluation of the gel capacity to 
overcome the critical size defect included whether or not the defect was bridged. This was 
defined by bone formation from both ends of the defect that is connected in the middle, 
with visible cortical bone connection or by relatively thick trabecular-like bone dispersed 
throughout the whole defect.
Statistical analysis
Data are presented as mean with SD for histomorphometric data and CT-scan analysis. 
Statistical analysis of quantitative data was performed using one-way analysis of variance 
(ANOVA) with a Tukey post-hoc test for comparison between the three different groups. 
Student’s t-tests were used for comparison between both conditions for selected materials. 
GraphPad Software (PRISM, La Jolla CA, USA) was used to carry out the statistical analysis. 
Values of p<0.05 were considered statistically significant.
559619-L-bw-vanHoudt





All of the 56 animals recovered well after orchidectomy or sham surgery. There were no 
wound problems and all but one animal remained in good condition. Two days after 
surgical segmental defect creation, one animal was found dead (sham-operated, HABP-CaP); 
obduction did not reveal issues in the operated leg, however, ascitis and pleural effusion 
were observed. All 55 remaining animals were healthy and recovered well, presenting normal 
activity without signs of infection or other wound healing problems.
Validation of osteoporotic condition by serum TRAP analysis
The induced osteoporotic bone condition after orchidectomy resulted in significantly 
decreased serum TRAP enzyme activity (p<0.001) compared to healthy animals (Figure 3), 
with activity values of 1.2 ±0.5 and 2.5 ±0.6 U/L/h, respectively.
X-ray imaging
Representative X-ray images are depicted in Figure 4. These images showed substantial 
healing for HABP-CaP-lowBMP2 and HABP-CaP-highBMP2, but low radiopacity in the defect 
region for HABP-CaP and empty tube controls. In one of the four femurs with no tube the 
screws were broken and in a second animal of this group the screws were loosened resulting 
in a 45° angle of the distal femur.
Figure 3: Serum TRAP enzyme activity (mean ±SD) 
comparing ORX and SHAM operated animals, ***] 
significant difference between ORX and SHAM (p<0.001)
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Micro-CT analysis
Representative micro-CT images of the segmental defects are depicted in Figure 5A. Data 
of the micro-CT analysis are shown in Table 1A and Figure 5B. Overall bone formation in 
ROIIN demonstrated that defects could not be bridged by the gel alone. Only two out of 
eight defects in the ORX animals showed bridging. For SHAM animals this material had the 
least amount of bone formation compared to other materials and none bridged the defect.
Further specification within the different experimental groups showed bone formation to be 
highest for HABP-CaP-lowBMP2 in both SHAM and ORX animals (38.5% and 37.0% respectively). 
Bone formation was significantly highest for HABP-CaP-lowBMP2 compared to all other groups 
for both conditions (p<0.001, p<0.001 and p<0.01 compared to, respectively, control group, 
HABP-CaP and HABP-CaP-highBMP2). Bone formation was not only seen within the original 
Figure 4: Representative X-ray images of all material groups in SHAM and ORX animals, and of the SHAM 
animals with an empty tube control
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Figure 5 A-B: A] Representative micro-CT images (reproduced with DataViewer) of all 3 experimental 
groups of SHAM and ORX animals and of the SHAM animals with an empty tube control. Green boxed 
images are coronal cross-sections with the plate to the right side of the image, being the anterolateral 
side of the femur. The blue boxed (middle) images are of sagittal planes through the femur. The red 
boxes are transverse planes with the plate to the right side of the image. The colors are a pre-selected 
setting in DataViewer (Color 2), which represents density B] Quantitative analysis based on micro-CT 
images of bone formation (percentage % bone area in mean data ±SD) within and outside the ROI. 
With the larger graph comparing between groups and the smaller between ROIIN and ROIOUT and per 
material group; showing significant differences of *] p<0.05, **] p<0.01 and ***] p<0.001. 
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defect area, but also outside of this area. Particularly for those groups with added BMP-2, 
substantial bone tissue was formed outside the original defect area. Outside the ROI there 
was significantly less bone in SHAM animals for HABP-CaP compared to HABP-CaP-lowBMP2 
and HABP-CaP-highBMP2 (both p<0.001). In ORX animals the bone in ROIOUT was significantly 
higher for HABP-CaP-lowBMP2 compared to HABP-CaP and HABP-CaP-highBMP2 (both p<0.001). 
Between conditions there was a significant difference in the favor of SHAM for HABP-CaP-
highBMP2 both inside and outside the ROI (ROIIN p<0.05 and ROIOUT p<0.01).
Table 1 A-B; Mean data ±SD of bone formation percentage (%) by A] micro-CT analysis and B] 
histomorphometry.
SHAM ORX
ROIIN ROIOUT ROIIN ROIOUT
Table A
HABP-CaP 20.0 ± 4.9 12.4 ± 4.4 18.5 ± 8.3 10.6 ± 4.8
HABP-CaP-lowBMP2 38.5 ± 7.7 25.2 ± 2.3 37.0 ± 9.0 24.0 ± 4.0
HABP-CaP-highBMP2 24.8 ± 12.3 22.4 ± 7.1 14.0 ± 2.5 15.3 ± 1.8
Empty tube 15.2 ± 2.1 8.5 ± 1.0 NA NA
Table B
HABP-CaP 24.9 ± 6.1 4.9 ± 3.2 28.3 ± 7.8 4.8 ± 4.6
HABP-CaP-lowBMP2 34.2 ± 5.5 23.5 ± 3.8 38.5 ±11.4 22.6 ± 5.1
HABP-CaP-highBMP2 26.4 ± 7.4 24.6 ± 6.6 15.2 ± 3.8 21.8 ± 3.0
Empty tube 26.2 ± 3.6 6.2 ± 3.0 NA NA
Table 2; Segmental defect bridging*.
SHAM ORX
ROIIN ROIOUT ROIIN ROIOUT
HABP-CaP 1/7 0/7 2/8 0/8
HABP-CaP-lowBMP2 8/8 8/8 8/8 8/8
HABP-CaP-highBMP2 4/8 8/8 3/8 8/8
Empty tube 0/4 0/4 NA NA
* Bridging was assessed histologically; numbers indicate number of defects showing complete segmental 
defect bridging out of total number of defects per experimental group.
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Descriptive histology
Representative histology images of the segmental defects are depicted in Figure 6A. 
Histological images of both control groups (with no tube or empty tube) confirmed that the 
used segmental defect can be classified as critical size defect.
In all three of the experimental groups (HABP-CaP, HABP-CaP-lowBMP2, HABP-CaP-highBMP2) 
there was apparent bone formation. There was a difference between bone formed with or 
without BMP-2. When using the gel only (HABP-CaP) bone regeneration was seen at both ends 
of the defect as a cortical edge growing towards the center. However, none of the samples 
with HABP-CaP had fully bridged bone defects (Table 2). For the HABP-CaP-lowBMP2 samples 
all had complete filling of bone within the defect areas for both ORX and SHAM. The newly 
formed bone in these samples was spongeous-like and dispersed throughout the ROIIN. In 
the HABP-CaP-highBMP2 samples bone defects were filled with bone but the bone formation 
was cyst-like with a very thin shell. Also, around the tube and both side of the fixation plate 
an even thinner layer of bone was formed. 
Magnifications of the samples showed almost all material has degraded. Only in a few 
samples material remnants were detected, as small uncouloured particles with irregular 
shaped edges, entrapped within the newly formed bone (Figure 6A, black arrows indicate 
material remnants). Higher magnification showed the cysts formed with high dosage of 
BMP-2 were filled with adipose cells (Figure 6A). Defects bridged by bone with low dose of 
BMP-2 also contained more adipose cells within the defect area compared to the defects 
without BMP-2.
Histomorphometry analysis
Histomorphometrical data are depicted in Figure 6B. For SHAM animals this material had the 
least amount of bone formation compared to other materials and none bridged the defect. 
Histomorphometry analysis between the different experimental groups bone formation 
showed to be highest for HABP-CaP-lowBMP2 in both SHAM and ORX animals (34.2% and 38.5% 
respectively). As already mentioned bone formation was not only seen within the original 
defect area, but also outside of this area. Particularly for those groups with added BMP-2, 
substantial bone tissue was formed outside the original defect area.
Statistical analysis for histomorphometric bone formation was significantly higher for 
HABP-CaP-lowBMP2 compared other material groups (p<0.05 compared to HABP-CaP in both 
conditions and p<0.01 compared to HABP-CaP-highBMP2 for SHAM animals). In ORX, HABP-CaP-
highBMP2 showed significantly less bone compared to HABP-CaP (p<0.01). Bone formation 
outside the ROI was significantly lower for HABP-CaP compared to HABP-CaP-lowBMP2 and 
HABP-CaP-highBMP2 in both SHAM and ORX animals (all p<0.001). 
Between the two bone conditions, there was more bone in favour of SHAM for HABP-CaP-
highBMP2 within the defect area compared to osteoporotic bone conditions (p<0.05). 
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Figure 6 A-B: A] Representative histological images and magnifications (orange =20x and red 40x) of all 3 
material groups of SHAM and ORX animals and of the SHAM animals with an empty tube. Green asterisks 
are placed below pieces of the tube. Black arrows indicate material remnants. Orange A’s are placed 
in adipose tissue. B] Quantitative analysis based on histomorphometry of bone formation (percentage 
% bone area in mean data ±SD) within and outside the ROI. With the larger graph comparing between 
groups and the smaller between ROIIN and ROIOUT and per material group; analysis showing significant 
differences of *] p<0.05, **] p<0.01 and ***] p<0.001.
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In the current study, bone regeneration was examined using a rat critical sized femoral 
defect model, in which the effects of bone condition (healthy versus osteoporotic bone) 
and BMP-2 incorporation into the HABP-CaP hydrogel were comparitively evaluated. We 
hypothesized that (i) an osteoporotic condition would negatively affect defect healing, and 
(ii) that enrichment of the HABP-CaP gel with BMP-2 would improve defect healing in both 
healthy and osteoporotic conditions.
The osteoporotic model was validated by serum TRAP analysis. In a previous study, we used 
in vivo micro-CT to analyze trabecular bone morphometry after orchidectomy and found 
less trabecular bone compared to healthy rats 17. Also, the segmental femoral bone defect 
model of 6 mm proved to be of critical size as none of the control groups showed bridging. 
This corroborates with other studies using the RatFix system 20-24.
For this study, the hydrogel was applied in a PTFE tube to contain it within the defect area. 
The strong bond of the cabon-fluorine gives PTFE the durable properties, inertness and 
resistance to chemical, biological and physical degradation 25. PTFE as biomaterial has been 
widely used in clinics for several years 26-35, and is generally considered to be a well-tolerated 
material and useful when autologous tissue is not available. One major drawback is the 
risk of infection. In our study, no infection was observed in any of the animals. To study the 
effect of the tube on the bone formation two control groups were included, one with and 
one without the tube. The distal femur of two out of four defects without tube were found 
to be loosened. The other two femurs had intact plate and screws and showed some bone 
formation on the plate side of the defect. The four femurs with an empty tube showed 
more equally distributed bone formation starting from each side of the defect, suggesting 
a scaffolding effect of the tube. However, none of the control group, with or without tube, 
showed complete bridging of the defect. 
In view of increased demands for synthetic bone grafts with advantageous properties, we 
previously designed an injectable, hydrogel consisting of bisphosphonated hyaluronan 
and CaP nanoparticles 16. The major biological advantage of this material at the time was 
ingrowth of newly-formed trabecular-like bone interspersed throughout the material after 4 
weeks in a femoral condyle defect in rats 16. Our results show that the hydrogel was almost 
all resorbed by 12 weeks and did allow for bone ingrowth. However, the results of this study 
demonstrate that this material alone is insufficient to regenerate 6 mm rat critical size 
segmental bone defects.
Additionally, the efficacy of BMP-2 loading in the hydrogel was examined in this study and 
found to be effective and dose-dependent. Qualitative and quantitative analysis for bone 
formation by radiography, micro-CT and histomorphometry showed optimal healing for HABP-
CaP-lowBMP2 in both healthy and osteoporotic bone conditions. Qualitative data showed 
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the type of bone formation was different depending on the material used. When the tube 
was empty or filled with gel only more cortical bone was formed from the edges of the bone 
inwards. Whereas when BMP-2 was used bone formation was more spongeous-like, especially 
for low dose BMP-2. A more cyst-like formation was seen when high dosage of BMP-2 was 
used. The quantitative data showed the most bone volume for the hydrogel with low dosage 
of BMP-2. However, the spongious-like bone was not tested for strength and more research 
should be performed to further inform on the quality of the two different bone formations 
with or without BMP-2.
Since the discovery of BMP-2 by Urist in 1965, many studies show similar promising effect 
of BMP-2. In 2007 it was first approved by the FDA (Food and Drug Administration) for 
clinical purpose reporting “near perfect” safety 36. In the recent years, however, several 
(pre-)clinical studies with the use of BMP-2 for bone regeneration do show several adverse 
effects 36,37. These include in general inflammatory and wound complications, ectopic bone, 
osteoclast activation, osteolysis and graft subsidence 36. More specifically for spinal fusion, 
complications can be radiculopathy, urogenital events (retrograde ejaculation and bladder 
retention) and most concerning cervical spine swelling to the extent of being potentially 
life-threatening 36,37. Remarkably, we observed significantly less bone and lower quality of 
formed bone for HABP-CaP-highBMP2 compared to HABP-CaP-lowBMP2. Studies analyzing the 
signaling of BMP-2 have found that BMP-2 induces expression of numerous inflammatory 
cytokines and chemokines, including TNF-α and interleukins 38-40. Yamazaki et al. found that 
TNF-α represses BMP-2, which is increased by the use of BMP-2, therefore not only resulting 
in inflammation but also in inhibition of osteoblastgenesis 41. Liao et al. found that BMP-2 
not only affects MSCs by inducing both osteogenic and chondrogenic differentiation through 
RUNX2 pathway, but also can promote adipogenic differentiation 36,42. The latter could be 
related to bone cyst formation with decreased overall bone quality 36. This was also seen in 
the study by Zara et al., who used the same segmental defect as was used in this study, filled 
with collagen sponges infused with several dosages of BMP-2 43. Their study showed that high 
dosages of BMP-2 induce inflammation resulting in structurally abnormal bone in vivo, with 
the formation of cyst-like bony shells filled with adipose tissue 43. This corroborates with 
our results of high BMP-2 dosage showing bone formation outside the defect in a similar 
matter. Also, the increased number of adipose cells within the defect area for both high 
and low dose BMP-2 corresponds with these studies 36,42,43. Zara et al. postulated that high 
dosage of BMP-2 disregulates Wnt signaling and activate PPARγ leading to abnormal structure 
decreasing bone quality and probably influencing the mechanical properties. 
As osteoporosis is increasingly becoming a major health problem, we aimed to examine 
bone regenerating capacity of a bone substitute material in both healthy and osteoporotic 
conditions. However, very few differences were observed between the healthy and 
osteoporotic conditions. Only for the HABP-CaP-highBMP2, superior regeneration in healthy 
conditions was found. This observation corroborates with one of our other studies, in which 
CPC/PLGA and Bio-Oss® were compared in healthy and osteoporotic conditions in a rat 
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femoral bone defect model and also no significant differences between the two conditions 
in terms of bone regeneration were found 44. As already mentioned, a high dosage BMP-2 can 
have adverse effects, such as general inflammatory and wound complications, ectopic bone, 
osteoclast activation, osteolysis and graft subsidence. In this study these adverse effects 
of a high dosage of BMP-2 on bone regeneration seems less pronounced in osteoporotic 
conditions. An explanation for this could be found in the serum TRAP analysis. Our results 
show significantly lower amounts of serum TRAP in osteoporotic conditions, which is in 
concurrence with a previous studies 45,46. We concluded that the lower amount of TRAP 
indicates a decreased absolute number of active osteoclast due to a decreased amount of 
bone 45,46. This absolute decreased amount of active osteoclasts combined with less bone 
volume can explain why BMP-2 has less effect in osteoporotic conditions. Furthermore, the 
high dosage of BMP-2 could result in more bone resorption by further increasing the number 
of active osteoclast 36,43. To confirm this hypothesis more research with gene expression 
analysis in osteoporotic conditions should be performed.
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Conclusion
The current study shows that critical size, segmental femoral bone defects cannot be healed 
with HABP-CaP gel alone. Loading of the HABP-CaP gel with low dose BMP-2 significantly 
improved bone formation and resulted in defect bridging in 100% of the defects. Alternatively, 
high dose BMP-2 loading of the HABP-CaP gel did not improve bone formation within the 
defect area, but led to excessive bone outside the defect area by cyst-like formation. 
Surprisingly, bone defect healing was not negatively affected by osteoporotic bone 
conditions, except when using high dose BMP-2.
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Bone has the regenerative capacity to completely heal defects and fracture, and restore 
its properties as was before the damage (Thorne et al. 2014, Gianoudis et al. 2007). A 
disruption to this regenerative capacity can lead to uncomplete healing (Gianoudis et al. 
2007). Surgical intervention using bone grafting is used to repair and augment damaged or 
diseased bone in cases that exceed the critical boundaries for spontaneous healing. The 
gold standard in bone regeneration is the use of autologous bone graft; however, there are 
several disadvantages when using autologous bone, such as an additional surgical site and 
patient-related compromised bone quality. Therefore, synthetic bone substitutes have been 
developed to overcome these drawbacks. Beside the material choice, it is also important 
to consider the conditions in which the bone substitutes have to perform, which may not 
be optimal. This thesis focuses specifically on critically sized defects and the systemically 
compromised bone condition osteoporosis. When using autologous bone graft to aid bone 
healing, osteoporosis causes added complexity because of the systemic nature of the disease 
(Fini et al. 2004). Because osteoporosis is an age-related disease, the challenge of bone 
regeneration in osteoporotic conditions is becoming more relevant with the number of 
elderly patients expecting to increase significantly over the next several decades (Carmona 
et al. 2004, Johnell et al. 2006, Burge et al. 2007).
Based on the above mentioned, the main objective of this thesis was to evaluate bone 
regeneration using bone graft substitutes, both commercially available and novel materials, 
in healthy and compromised conditions using in vivo animal models. For this, we focused on 
evaluation of bone regeneration in osteoporotic conditions, challenged bone regeneration 
using defect size, and explored novel experimental bone substitute materials with appealing 
properties for stimulation of bone regeneration. The following sections recapitulate the 
specific objectives and performed experimental work for this thesis.
Chapter 2 
Evaluate the efficacy of two commercially available materials, Biosilicate® and 
Bio-Oss®, in healthy and osteoporotic conditions at both tissue and molecular 
level by gene-expression analysis.
Biosilicate® and Bio-Oss® are two commercially available bone substitutes, however, little is 
known regarding their efficacy in osteoporotic conditions. The purpose of this study was to 
evaluate the osteogenic properties of both materials, at tissue and molecular level. Thirty-
six Wistar rats were submitted to ovariectomy (OVX) for inducing osteoporotic conditions 
and sham surgery (SHAM) as a control. Bone defects were created in both femurs, which 
were filled with Biosilicate® or Bio-Oss®, and empty defects were used as control. Results 
showed for the healthy condition both Biosilicate® and Bio-Oss® did not improve bone 
formation after 4 weeks. Histomorphometric evaluation of osteoporotic bone defects with 
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bone substitutes showed more bone formation compared to empty controls. To determine 
effects of the bone condition on mesenchymal stem cells (MSCs), molecular biological 
evaluation was performed by gene-expression analysis (Runx-2, ALP, OC, OPG, RANKL). The 
relative gene expression was increased with Biosilicate® for all genes in MSCs from OVX rats 
and for Runx-2, ALP, OC and RANKL in MSCs from SHAM rats. In contrast, with Bio-Oss®, the 
relative gene expression of MSCs from OVX rats was similar for all three groups. For MSCs 
from SHAM rats, gene expression was increased for Runx-2, ALP, OC and RANKL. Since both 
materials improved bone regeneration in osteoporotic conditions, our results suggest that 
bone defects in osteoporotic conditions can be efficiently treated with these two bone 
substitutes.
Chapter 3 
Evaluate the efficacy of calcium phosphate cement with porogens in bone defects 
created in healthy and osteoporotic conditions.
Next to the two commercially available bone substitutes mentioned in the previous 
chapter, we aimed to analyse the efficacy of a novel biomaterial with appealing handling 
properties and controllable degradation. Calcium phosphate (CaP) based materials are 
synthetic inorganic biomaterials that show high similarity to bone tissue by resembling 
the mineral phase of bone and are already popular implant materials in several fields of 
surgery. CaP based materials are available in several forms, such as pre-set samples as 
well as in an injectable form. As an injectable CaP cement (CPC), the main disadvantage 
is its low degradation rate mainly due to the inadequate intrinsic porosity. We questioned 
to what extent an osteoporotic bone condition affects the biological performance of CPC, 
more specifically material degradation and bone regenerative capacity. To answer these 
questions, we aimed to comparatively evaluate the biological performance of CPC combined 
with polylactic-co-glycolic acid (PLGA) micro-particles and Bio-Oss® in ovariectomized and 
healthy rats. Thirty-two Wistar rats received alternating experimental CPC/PLGA and Bio-Oss® 
in femoral condyle defects in both femurs 6 weeks after ovariectomy (OVX, n=16) or sham 
operation (SHAM, n=16). Six weeks after OVX or SHAM surgery, bone morphology was analysed 
by in vivo computed tomography (CT) to confirm osteoporotic bone condition. Analysis of 
bone formation and material remnants at 4 and 12 weeks after material implantation was 
performed by micro-CT, descriptive histology, histomorphometry and bone dynamics by 
fluorochrome labelling. The in vivo CT scans showed effective induction of an osteoporotic 
bone condition by ovariectomy. Our data showed that CPC/PLGA degraded faster and more 
steadily in osteoporotic conditions. However, Bio-Oss® had significantly less material 
remnants and showed significantly more bone formation compared to CPC/PLGA. Overall, 
our data showed relatively high amounts of CPC/PLGA at each time point, hampering new 
bone formation within the defect area. Osteoporotic conditions proved to significantly affect 
degradation rates, but did not significantly influence bone formation. We concluded that an 
osteoporotic bone condition affects degradation of CPC/PLGA, which is vital information for 
its potential use in osteoporotic conditions.
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Evaluate bone regeneration and material degradation by altering the PLGA 
porogen content in calcium phosphate cement.
To futher analyse the degradation rate of CPC and increase bone regeneration, this chapter 
aimed to improve both using different porogens and ratios. We comparatively evaluated 
the in vitro degradation effects of dense PLGA microspheres and milled PLGA particles as 
porogens within CPC. We hypothesized that milled PLGA particles would evoke similar CPC/
PLGA degradation compared to dense PLGA microspheres. Additionally, we aimed to examine 
the effect of PLGA porogen amount in CPC/PLGA via an in vivo rat femoral bone defect model 
to determine CPC degradation and bone formation. We hypothesized that a higher PLGA 
porogen amount would increase the porosity leading to faster degradation and consequently 
more bone formation in vivo. Our in vitro results showed no differences between both forms 
of PLGA particles (as porogens in CPC) regarding morphology, porosity and degradation. 
Using milled PLGA particles as porogens within CPC/PLGA, we evaluated the effect of porogen 
amount on degradation and bone forming capacity in a rat femoral bone defect model. 
Titanium landmarks surrounded by CPC/PLGA, at a weight percentage of 50/50 and 70/30wt%, 
were implanted in the femurs of twenty male Wistar rats. Histomorphometric results showed 
a significant temporal decrease in the amount of cement for both formulas, and confirmed 
that 50/50wt% of CPC/PLGA degrades faster than 70/30wt% and allows for a 1.5-fold higher 
amount of newly formed bone tissue. Taken together, this study demonstrated that (i) PLGA 
porogens in the form of milled particles perform equal to dense PLGA microspheres, and 
(ii) tuning of the PLGA content in CPC/PLGA is a feasible approach to leverage material 
degradation and bone formation.
Chapter 5  
Challenge bone regeneration by introducing demineralized bone matrix as bone 
substitute material into a critical sized calvarial bone defect.
Further challenging bone healing, we examined bone regeneration in a critical sized calvarial 
bone defect. For this study, we examined demineralised bone matrix (DBM), which is an 
allograft bone substitute used for bone repair surgery to overcome drawbacks of autologous 
bone grafting such as limited supply and donor-site comorbidities. In view of different 
demineralization treatments to obtain DBM, we examined the biological performance of 
two differently demineralised types of DBM (i.e. by acidic treatment using hydrochloric 
acid, HCl, or treatment with the chelating agent ethylenediaminetetraacetate, EDTA). 
Firstly, we evaluated osteoinductive properties of both DBMs by implanting the materials 
subcutaneously in rats. Secondly, we evaluated effects on bone formation by incorporating 
DBM in a hyaluronic acid (HA) gel to fill a porous titanium scaffold for use in a critical-sized 
calvarial defect model in 36 male Wistar rats. These porous titanium scaffolds were implanted 
empty or filled with HA-gel containing either DBMHCl or DBMEDTA. Ectopically implanted 
DBMHCl and DBMEDTA did not induce ectopic bone formation over the course of 12 weeks. For 
the calvarial defects, mean percentages of newly formed bone at 2 weeks were significantly 
higher for Ti-Empty compared to Ti-HA+DBMHCl, but not compared to Ti-HA+DBMEDTA. Significant 
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temporal bone formation was observed for Ti-Empty and Ti-HA+DBMHCl, but not for Ti-
HA+DBMEDTA. At 8 weeks, there were no significant differences in values of bone formation 
between the three experimental constructs. In conclusion, these results showed that under 
the current experimental conditions both DBMHCl and DBMEDTA do not possess osteoinductive 
properties. Additionally, in combination with an HA-gel loaded in a porous titanium scaffold, 
DBMHCl and DBMEDTA showed similar amounts of new bone formation after 8 weeks, which 
were lower compared to the empty porous titanium scaffold.
Chapter 6 
Evaluate bone regeneration using an “improved” novel material by adding 
alendronate into the CPC/PLGA and test the efficacy in osteoporotic conditions.
As mentioned before, osteoporosis represents a major health problem in terms of 
compromising bone strength and increasing the risk of bone fractures. It can be medically 
treated with bisphosphonates, which act systemically upon oral or venous administration. 
Further, bone regenerative treatments in osteoporotic conditions present a challenge. 
Here, we focused on the development of a synthetic bone substitute material with local 
diminishing effects on osteoporosis. Composites were created using calcium phosphate 
cement (CPC; 60 wt%) and polylactic-co-glycolic acid (PLGA; 40 wt%), which were loaded with 
alendronate (ALN). In vitro results showed that ALN-loaded CPC/PLGA composites presented 
clinically suitable properties, including setting times, appropriate compressive strength, 
and controlled release of ALN, the latter being dependent on composite degradation. Using 
a rat femoral condyle bone defect model in osteoporotic animals, ALN-loaded CPC/PLGA 
composites demonstrated stimulatory effects on bone formation both within and outside 
the defect region.
Chapter 7  
Evaluate bone regeneration in a critical sized defect with osteoporotic conditions 
and enhance the bone substitute material (a self-healing hydrogel containing BP 
and calcium phosphate) with BMP-2.
Ultimately, we challenged bone regeneration by combining two compromising conditions: 
a critical sized defect and osteoporotic conditions. In this study, we first aimed to evaluate 
the biological response to experimental hydrogels with calcium phosphate (CaP) and 
hyaluronan (HA) with bisphosphonate (BP) physical gelation and BMP-2 in a critical-sized 
segmental femoral bone defect model in rats. Additionally, we aimed to evaluate the effect 
of the hydrogels in osteoporotic condition using the same defect model. Fifty-six Wistar rats 
received either a sham surgery (SHAM) or orchydectomie (ORX). After six weeks to establish 
osteoporotic conditions for the ORX animals, a critical-sized segmental femoral defect was 
created in one femur per rat. Two control groups were used: one with only a plate to fixate 
the defect and a second with the same plate adding an empty PTFE tube. The experimental 
groups consisted of the plate and tube filled with our hydrogel (HABP-CaP) and the hydrogel 
with BMP-2 in a low dosage (HABP-CaP-lowBMP2) or high dosage (HABP-CaP-highBMP2). 
Twelve weeks after the bone defect surgery, bone formation analysis was performed by 
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X-ray examination, micro-CT analysis, descriptive histology and histomorphometry. Our data 
from micro-CT analysis showed significantly more bone for HABP-CaP-lowBMP2 compared 
to HABP-CaP and HABP-CaP-highBMP2 in both healthy and osteoporotic bone conditions. 
Histomorphometry also showed significantly more bone for HABP-CaP-lowBMP2 compared to 
HABP-CaP and HABP-CaP-highBMP2 in both healthy and osteoporotic conditions. For defects 
filled with either low or high dosages of BMP-2, an increased amount of bone around 
the defect area was observed compared to BMP-2 free hydrogels. Only for the HABP-CaP-
highBMP2, a difference between healthy and osteoporotic bone conditions was observed 
in favour of SHAM. We conclude that the critical-sized defects could be regenerated using 
our hydrogel, showing most bone formation for hydrogels with low dose BMP-2, regardless 
of the bone condition.
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Closing remarks
Continuous progress in healthcare contributes to extended life-expectancy. With people 
living longer, the number of people suffering from age-related diseases also increases. 
Considering bone, the most common age-related disease is osteoporosis, a systemic bone 
condition in which the remodeling process of bone is out of balance resulting in porous 
and fragile bone. Patients with osteoporosis have an increased risk for bone fractures as 
well as impaired bone healing. An increase in the need for bone grafting surgery is expected 
over the coming decades. With impaired bone healing in osteoporotic patients and the 
drawbacks of autologous bone grafting (i.e. limited amount and quality of donor bone and 
extra surgical time and donor site morbidity) the possibility to replace autologous bone by 
bone substitutes has been explored heavily over the last century. However, the effect of 
osteoporosis on the performance of such bone substitutes is not clear. The overall aim of 
this thesis was to investigate the effect of the compromising condition osteoporosis on bone 
healing using bone graft substitutes. Our research showed that when using two commercially 
available bone graft substitutes (i.e. Bio-Oss® and Biosilicate®) both materials improve 
bone regeneration in osteoporotic conditions, but do not in healthy conditions (Chapter 
2). These data suggest that bone defects in osteoporotic conditions can be successfully 
treated with synthetic bone substitutes and that bone substitutes are of additional value 
for bone defect treatment particularly in osteoporotic patients. When examining the effect 
of osteoporosis on bone substitute degradation, we found that CPC/PLGA degraded faster 
and more steadily compared to Bio-Oss® in osteoporotic conditions (Chapter 3). However, 
in absolute values, Bio-Oss® showed significantly fewer material remnants and more bone 
formation compared to CPC/PLGA. Our data confirmed our hypothesis that an osteoporotic 
condition affects degradation of CPC/PLGA, which is vital information for its future use 
in osteoporotic patients. Alternatively, no effects of an osteoporotic condition on bone 
formation were observed. Consequently, different bone conditions require the selection of 
a bone graft material with suitable degradation characteristics.
Continuous improvement of healthcare not only results in an increase in life-expectancy, 
but also comes with better survival, for example, in high energy traumas and after cancer 
treatment. In both cases, large bone defects can occur in a variety of forms, anatomic 
locations and patient ages. To overcome these critically sized defects, also here great benefit 
can be obtained from the use of synthetic instead of autologous bone. To provide support, 
such large defects often require to be combined with some form of scaffold (carrier) adapted 
to the bone type and anatomical location of the defect (i.e. long bone or flat, load bearing 
site or non-load bearing). A second aim of this thesis was to explore the possibility to 
overcome such large critical size defects with bone substitute materials combined with a 
stable supporting scaffold. Our results showed that under healthy conditions, bone forming 
capacity of hyaluronic gel composite with DBM in titanium constructs was not enhanced 
compared to the osteoconductive properties of an empty porous titanium scaffold alone 
(Chapter 5). In another experimental setting using segmental defects, our results showed 
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that a critical size segmental defect of 5mm in the rat femur can heal using a self-healing 
hybrid nano-composite hydrogel in both healthy and osteoporotic conditions (Chapter 7).
For almost a century, bone substitutes have been under investigation to improve surgical 
treatment of bone fractures and defects. Since compromising conditions more and more 
become an interfering factor regarding bone healing, we aimed to examine the effect of 
osteoporosis to better predict the outcome of bone grafting procedures. A next step is 
to investigate how to improve bone grafting procedures by altering properties of bone 
substitutes and possibly further enhance their performance by adding molecules that can 
elute and locally treat diseased bone. This was our third aim for this thesis. The results of 
our in vitro study with CPC containing equal amounts of either PLGA microspheres or milled 
particles showed similar scaffold morphology, CPC porosity and degradation (Chapter 4). By 
increasing the amount of PLGA porogens within CPC, we accelerated CPC/PLGA degradation 
in vitro. The in vivo results of CPC/PLGA with milled PLGA showed a favorable bone response. 
Furthermore, a higher amount of milled PLGA particles (i.e. 50 versus 30 wt%) accelerated 
both CPC degradation and new bone formation. For future clinical application, milled PLGA 
particles appear to be promising as CPC porogen. Moreover, the degradation rate of CPC 
is tunable to meet desired demands at different defect sites and with different patient 
conditions.
Addition of drugs or growth factors into the material could possibly further enhance and 
stimulate bone regeneration. The in vitro analysis in our study of alendronate (ALN; a 
frequently used bisphosphonate for osteoporosis) release from calcium phosphate cement 
for bone regeneration in osteoporotic conditions showed that ALN-loaded CPC/PLGA 
presents clinically acceptable handling, suitable compressive strength, and a controlled ALN 
release (Chapter 6). In an in vivo bone defect model, application of ALN-loaded CPC/PLGA 
showed that a relative low dose of ALN (0.5 wt%) significantly increased bone formation in 
the peri-defect region in osteoporotic conditions, without effect on CPC/PLGA degradation. 
The data suggest that future clinical application of ALN-loaded CPC/PLGA can be beneficial 
for the healing of bone defects in a compromised osteoporotic condition.
In another experimental set-up, our in vivo result showed that a critical size, segmental 
femoral bone defects could not be healed with HABP-CaP gel alone (Chapter 7). Loading 
of the HABP-CaP gel with a low dose of BMP-2 significantly improved bone formation and 
resulted in defect bridging in 100% of the defects. Alternatively, high dose BMP-2 loading of 
the HABP-CaP gel did not improve bone formation within the defect area, but led to excessive 
bone formation outside the defect area. Future use of BMP-2 appears to beneficial, however, 
the effect is highly dose dependent.
Future perspectives
The process of bone healing has been a research topic for several decades with the aim to 
prevent and/or treat fractures and bone defects. The multifactorial aspect of healing makes 
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it an interesting and complex subject for researchers worldwide. In this thesis, we aimed to 
examine the effect of osteoporosis as a systemic condition interfering with bone homeostasis 
on the performance of bone substitutes in challenging conditions to add information and 
hopefully provide basis for more research that can ultimately result in complete healing and/
or prevention of complex fractures and bone defects in osteoporotic patients.
Development of bone substitutes with improved biological performance
Autologous bone has the advantage of having both properties of osteoconduction and 
osteoinduction. Therefore, autologous bone remains the gold standard in bone grafting 
procedures. The term osteoconduction refers to the ability of bone to grow along a 
surface, i.e. to conduct bone from one end of the defect to the other. In other words, bone 
regeneration is established by growing bone tissue that exploits the material within the 
defect (formed or placed) as a scaffold. Bone substitutes generally also have osteoconductive 
properties. This can be influenced by the number and sizes of pores within the material 
and also by the degradation rate. These properties can be tunable in bone substitutes, 
and hence can be adjusted to specific needs in different patients and/or defect properties. 
Since bone healing is multifactorial, tailor-made bone substitutes specifically designed to 
have patient-specific degradation would be desirable to optimally match physico-chemical 
material properties with biological conditions in a specific defect site for individual patients.
To further improve bone substitutes, more and more research is performed to engineer 
biomaterials that also have osteoinductive properties, in order to become capable of healing 
large and compromised defects. Osteoinduction involves the stimulation of osteoprogenitor 
cells to differentiate into osteoblasts to form new bone. Bone morphogenetic proteins (BMPs) 
represent a group of growth factors that are widely used to provide osteoinductive capacity. 
In this thesis, we found the effect of BMP-2 to be dose-dependent. Further research is 
needed to reveal the optimal osteoinductive material and determine the correct use of such 
growth factors regarding their safe loading, release, and biological activity. Also, here, more 
knowledge can lead to engineering bone substitutes for individual patients with specific 
bone defect characteristics and patient conditions.
Novel predictive & preventive medicine
As mentioned before, improving healthcare results in an increased life-expectancy and 
better survival. This is also true for bone trauma or bone cancer treatment, giving rise to 
more complex and large bone defects. In the previous paragraph, we hypothesized on how 
bone substitute properties can be changed to improve the biological performance of bone 
substitutes. To offer optimal treatment of bone defects or fractures in these complex patient 
conditions, however, research should also continue to focus on patient- and defect-related 
risk factors in order to optimize outcome. The effect of patient- and defect-related factors 
on bone healing is quintessential for choosing which surgical procedure and bone substitute 
to use in order to provide the best care for each individual patient. Nowadays, healthcare 
is already worldwide changing its strategy to become preventive rather than curative. For 
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bone fractures, this is the case especially for osteoporosis. Lifestyle changes, better diet 
advise, and medical treatment for the prevention of osteoporosis are already implemented 
in global healthcare systems to prevent osteoporotic fractures. Still, a large number of men 
and women, especially those above 50 years of age, will encounter the complications of this 
disease. Although bone substitutes cannot be used for the prevention of osteoporosis, they 
likely can aid in the surgical treatment of bone defects or fractures. Further, once implanted, 
they can provide prevention of bone fractures by locally releasing suitable anti-osteoporotic 
or anabolic molecules.
Predictive models for risk of non-unions have been successfully investigated (Zura et al. 
2017). Still, the prevention of non-unions remains difficult and the treatment remains a 
challenge for surgeons and patients. In the case of non-unions, younger patients with 
comorbidities as smoking, alcoholism, obesity, osteo- or rheumatoid arthritis, type 2 diabetes 
and/or open fractures are more at risk. Using the information at hand on who will have a 
high risk of developing a non-union, possibly bone substitutes can be further improved 
in order to use as a therapeutic. Knowing which risk factor is involved in a patient with 
a fracture that can contribute to a non-union, adding a tailor-made bone substitute with 
therapeutic drugs can result in improved bone regeneration and a lower risk of non-union 
compared to autologous bone graft. When a fracture does not require surgery but is at risk 
for non-union, another bone substitute with features specifically tailored for the patient can 
be used. This is a time-consuming, costly and complex research strategy that, however, can 
help a wide variety of patients.
Local versus systemic treatment of bone conditions
To continuously improve bone substitutes, we discussed the development to upgrade bone 
substitutes with osteoinductive properties and exploit tunable properties specifically tailored 
to the need of the individual patient and defect conditions. Addition of drugs (i.e. antibiotics 
or anti-osteoporotic drugs) to bone substitutes is an example of such a tailor-made property. 
In the case of osteoporosis, bone turnover imbalance is counteracted by anti-osteoporotic 
drugs, such as bisphosphonates. These drugs inhibit osteoclast function, resulting in less 
bone resorption and reduced risk of bone fractures. There are a variety of side effects that 
can occur, such as stomach problems, kidney failure, osteonecrosis of the jaw, and even 
an increased risk of esophageal cancer (Kenal et al. 2009). When treating an osteoporotic 
fracture, anti-osteoporotic drugs can be added to a bone substitute to improve and speed 
up bone healing. An advantage of locally administered drugs is that the dosage can be 
reduced and therefore there is less risk of systemic side effects. Combined with preventive 
medicine, such as healthy nutrition and enough exercise, this can hopefully reduce the need 
for systemically administration. 
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Bot heeft het regeneratieve vermogen om defecten en breuken volledig te genezen en zijn 
eigenschappen te herstellen zoals voordat de schade ontstond (Thorne et al. 2014, Gianoudis 
et al. 2007). Een verstoring van het regeneratieve vermogen van bot kan leiden tot een 
onvolledige genezing (Gianoudis et al. 2007). Chirurgische interventie met bottransplantatie 
wordt gebruikt om beschadigd of ziek bot te herstellen en bot toe te voegen in gevallen 
die de kritische grenzen voor spontane genezing overschrijden. De gouden standaard bij 
botregeneratie is het gebruik van autoloog bottransplantaat. Er zijn echter verschillende 
nadelen bij het gebruik van autoloog bot, zoals een extra operatie wond en patiënt 
gerelateerde verminderde botkwaliteit. Daarom zijn synthetische botvervangers ontwikkeld 
om deze nadelen te ondervangen. Naast de materiaalkeuze is het ook belangrijk om rekening 
te houden met de omstandigheden waarin de botvervangers moeten presteren, die wellicht 
niet optimaal zijn. Dit proefschrift richt zich specifiek op defecten van kritieke grootte en 
de systemisch botaandoening osteoporose. Bij gebruik van autoloog bottransplantaat 
om botgenezing te bevorderen, zorgt osteoporose voor extra complexiteit vanwege de 
systemische aard van de ziekte met negatieve invloed op botgenezing (Fini et al. 2004). 
Omdat osteoporose een leeftijdsgebonden ziekte is, wordt de uitdaging van botregeneratie 
bij osteoporotische aandoeningen relevanter, aangezien het aantal oudere patiënten dat 
verwacht aanzienlijk te stijgen in de komende decennia (Carmona et al. 2004, Johnell et al. 
2006, Burge et al. 2007).
Gebaseerd op het bovenstaande, was het hoofddoel van dit proefschrift om botregeneratie 
te evalueren met behulp van bottransplantaatvervangers, zowel commercieel verkrijgbaar 
als nieuwe materialen, in gezonde en gecompromitteerde condities met behulp van in 
vivo diermodellen. Hiervoor hebben we ons gericht op de evaluatie van botregeneratie 
in osteoporotische condities, botregeneratie uitgedaagd door gebruik te maken van 
defectgrootte, en nieuwe experimentele botvervangende materialen onderzocht met gunstige 
eigenschappen voor bevorderen van botregeneratie. De volgende hoofdstukken geven een 
samenvatting van de specifieke doelstellingen en het de uitgevoerde experimenten die 
verricht zijn voor dit proefschrift.
Hoofdstuk 2 
Evalueren van de werkzaamheid van twee commercieel verkrijgbare materialen, 
Biosilicate® en Bio-Oss®, in gezonde en osteoporotische condities op zowel 
weefsel- als moleculair niveau door middel van genexpressieanalyse
Biosilicate® en Bio-Oss® zijn twee in de handel te verkrijgen botvervangers, maar er is 
weinig bekend over hun werkzaamheid bij osteoporotische aandoeningen. Het doel van 
deze studie was om de osteogene eigenschappen van beide materialen te evalueren, op 
weefsel- en moleculair niveau. Zesendertig Wistar-ratten werden onderworpen aan een 
ovariëctomie (OVX) voor het induceren van osteoporotische aandoeningen en vergeleken 
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met gezonde (SHAM) ratten ter contole. Botdefecten werden gecreëerd in beide dijbenen, die 
werden gevuld met Biosilicate® of Bio-Oss®, en lege defecten werden gebruikt als controle. 
Resultaten toonden voor de gezonde toestand dat zowel Biosilicate® als Bio-Oss® de 
botvorming na 4 weken niet verbeterden. Histomorfometrische evaluatie van osteoporotische 
botdefecten met botvervangers liet meer botvorming zien in vergelijking met lege controles. 
Om de effecten van de botaandoening op mesenchymale stamcellen (MSC’s) te bepalen, werd 
moleculair biologische evaluatie uitgevoerd door middel van genexpressie-analyse (Runx-2, 
ALP, OC, OPG, RANKL). De relatieve genexpressie werd verhoogd met Biosilicate® voor alle 
genen in MSC’s van ratten met osteoporotische condities en voor Runx-2, ALP, OC en RANKL in 
MSC’s van gezonde ratten. Bij Bio-Oss® daarentegen was de relatieve genexpressie van MSC’s 
van ratten met osteoporotische condities vergelijkbaar voor alle drie de groepen. Voor MSC’s 
van gezonde ratten was de genexpressie verhoogd voor Runx-2, ALP, OC en RANKL. Omdat 
beide materialen de botregeneratie bij osteoporotische condities verbeterden, suggereren 
onze resultaten dat botdefecten bij osteoporotische condities efficiënt kunnen worden 
behandeld met deze twee botvervangers.
Hoofdstuk 3 
Evalueren van de werkzaamheid van calciumfosfaatcement met porogenen bij 
botdefecten die ontstaan onder gezonde en osteoporotische aandoeningen
Naast de twee commercieel verkrijgbare botvervangers die in het vorige hoofdstuk zijn 
genoemd, wilden we de werkzaamheid analyseren van een nieuw biomateriaal met 
gunstige hanteringseigenschappen en controleerbare degradatie. Materialen op basis van 
calciumfosfaat (CaP) zijn synthetische anorganische biomaterialen die in hoge mate gelijkenis 
vertonen met botweefsel doordat ze lijken op de minerale fase van bot en daardoor al 
populaire botvervangende materialen zijn in verschillende chirurgische vakgebieden. Op 
CaP gebaseerde materialen zijn verkrijgbaar in verschillende vormen, zowel in verschillende 
vormen en mate als ook mede in een injecteerbare vorm die zich vormt naar het defect. 
Als injecteerbaar CaP-cement (CPC) is het belangrijkste nadeel de lage afbraaksnelheid, 
voornamelijk als gevolg van de onvoldoende intrinsieke porositeit. We vroegen ons af in 
hoeverre osteoporotische condities de biologische prestatie van CPC in bot beïnvloedt, 
meer specifiek de materiaalafbraak en botregeneratieve capaciteit. Om deze vragen te 
beantwoorden, wilden we de biologische prestatie van CPC in combinatie met polymelk-
co-glycolzuur (PLGA) microdeeltjes en Bio-Oss® in gezonde ratten die ovariëctomie hebben 
ondergaan, relatief evalueren. Tweeëndertig Wistar-ratten kregen 6 weken na ovariëctomie 
(OVX, n = 16) of schijnoperatie (SHAM, n = 16) afwisselend experimentele CPC / PLGA en 
Bio-Oss® in femurdefecten beiderzijds. Zes weken na OVX- of SHAM-chirurgie werd de 
botmorfologie geanalyseerd door in vivo computertomografie (CT) om de osteoporotische 
botaandoening te bevestigen. Analyse van botvorming en materiaalresten op 4 en 12 
weken na implantatie van het materiaal werd uitgevoerd door micro-CT, beschrijvende 
histologie, histomorfometrie en botdynamica door middel van fluorochrome labeling. De 
in vivo CT-scans lieten een effectieve inductie zien van een osteoporotische conditie door 
ovariëctomie. Onze gegevens toonden aan dat CPC / PLGA sneller en gestaag degradeerde 
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onder osteoporotische condities. Bio-Oss® had echter significant minder materiaalresten en 
vertoonde significant meer botvorming in vergelijking met CPC / PLGA. Over het algemeen 
lieten onze gegevens op elk tijdstip relatief hoge hoeveelheden CPC / PLGA zien, waardoor 
de vorming van nieuw bot in het defectgebied werd belemmerd. Osteoporotische conditie 
bleek de afbraaksnelheid significant te beïnvloeden, maar hadden geen significante invloed 
op de botvorming. We concludeerden dat een osteoporotische conditie de afbraak van 
CPC / PLGA beïnvloedt, wat essentiële informatie is voor het mogelijke gebruik ervan bij 
osteoporotische aandoeningen.
Hoofdstuk 4
Evalueren van botregeneratie en materiaalafbraak door het PLGA-partikel gehalte 
in calciumfosfaatcement te veranderen
Om de afbraaksnelheid van CPC verder te analyseren en de botregeneratie te verhogen, had 
dit hoofdstuk als doel om beide te verbeteren door verschillende partikels en verhoudingen 
te gebruiken. We evalueerden relatief de in vitro afbraakeffecten van dichte PLGA-microsferen 
en gemalen PLGA-deeltjes als partikels binnen CPC. Onze hypothese was dat gemalen PLGA-
deeltjes vergelijkbare CPC / PLGA-degradatie zouden oproepen in vergelijking met dichte 
PLGA-microsferen. Bovendien wilden we het effect van hoeveelheid PLGA partikels in CPC 
onderzoeken via een in vivo model van botdefecten in de femur bij ratten om CPC-afbraak 
en botvorming te bepalen. Onze hypothese was dat een hogere hoeveelheid PLGA partikels 
de porositeit zou verhogen, wat zou leiden tot snellere afbraak en bijgevolg meer botvorming 
in vivo. Onze in vitro resultaten toonden geen verschillen tussen beide vormen van PLGA 
partikels (microsferen of gemalen deeltjes) wat betreft morfologie, porositeit en degradatie. 
Met behulp van gemalen PLGA-deeltjes als partikels binnen CPC / PLGA, evalueerden we 
het effect van de hoeveelheid partikels op afbraak en botvormend vermogen in een femur 
botdefectmodel van de rat. Titanium oriëntatiepunten omgeven door CPC / PLGA, met een 
gewichtspercentage van 50/50 en 70/30 gew.%, werden geïmplanteerd in de femora van 
twintig mannelijke Wistar-ratten. Histomorfometrische resultaten toonden een significante 
geleidelijke afname van de hoeveelheid cement voor beide formules, en bevestigden dat 
50/50 gew.% van CPC / PLGA sneller afbreekt dan 70/30 gew.% en 1,5 keer meer nieuw 
botvorming mogelijk maakt. Alles bij elkaar heeft deze studie aangetoond dat (i) PLGA 
partikels in de vorm van gemalen deeltjes gelijk presteren als dichte PLGA-microsferen, 
en (ii) afstemming van het PLGA-gehalte in CPC / PLGA is een haalbare benadering om 
materiaalafbraak en botvorming te benutten.
Hoofdstuk 5 
Botregeneratie stimuleren door gebruik van gedemineraliseerde botmatrix als 
botvervangend materiaal in een schedel botdefect van kritieke grootte
Om botgenezing nog verder uit te dagen wilden we botregeneratie onderzoeken 
in een schedeldefectmodel van kritieke grootte. Voor deze studie hebben we 
gedemineraliseerde botmatrix (DBM) onderzocht, een allograft botvervanger die wordt 
gebruikt voor bothersteloperaties om de nadelen van autologe bottransplantatie, zoals 
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een beperkte voorraad en comorbiditeit op de donorplaats, te beperken. Met het oog 
op verschillende demineralisatiebehandelingen om DBM te verkrijgen, onderzochten 
we de biologische prestaties van twee verschillend gedemineraliseerde soorten DBM 
(d.w.z. door zure behandeling met zoutzuur, HCl of behandeling met het chelaatvormer 
ethyleendiaminetetraacetaat, EDTA). Ten eerste hebben we de osteo-inductieve 
eigenschappen van beide DBM’s geëvalueerd door de materialen subcutaan in ratten te 
implanteren. Ten tweede hebben we effecten op botvorming geëvalueerd door DBM op te 
nemen in een hyaluronzuur (HA) -gel om een poreuze titanium implantaat te vullen voor 
gebruik in een schedeldefectmodel van kritieke grootte bij 36 mannelijke Wistar-ratten. 
Deze poreuze titanium implantaten werden leeg geïmplanteerd of gevuld met HA-gel die 
ofwel DBM-HCl of DBM-EDTA bevatte. Ectopisch geïmplanteerde DBM-HCl en DBM-EDTA 
veroorzaakten geen ectopische botvorming in de loop van 12 weken. Voor de schedel 
defecten waren de gemiddelde percentages nieuw gevormd bot na 2 weken significant hoger 
voor Ti-Empty vergeleken met Ti-HA + DBM-HCl, maar niet vergeleken met Ti-HA + DBM-EDTA. 
Significante botvorming in de tijd werd waargenomen voor Ti-Empty en Ti-HA + DBM-HCl, 
maar niet voor Ti-HA + DBM-EDTA. Na 8 weken waren er geen significante verschillen 
botvorming tussen de drie experimentele constructen. Concluderend lieten deze resultaten 
zien dat onder de huidige experimentele omstandigheden zowel DBM-HCl als DBM-EDTA geen 
osteo-inductieve eigenschappen bezitten. Bovendien vertoonden DBM-HCl en DBM-EDTA, 
in combinatie met een HA-gel geladen in een poreuze titanium implantaat, vergelijkbare 
hoeveelheden nieuwe botvorming na 8 weken, die lager waren in vergelijking met de lege 
poreuze titanium implantaat.
Hoofdstuk 6 
Evalueren van botregeneratie met behulp van een “verbeterd” nieuw materiaal 
door alendronaat toe te voegen aan de CPC / PLGA en de werkzaamheid te testen 
bij osteoporotische condities
Zoals eerder vermeld, vormt osteoporose een groot gezondheidsprobleem in termen van 
verminderde botsterkte en verhoging van het risico op botbreuken. Het kan medisch worden 
behandeld met bisfosfonaten, die systemisch werken na orale of veneuze toediening. 
Bovendien vormen osteoporotische condities ook een uitdaging voor botregeneratieve 
behandelingen. Hier hebben we ons gericht op de ontwikkeling van een synthetisch 
botvervangend materiaal met lokaal afnemende effecten op osteoporose. Composieten 
werden gemaakt met calciumfosfaatcement (CPC; 60 gew.%) en polymelk-co-glycolzuur 
(PLGA; 40 gew.%), met toevoeging van alendronaat (ALN). In vitro resultaten toonden aan 
dat ALN-beladen CPC / PLGA-composieten klinisch geschikte eigenschappen vertoonden, 
waaronder tijden voor uitharding, geschikte weerstand tegen druk en gecontroleerde afgifte 
van ALN, waarbij de laatste afhankelijk is van de afbraak van het materiaal. Met behulp 
van een femoraal botdefect bij ratten met osteoporotische condities, vertoonden de CPC / 
PLGA-composieten met ALN toevoeging een stimulerende effect op botvorming te hebben 
zowel binnen als buiten het defectgebied.
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Evalueren van botregeneratie in een defect van kritische grootte met 
osteoporotische condities en verbeteren van het botvervangende materiaal (een 
zelfherstellende hydrogel die BP en calciumfosfaat bevat) met BMP-2.
Uiteindelijk hebben we botregeneratie nog verder willen uit dagen door twee 
compromitterende factoren te combineren: een defect van kritieke grootte en 
osteoporotische condities. In deze studie wilden we eerst de biologische respons evalueren 
op experimentele hydrogels met calciumfosfaat (CaP) en hyaluronan (HA) met fysische 
gelering van bisfosfonaat (BP) en BMP-2 in een segmentaal femoraal botdefect van kritische 
grootte bij ratten. Bovendien wilden we het effect van de hydrogels in osteoporotische 
conditie evalueren met behulp van hetzelfde defectmodel. Zesenvijftig Wistar-ratten 
kregen ofwel een schijnoperatie (SHAM) of orchydectomie (ORX). Na zes weken werd een 
segmentaal femurdefect van kritische grootte gecreëerd in één femur per rat. Er werden 
twee controlegroepen gebruikt: een met alleen een plaatje om het defect te fixeren en een 
tweede met dezelfde plaat met een lege PTFE-buis. De experimentele groepen bestonden 
uit de plaat en buis gevuld met onze hydrogel (HABP-CaP) en de hydrogel met BMP-2 in 
een lage dosering (HABP-CaP-lowBMP2) of hoge dosering (HABP-CaP-highBMP2). Twaalf 
weken na de botdefectoperatie werd botvormingsanalyse uitgevoerd door middel van 
röntgenonderzoek, micro-CT-analyse, beschrijvende histologie en histomorfometrie. Onze 
gegevens van micro-CT-analyse lieten significant meer bot zien voor HABP-CaP-lowBMP2 in 
vergelijking met HABP-CaP en HABP-CaP-highBMP2 in zowel gezonde als osteoporotische 
condities. Histomorfometrie toonde ook significant meer bot voor HABP-CaP-lowBMP2 in 
vergelijking met HABP-CaP en HABP-CaP-highBMP2 in zowel gezonde als osteoporotische 
condities. Voor defecten gevuld met ofwel lage of hoge doseringen BMP-2, werd een 
grotere hoeveelheid bot rond het defectgebied waargenomen in vergelijking met hydrogels 
zonder BMP-2. Alleen voor de HABP-CaP-highBMP2 werd een verschil tussen gezonde en 
osteoporotische botaandoeningen waargenomen in het voordeel van de gezonde conditie. 
We concluderen dat de defecten van kritieke grootte kunnen worden overbrugt met behulp 
van onze hydrogel, die de meeste botvorming vertoont voor hydrogels met een lage dosis 
BMP-2, ongeacht de botconditie.
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Voortdurende vooruitgang in de zorg draagt bij aan een langere levensverwachting. Doordat 
mensen langer leven, neemt ook het aantal mensen dat aan leeftijd gerelateerde ziekten 
lijdt toe. Wat bot betreft, is de meest voorkomende leeftijdsgebonden ziekte osteoporose, 
een systemische botaandoening waarbij het herstelling proces van bot uit balans is, wat 
resulteert in poreus en kwetsbaar bot. Patiënten met osteoporose hebben een verhoogd 
risico op botbreuken en een verminderde botgenezing. De komende decennia wordt een 
toename van de behoefte aan bottransplantatiechirurgie verwacht. Met verminderde 
botgenezing bij osteoporotische patiënten en de nadelen van autologe bottransplantatie 
(d.w.z. beperkte hoeveelheid en kwaliteit van donorbot en extra operatietijd en morbiditeit 
op de donorplaats) is de mogelijkheid om autoloog bot te vervangen door botvervangers 
de afgelopen eeuw intensief onderzocht. Het effect van osteoporose op de prestatie van 
dergelijke botvervangende materialen is echter nog niet duidelijk. Het algemene doel van 
dit proefschrift was om het effect van de compromitterende aandoening osteoporose op 
botgenezing te onderzoeken met behulp van bottransplantaatvervangers. Ons onderzoek 
toonde aan dat bij gebruik van twee in de handel verkrijgbare bottransplantaatvervangers 
(d.w.z. Bio-Oss® en Biosilicate®) beide materialen de botregeneratie verbeteren in 
osteoporotische condities, maar niet in gezonde omstandigheden (Hoofdstuk 2). Deze 
gegevens suggereren dat botdefecten bij osteoporotische condities met succes kunnen 
worden behandeld met synthetische botvervangers en dat botvervangers van toegevoegde 
waarde zijn voor de behandeling van botdefecten, met name bij osteoporotische patiënten. 
Bij het onderzoeken van het effect van osteoporose op de afbraak van botvervangers, 
ontdekten we dat CPC / PLGA sneller en gestaag degradeerde in vergelijking met Bio-Oss® 
in osteoporotische condities (Hoofdstuk 3). In absolute waarden vertoonde Bio-Oss® echter 
significant minder materiaalresten en meer botvorming in vergelijking met CPC / PLGA. Onze 
gegevens bevestigden onze hypothese dat een osteoporotische aandoening de afbraak van 
CPC / PLGA beïnvloedt, wat essentiële informatie is voor het toekomstige gebruik ervan bij 
osteoporotische patiënten. Als alternatief werden geen effecten van een osteoporotische 
aandoening op botvorming waargenomen. Daarom zijn er voor de verschillende botcondities 
ook een verschillende keuze van bottransplantaatmateriaal nodig met de meest geschikte 
degradatiekenmerken per aandoening.
Voortdurende verbetering van de zorg leidt niet alleen tot een verhoging van de 
levensverwachting, maar ook tot een betere overleving, bijvoorbeeld bij hoogenergetische 
trauma’s en na een kankerbehandeling. In beide gevallen kunnen grote botdefecten optreden 
in verschillende vormen, anatomische locaties en leeftijd van de patiënt. Om deze defecten 
van kritieke grootte te overwinnen, kan ook hier een groot voordeel worden verkregen door 
het gebruik van synthetisch in plaats van autoloog bot. Om ondersteuning te bieden, moeten 
dergelijke grote defecten vaak worden gecombineerd met een of andere vorm van implantaat 
die is aangepast aan het bottype en de anatomische locatie van het defect (d.w.z. lang bot of 
plat, gewicht dragend of niet gewicht dragende locatie). Een tweede doel van dit proefschrift 
was om de mogelijkheid te onderzoeken om zulke grote defecten van kritische afmetingen te 
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overwinnen met botvervangende materialen in combinatie met een stabiele ondersteunende 
steiger. Onze resultaten toonden aan dat onder gezonde omstandigheden het botvormend 
vermogen van botvervangende gel met DBM in titaniumconstructies niet verbeterd was in 
vergelijking met de osteoconductieve eigenschappen van alleen een lege poreuze titanium 
implantaat (Hoofdstuk 5). In een andere experimentele setting waarbij gebruik werd gemaakt 
van segmentale defecten, toonden onze resultaten aan dat een segmentaal defect van 5 
mm in het dijbeen van de rat kan genezen met behulp van een zelfherstellende hybride 
nano-composiet hydrogel in zowel gezonde als osteoporotische condities (Hoofdstuk 7).
Al bijna een eeuw worden botvervangers onderzocht om de chirurgische behandeling van 
botbreuken en defecten te verbeteren. Omdat compromitterende aandoeningen steeds meer 
een belemmerende factor worden bij botgenezing, wilden we het effect van osteoporose 
onderzoeken om de uitkomst van bottransplantatieprocedures beter te voorspellen. Een 
volgende stap is om te onderzoeken hoe bottransplantatieprocedures kunnen worden 
verbeterd door de eigenschappen van botvervangers te aanpassen en mogelijk hun 
prestaties verder te verbeteren door toevoeging van middelen om het aangedane bot lokaal 
te kunnen behandelen. Dit was ons derde doel voor dit proefschrift. De resultaten van onze 
in vitro studie met CPC die gelijke hoeveelheden PLGA-microbolletjes of gemalen deeltjes 
bevatte, lieten een vergelijkbare morfologie, CPC-porositeit en degradatie zien (Hoofdstuk 
4). Door de hoeveelheid PLGA-partikels binnen CPC te verhogen, hebben we de afbraak 
van CPC / PLGA in vitro versneld. De in vivo resultaten van CPC / PLGA met gemalen PLGA 
lieten een gunstige botrespons zien. Bovendien versnelde een grotere hoeveelheid gemalen 
PLGA-deeltjes (d.w.z. 50 versus 30 gew.%) zowel de afbraak van CPC als de vorming van nieuw 
bot. Voor toekomstige klinische toepassingen lijken gemalen PLGA-deeltjes veelbelovend om 
de porositeit van CPC te bepalen. Bovendien is de afbraaksnelheid van CPC aan te passen 
om aan de gewenste eisen te voldoen op verschillende defectlocaties en met verschillende 
patiëntcondities.
Toevoeging van medicijnen of groeifactoren aan het materiaal zou mogelijk de botregeneratie 
verder kunnen versterken en stimuleren. De in vitro analyse in onze studie van de afgifte 
van alendronaat (ALN) uit calciumfosfaatcement voor botregeneratie bij osteoporotische 
aandoeningen toonde aan dat toevoeging van ALN aan CPC / PLGA een klinisch aanvaardbare 
behandeling is met geschikte uithardingstijden en een gecontroleerde afgifte van ALN geeft 
(Hoofdstuk 6). In een in vivo botdefectmodel toonde aan dat de toevoeging van een relatief 
lage dosis ALN (0,5 gew.%) aan CPC / PLGA de botvorming in het gebied rondom het defect 
bij osteoporotische condities significant verhoogde, zonder effect op CPC / PLGA-degradatie. 
De gegevens suggereren dat toekomstige klinische toepassing van ALN toevoeging aan 
CPC / PLGA gunstig kan zijn voor de genezing van botdefecten in bij patienten met een 
osteoporotische aandoening.
In een andere experimentele opstelling toonde ons in vivo resultaat aan dat segmentale 
femorale botdefecten van kritieke grootte niet konden worden genezen met alleen 
HABP-CaP-gel (Hoofdstuk 7). Het laden van de HABP-CaP-gel met een lage dosis BMP-2 
verbeterde de botvorming significant en resulteerde in defectoverbrugging in 100% van de 
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defecten. Als alternatief verbeterde de hoge dosis BMP-2-belading van de HABP-CaP-gel de 
botvorming binnen het defectgebied niet, maar leidde tot overmatige botvorming buiten 
het defectgebied. Toekomstig gebruik van BMP-2 lijkt gunstig te zijn, maar het effect is sterk 
dosisafhankelijk.
Toekomstperspectieven
Het proces van botgenezing is al tientallen jaren een onderwerp voor onderzoek met als 
doel breuken en botdefecten te voorkomen en/of te behandelen. Het multifactoriële aspect 
van genezing maakt het een interessant en complex onderwerp voor onderzoekers over de 
hele wereld. In dit proefschrift wilden we het effect onderzoeken van osteoporose als een 
systemische aandoening die bothomeostase verstoort op de prestatie van botvervangers in 
uitdagende omstandigheden om informatie toe te voegen en hopelijk een basis te bieden 
voor meer onderzoek dat uiteindelijk kan resulteren in volledige genezing en/of preventie 
van complexe fracturen en botdefecten bij osteoporotische patiënten.
Ontwikkeling van botvervangers met verbeterde biologische prestaties
Autoloog bot heeft het voordeel dat het beide eigenschappen van osteoconductie 
en osteoinductie heeft. Daarom blijft autoloog bot de gouden standaard bij 
bottransplantatieprocedures. De term osteoconductie verwijst naar het vermogen van 
bot om langs een oppervlak te groeien, d.w.z. om bot van het ene uiteinde van het defect 
naar het andere te geleiden. Met andere woorden, botregeneratie wordt tot stand gebracht 
door botweefsel te laten groeien over het materiaal dat in het defect wordt geplaatst en 
als een ladder wordt gebruikt. Botvervangers hebben doorgaans ook osteoconductieve 
eigenschappen. Dit kan worden beïnvloed door het aantal en de grootte van de poriën in het 
materiaal en ook door de afbraaksnelheid. Deze eigenschappen kunnen worden afgestemd 
in botvervangers en kunnen daarom worden aangepast aan specifieke behoeften bij 
verschillende patiënten en/of defecte eigenschappen. Omdat botgenezing multifactorieel is, 
zouden op maat gemaakte botvervangers die specifiek zijn ontworpen om patiënt specifieke 
afbraak te hebben, wenselijk zijn om de fysisch-chemische materiaaleigenschappen optimaal 
te matchen met biologische omstandigheden op een specifieke defectlocatie voor individuele 
patiënten.
Om botvervangers verder te verbeteren, wordt er steeds meer onderzoek gedaan 
naar biomaterialen die ook osteoinductieve eigenschappen hebben, om zo grote en 
gecompromitteerde defecten te kunnen genezen. Osteoinductie omvat de stimulatie van 
osteoprogenitor cellen om zich te differentiëren tot osteoblasten om nieuw bot te vormen. 
Botmorfogenetische eiwitten (BMP’s) vertegenwoordigen een groep groeifactoren die op 
grote schaal worden gebruikt om osteoinductieve capaciteit te bieden. In dit proefschrift 
hebben we gevonden dat het effect van BMP-2 dosisafhankelijk is. Verder onderzoek is 
nodig om het optimale osteoinductieve materiaal te onthullen en het juiste gebruik 
van dergelijke groeifactoren te bepalen met betrekking tot hun veilige lading, afgifte en 
biologische activiteit. Ook hier kan meer kennis leiden tot de ontwikkeling van botvervangers 
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voor individuele patiënten met specifieke kenmerken van botdefecten en patiëntcondities.
Nieuwe voorspellende en preventieve geneeskunde
Zoals eerder vermeld, leidt het verbeteren van de gezondheidszorg tot een hogere 
levensverwachting en een betere overleving. Dit geldt ook voor bottrauma of behandeling 
van botkanker, waardoor complexere en grotere botdefecten ontstaan. In de vorige paragraaf 
hebben we een hypothese opgesteld over hoe botvervangende eigenschappen kunnen 
worden veranderd om de biologische prestaties van botvervangers te verbeteren. Om een 
optimale behandeling van botdefecten of fracturen in deze complexe patiëntcondities te 
bieden, moet het onderzoek zich echter ook blijven richten op patiënt- en defect gerelateerde 
risicofactoren om de uitkomst te optimaliseren. Het effect van patiënt- en defect gerelateerde 
factoren op botgenezing is essentieel voor het kiezen van welke chirurgische procedure 
en botvervanger te gebruiken om de beste zorg voor elke individuele patiënt te bieden. 
Tegenwoordig verandert de gezondheidszorg al wereldwijd haar strategie om preventief 
in plaats van curatief te worden. Bij botbreuken is dit vooral het geval bij osteoporose. 
Veranderingen in levensstijl, beter voedingsadvies en medische behandeling voor de 
preventie van osteoporose zijn al geïmplementeerd in wereldwijde gezondheidszorgsystemen 
om osteoporotische fracturen te voorkomen. Toch zal een groot aantal mannen en vrouwen, 
vooral boven de 50 jaar, met de complicaties van deze ziekte te maken krijgen. Hoewel 
botvervangers niet kunnen worden gebruikt voor de preventie van osteoporose, kunnen 
ze waarschijnlijk helpen bij de chirurgische behandeling van botdefecten of botbreuken. 
Verder kunnen ze, eenmaal geïmplanteerd, botbreuken voorkomen door plaatselijk geschikte 
anti-osteoporotische of anabole moleculen vrij te geven.
Voorspellende modellen voor het risico van onvolledige botgenezing (non-union) zijn met 
succes onderzocht (Zura et al. 2017). Toch blijft het voorkomen van non-union moeilijk 
en blijft de behandeling een uitdaging voor chirurgen en patiënten. Bij non-union lopen 
jongere patiënten met comorbiditeiten zoals roken, alcoholisme, obesitas, osteo- of 
reumatoïde artritis, diabetes type 2 en/of open fracturen meer risico. Met behulp van de 
beschikbare informatie over wie een hoog risico loopt om een  non-union te ontwikkelen, 
kunnen mogelijk botvervangers verder worden verbeterd om als een therapeutisch middel 
te gebruiken. Wetende welke risicofactor betrokken is bij een patiënt met een fractuur 
die kan bijdragen aan een non-union, kan het toevoegen van een op maat gemaakte 
botvervanger met therapeutische geneesmiddelen resulteren in verbeterde botregeneratie 
en een lager risico op niet-hechting in vergelijking met autoloog bottransplantaat. Wanneer 
een fractuur geen operatie vereist, maar het risico loopt om niet te genezen, kan een 
ander botvervangingsmiddel worden gebruikt met functies die specifiek op de patiënt zijn 
afgestemd. Dit is een tijdrovende, kostbare en complexe onderzoeksstrategie die echter een 
grote verscheidenheid aan patiënten kan helpen.
Lokale versus systemische behandeling van botaandoeningen
Om botvervangers continu te verbeteren, hebben we de ontwikkeling besproken 
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om botvervangers te upgraden met osteoinductieve eigenschappen en afstembare 
eigenschappen te benutten die specifiek zijn afgestemd op de behoefte van de individuele 
patiënt en defecten. Toevoeging van geneesmiddelen (d.w.z. antibiotica of anti-
osteoporotische geneesmiddelen) aan botvervangers is een voorbeeld van een dergelijke 
op maat gemaakte eigenschap. In het geval van osteoporose wordt een onbalans in de 
botomzetting tegengegaan door anti-osteoporotische geneesmiddelen, zoals bisfosfonaten. 
Deze medicijnen remmen de osteoclastfunctie, wat resulteert in minder botresorptie en een 
verminderd risico op botbreuken. Er zijn verschillende bijwerkingen die kunnen optreden, 
zoals maagproblemen, nierfalen, osteonecrose van de kaak en zelfs een verhoogd risico op 
slokdarmkanker (Kenal et al. 2009). Bij de behandeling van een osteoporotische fractuur 
kunnen anti-osteoporotische geneesmiddelen worden toegevoegd aan een botvervanger 
om de botgenezing te verbeteren en te versnellen. Een voordeel van lokaal toegediende 
medicijnen is dat de dosering verlaagd kan worden en daardoor minder kans op systemische 
bijwerkingen. In combinatie met preventieve geneeskunde, zoals gezonde voeding en 
voldoende beweging, kan dit hopelijk de behoefte aan systemische toediening verminderen.
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Wetenschap heb ik altijd een belangrijk onderdeel gevonden van de opleiding tot arts. 
Daarom heb ik ook niet getwijfeld toen ik voor de keuze stond om te mogen solliciteren 
voor een promotie traject bij de afdeling Biomaterialen. Hoewel je er een voorstelling van 
probeert te maken, kun je nooit echt inschatten wat een impact dit heeft op jezelf en je 
omgeving. Zoals een van mijn stellingen luidt: “If we knew what it was we were doing, it would 
not be called research, would it?” (Einstein). Terugkijkend op het geheel kan ik zeggen dat 
ik veel heb geleerd en hoop dat dit onderzoek zal bijdragen aan de verdere ontwikkeling en 
verbetering van de wetenschap en de zorg. 
Natuurlijk is dit allemaal niet mogelijk geweest zonder de hulp en steun van een groot aantal 
mensen. Een aantal wil ik in het bijzonder noemen om te bedanken.
Prof. Dr. J.A. Jansen – Beste John, bedankt voor het geloof in mij en voor de kans die ik 
heb gekregen. Ik kan me de dag dat ik solliciteerde nog goed herrinneren en je gaf me 
het vertrouwen om aan dit project te beginnen. Gedurende de jaren heb ik altijd de steun 
gevoeld die in het begin was gegeven. Ook bedankt voor uw geduld aangezien het toch een 
heel veel langer traject is geworden dan we van te voren hadden afgesproken.
Prof. Dr. D.J.O. Ulrich – Beste Dietmar, ik heb erg veel respect voor jou en ben ik blij dat je in 
2011 naar de afdeling plastische chirurgie van het Radboud bent gekomen. Ik voel me ook 
vereerd dat ik een onderdeel heb mogen zijn van de groei die de afdeling heeft gemaakt. Ook 
ben ik heel blij met het vertrouwen dat je in mij hebt gehad en de kansen die ik heb gekregen 
door te kunnen promoveren en ook met mogelijkheid om de opleiding tot plastisch chirurg 
te kunnen starten. Nu er een van de twee trajecten (eindelijk) is afgerond en de tweede 
bijna kan ik tevreden terug kijken en zien dat ik een persoonlijke en professionele groei heb 
doorgemaakt, voor een groot deel door jouw hulp en steun. Dankzij onze samenwerking heb 
ik kunnen bijdragen aan de wetenschap en de medische zorg. Naast een harde werk ethos 
was er ook altijd ruimte voor gezellige momenten (bvb concerten, bbq’s en ski-uitjes) en was 
er ook nog ruimte voor persoonlijke steun bij wat drukkere tijden. Hoewel straks onze tijd 
in het kader van mijn opleiding afgerond zal zijn, hoop (en verwacht) ik dat er bij jou nooit 
een einde zal komen aan je inzet voor de zorg van je patienten, de steun aan je collega’s en 
de ambitie om de plastische chirurgie in Nijmegen, en zelfs ver daar buiten,  te verbeteren. 
Dr. Ing. J.J.P. van den Beucken – Beste Jeroen, ik had dit zeker nooit kunnen doen 
zonder jouw hulp! Door jouw wijze adviezen, heldere inzichten, aanpassingen van mijn 
manuscripten (en zelf mails) was dit boekje er nooit gekomen. Je directe feedback heb ik 
altijd erg kunnen waarderen en heeft me geholpen om snel te schakelen. Voornamelijk 
wil ik je bedanken voor je eeuwige beschikbaarheid, je eindeloze geduld en ook het 
vertrouwen dat je me hebt gegeven. We konden altijd goed kletsen over het onderzoek, 
maar ook heerlijk over andere levenskwesties waardoor het altijd erg gezellig was. 
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Paranimfen – Kassandra van Houdt en Femke van de Peppel-Mauritz, mijn lieve zus en 
schoonzus. Het is niet voor niets dat ik deze bijzondere vraag om mij te steunen bij mijn 
promoveren bij jullie leg. Jullie zijn beide zowel waardevol als familie en als vriendin! 
Het maakt niet uit waarover het gaat, met elke vraag kan ik bij jullie terrecht. Daarom 
ben ik heel blij dat jullie deze dag samen met mij willen delen. 
Leden van de manuscriptcommisie; Prof. Dr. M.J.R. Edwards, Dr. H.C. Kroeze-Deutman 
en Prof. Dr.  P. Habibovic – Dank voor het plaatsnemen in de commissie en het kritisch 
beoordelen van het proefschrift. Ook de andere leden van de promotiecommissie wil ik 
bedanken voor deelname in de commissie.
Collega’s afdeling Biomaterialen – Hoewel alweer een hele tijd geleden ben ik natuurlijk 
ook zeer dankbaar voor de samenwerking met mijn mede (oud) promovendi. Hamdan 
Alghamdi, I woul like to thank you for sharing your wisdom and help me with starting 
this project, but also for our discussions mainly about the animal studies. Floor van 
de Wateringen, onze gesprekken aan de start van mijn promotie hebben geholpen om 
vooral ook de analyse met de beeldvorming een juiste richting te geven. Alle mede 
auteurs en specifiek Bart van Oirschot, Carla Tim, Paulo Gabbai-Armelin, Paula Lopez-
Perez, Daniel AlvesCardoso en Preetha Preethanath wil ik bedanken voor een hele 
fijne en productieve samenwerking. Ook mijn mede promovendi Jan-Willem Hoekstra, 
Manuela Ventura, Maria Cristina LoGiudice, Ruggero Bosco, Simone Mastrogiacomo, 
Eline-Claire Grosfeld, Na Yu, An Jie, Mani Diba, Astghik Hayarpetyan, Alexey Klymov, 
Xinjie Cai, Yue Sa, Kemal Sabriibrahimoglu, Kambiz Farbod, Winston Camargo, Matilde 
Bongio, Eva Raquel UrquíaEdreira, Wanxun Jang, Jinankan Song, Xiangzhen Yan, Rosa 
FelixLanao, Pedro DousaBabo en iedereen die mogelijk ben vergeten over de jaren. 
Jullie hebben bijgedragen aan een leerzame en leuke periode van onderzoek doen bij 
de afdeling Biomaterialen.
Stafleden afdeling Biomaterialen – Sander van Leeuwenburg, Frank Walboomers, Joop 
Wolke, Fang Yang, bedankt voor jullie feedback en ondersteuning op de juiste momenten.
Collega’s in het lab – Een speciale dank wil ik uitpreken naar de hulp die in het lab 
heb gekregen. Beste Natasja van Dijk, jij hebt mij gedurende mijn hele tijd bij de 
biomaterialen het meeste gezien en gesteund. Door jou had ik het vertrouwen om in 
het laboratiorium aan de slag te gaan. Voor mij een volledig nieuwe omgeving, maar 
door jou steun en toeverlaat was het direct een prettige werkomgeving. Naast al het 
eindeloze snijden en prepareren van de coupes hebben we gelukkig ook regelmatig 
tijdens koffie pauzes en lunch kunnen kletsen. Bedankt voor deze bijzondere tijd. Beste 
Vincent Cuijpers, ook jouw hulp is niet onopgemerkt gebleven. Jouw expertise was 
groots en dat bleek ook wel aangezien je ook bent gepromoveerd in 2016. Ook heb je mij 
geholpen met het verwerken van de data en daar ben ik je dankbaar voor. Verder kan 
ik natuurlijk ook Martijn Martens, Monique Kersten en Marjon Bloemen niet vergeten.
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Dr. M. Koolen – Beste Marianne, bedankt voor de prettige samenwerking. Ik heb veel van 
je kunnen leren. Ons gezamenlijk project heeft voor mooie resultaten gezorgd waarvan 
onder andere het figuur op de voorkant van dit proefschrift. Ook dank aan Prof. Dr. H.H. 
Weinans die deze samenwerking mede mogelijk heeft gemaakt.
Collega’s in het CDL – mijn onderzoek was niet mogelijk zonder de hulp en begeleiding 
vanuit het CDL. De biotechnichi en dierenwelzijns functionarissen hebben de dierproeven 
mogelijk gemaakt. Vooral wil ik mijn dank uiten naar de mensen die hier direct bij 
betrokken zijn geweest en altijd de wetenschap goed combineerde met de liefde en zorg 
voor de dieren. Dit zijn Daphne Reijnen, Denise Taks, Linda Derks-Wagemakers, Bianca 
Lemmers-van de Weem, Charlene de Kluijs-Bender, Saskia Mulder, Roel Sneepers en 
Pieter Verbost.
Afdeling Pathologie – Beste Meyke Hermsen, bedankt voor de mogelijkheid om onze 
coupes de kunnen scannen en de begeleiding hierbij.
Stafleden Plastische chirurgie – Graag bedankt ik Till Wagner, Pieter Hupkens, Hanneke 
Tielemans, Erik Walbeehm, nieuwe collega’s Franz Pronk, Tim de Jong, Tim Nijhuis, 
Brigitte van der Heijden en Marielle Vehmeijer. Maar ook oud collega’s Dalibor Vasilic, 
Marie-Claire Schreinemachers en Oliver Kloeters. In het bijzonder ook Prof. Hovius 
voor de leerzame onderwijsmomenten en Stefan Hummelink voor zowel de muzikale 
gesprekken als verzoek voor wetenschappelijke status updates.
Collega’s assistenten Plastische chirurgie – Inge Hoevenaren, Marijn Hameeteman en 
Marjolijn van Abeelen, samen met jullie is het allemaal begonnen in het Radboud. 
Toen kwamen Nicholas Slater, Vera Paulus, Tycho Wesselius, Anne-Sophie Kruit, Femke 
Mathot, Pepijn Sun en later nog Lennart Steenbeek, Kaj Brouwers, Bo Notermans, Laura 
Burlage, Harm Winters en Sakia de Roo. Weledelgeleerde dames en heren, jullie zijn 
allemaal zeer lieve collega’s en ook als assistentengroep is het altijd een super gezellige 
sfeer! Ik hoop dat waar we allemaal ook in de toekomst terrecht komen er altijd zulke 
lieve collega’s zullen zijn. Voor jullie allemaal wens ik het allerbeste en hopelijk zien 
we elkaar nog regelmatig, minstens op de NVPC-dagen wanneer die weer fysiek mogen.
Personeel Plastische chirurgie – dames van de poli en het secretariaat, maar ook Erik 
de Laat, Nienke Gort en Yasmille Winnen, ook jullie steun heb ik de afgelopen jaren 
zeer gewaardeerd. Stephan van Raay, zonder jou was dit boekje zeker niet zo mooi 
geworden. Dank voor je hulp.
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Lieve vrienden en vriendinnen
Geneeskundevriendinnen – Barbara Muller, Sophie Bekman, Willemijn van Hoesel-van 
Eeten, Sasja LeLoup, Siegrid de Meer, Joyce Heijenman en Anne Schmetz. Het was altijd 
fijn om werkgerelateerd te kunnen praten, grappen en reflecteren, maar ik ben vooral 
dankbaar voor de gezellige tijd. Ik koester jullie vriendschap. 
Suzanne Oosterwijk – mijn “oudste” vriendinnetje. Met weinig woorden begrijpen wij 
elkaar heel goed. Momenteel ben je nog steeds ver weg op avontuur in New York, maar 
het maakt niet uit waar je op de wereld bent we blijven altijd vriendinnen en hoelang 
het ook geleden is, als we kletsen voelt het altijd als vanouds.
Vala van Beek – lieve Vala, door omstandigheden zien en spreken we elkaar minder 
dan ik zou willen, maar onze middelbareschool periode en de vriendschap die hieruit 
is ontstaan zal ik altijd koesteren. 
Joyce Heijneman en Bas de Bruin, samen beleven wij al jaren mooie avonturen op 
onder andere festivals en onze weekendjes in de Ardennen. Dank jullie beide voor al 
deze heerlijke momenten die voor de nodige ontspanning zorgen naast al het harde 
werken. We hebben nog een hele bucket list te gaan en hopelijk lukt het ons om deze 
ervaringen allemaal samen te beleven.
Vrienden uit Wageningen – Lieve Sander van Houwelingen, Maikel Boos, Selko Smits, 
Joost Kettmann, Maartje Mulders, Paul Eijskoot en Caroline van Oostveen. Jullie hebben 
mijn komst naar Wageningen doen voelen als een warm bad. Alles begon in de Infinity 
waar we veel gezellige avonden hebben gehad. Wat fijn dat ik deze ontspannende 
momenten samen met jullie kan delen. 
Lieve familie 
Wim van Houdt en Jocelyne van Houdt-Albert – Lieve pap en mam, jullie hebben mij 
altijd geleerd dat je alles kunt worden in het leven als je maar graag genoeg wilt en je 
best hiervoor doet. Hieruit put ik mijn volhardendheid en daar ben ik trots op. Soms 
voelde het alsof het niet ging lukken, maar door jullie liefde en steun heb ik nu steeds 
kunnen bereiken wat ik beoogde. Ik blijf julli eeuwig dankbaar! Nu jullie rol verder is 
gegroeid tot papi en mami zie ik weer waarom het leve
David van Houdt – mijn grote, kleine broer, zoals ik het boekje heb zien groeien in 
een paar jaar, heb ik ook jou ook zien groeien. Hopelijk heb ik jou, als een van je grote 
zussen, kunnen inspireren. Inmiddels kan ik ook veel van jou leren (zie mijn stellingen) 
en hopelijk gaan daar nog veel wijze lessen bij komen. 
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Izak Mauritz en Inge Mauritz-Assendelft – lieve schoonouders, ik had geen betere 
kunnen wensen. Vanaf de eerste keer dat wij elkaar leerde kennen voelde het als een 
warm welkom in de nieuwe familie en sindsdien is dat alleen maar gegroeid. Ook jullie 
zijn er voor mij en ons gezin onvoorwaardelijk. De gezellige gesprekken van Izak en 
heerlijke kookkunsten van Inge maakt dat ik altijd graag bij jullie kom en dat doe ik dan 
ook regelmatig. Heel handig nu ook zo dicht in de buurt.
Schoonbroers – Marvin Renardus en Renz van de Peppel, wat ben ik blij dat mijn lieve 
zus en schoonzus zulke geweldige mannen hebben gevonden. Nu we ook allemaal 
ongeveer tegelijk een gezin zijn gestart voelt de band nog hechter. Bedankt voor het 
groter en leuker maken van deze familie.
Tobin Mauritz – mijn schatje, wat maak jij me gelukkig. Jou zien opgroeien is het mooiste 
wat er is. We gaan nog veel prachtige avonturen beleven, straks ook samen met je 
broertje.
Harm Mauritz – Loof, wat ben ik blij dat we samen het leven trotseren. Want hoewel we 
allebei altijd druk zijn met onze carriere ambities en daarbij nog ons uitbreidend gezin, 
heb je toch ook nog geduld om mij te steunen zoals bij het voltooien van dit proefschrift. 
Gelukkig was het de afgelopen jaren niet alleen maar hard werken, maar kunnen we 
samen ook erg genieten van het leven en het samen zijn. Nu mijn proefschrift klaar is 
kan ik hopelijk nog meer samen met jou en onze beide mannetjes het leven vieren.
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Claire van Houdt werd geboren op 10 oktober 1984 te Soest. Na het behalen van haar VWO 
diploma in 2003 aan het Baarnsch Lyceum startte zij met haar studie Geneeskunde aan de 
Universiteit van Utrecht. Tijdens haar studie is zij voor haar co-schap Tropengeneeskunde 
naar Haydom, Tanzania, gegaan en heeft zij haar keuze co-schap KNO in Marseille, Frankrijk, 
verricht bij prof. dr. J.P.Y. Magnan. In haar laatste jaar heeft zij op de afdeling plastische 
chirurgie in het UMC Utrecht, onder begeleiding van prof. dr. M. Kon en dr. A.H. Schuurman, 
co-schappen gelopen en heeft zij onderzoeksstage naar pijn bij hand en pols chirurgie 
gedaan. Hier werd haar voorkeur voor de plastische chirurgie bevestigd en werd de basis 
voor de wens om aanvullend wetenschappelijk onderzoek te doen gelegd. Na het afronden 
van haar studie in 2010 kon zij direct starten als arts-assistent bij de chirurgie in de Gelderse 
Vallei in Ede. In 2011 kwam de kans om als arts-assistent te werken in het Radboudumc. Toen 
prof. dr. D.J.O. Ulrich in 2012 als opleider en hoofd van de afdeling Plastische chirurgie in het 
Radboudumc kwam werd al snel gesproken over het verrichten van een promotietraject. In 
2013 kon zij in samenwerking met de vakgroep Biomaterialen van de afdeling Tandheelkunde 
in het Radboudumc starten met haar onderzoek naar “botvervangende materialen in 
gecompromitteerde condities”, onder begeleiding van prof. dr. J.A. Jansen en dr. ing. J.J.J.P. 
van den Beucken. Na 2 jaar fulltime onderzoek doen en data verzamelen is zij eerst terug 
gegaan naar de afdeling plastische chirurgie alvorens zij in 2016 met haar opleiding als 
plastisch chirurg startte. De opleiding startte zij bij de afdeling Chirurgie in het ziekenhuis 
Gelderse Vallei in Ede, met als opleiders dr. R.M.H.G. Mollen en dr. A.M. Bosch. Het onderzoek 
verricht binnen de vakgroep Biomaterialen is in de jaren erna verder afgerond en heeft 
uiteindelijk geresulteerd in dit proefschrift. In 2020 heeft Claire een jaar perifere ervaring 
opgedaan in het Jeroen Bosch ziekenhuis onder begeleiding van dr. R.J.P.M. Franken en dr. 
E.P.A. van der Heijden. Momenteel is zij bezig haar laatste jaar van de opleiding plastische 
chirurgie af te ronden. 
Claire woont samen met Harm Mauritz en hun zoon Tobin in Wageningen en in juni 
verwachten zij de komst van hun tweede zoon. 
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The data obtained during this PhD at the Radboud university medical center (Radboudumc) 
have been captured and stored on paper in traditional laboratory note books as well as on 
the local archive of the department of Biomaterials at the Radboudumc. All data was stored 
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remains accessible by the PhD candidate, (co-)promotors and assigned laboratory members 
of the department of Biomaterials for 15 years after publication of each study.
All animal experiments were conducted in accordance with institutional, national and 
international guidelines for animal care and the Dutch law concerning animal welfare. The 
studies were reviewed and approved by the Experimental Animal Committee of the Radboud 
University.
For reusability of the data provided in the Materials and Method section of each chapter 
has been written as detailed as possible. Published data is accessible via PubMed as well 
as all data files can be requested to the corresponding author of the articles or author of 
this thesis.
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Name PhD student: C.I.A. van Houdt 
Department: Biomaterials 
Research School: Radboud Institute for  
Molecular Life Sciences 
PhD period: 01-02-2013 – 01-02-2015 
Promotor(s): Prof. J.A. Jansen, Prof. D.J.O. Ulrich 
Co-promotor(s): Dr. Ing. J.J.J.P. van den Beucken 
 
 Year(s) ECTS 
TRAINING ACTIVITIES 
a) Courses & Workshops 
- Laboratory Animal Science 
- Brandwonden cursus  
- Management voor promovendi 











b) Seminars & lectures^ 
- "Around the nose" international course 








c) (Inter)national Symposia & congresses^ 
- Wetenschappelijke vergadering (NVPC, apr 2013) 
- 24th meeting EURAPS (Antalya, Turkey) 
- “Towards a new center for the treatment of complex osseous 
defects” (CTRM, Vu A’dam) 
- Scholingsdag & Wetenschappelijke vergadering (NVPC, okt 2013) 
- Scholingsdag & Wetenschappelijke vergadering (NVPC, apr 2014) 
- Conference for Society for Biomaterials* (SFB Denver USA, apr 2014) 
- Two-Day PhD retreat# (RIMLS, mei 2014) 
- Scholingsdag & Wetenschappelijke vergadering* (NVPC, okt 2014) 
























- Stagemarkt BMW 2013# 















- Wetenschapsdag Tandheelkunde* 





½   
¾  
TOTAL 20 ½ 
 
^Indicate oral and poster presentations with a * and # after the name of the activity, respectively. 
 
Addition: Since the PhD period was over 2 year’s time in stead of 4 years the total of 20 points (in stead of 40) 
was considered sufficient by Mentor,        Promotors and Co-promotor.  
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